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Abstract 
 
Necrotising fasciitis (NF) due to invasive Group A streptococcus (iGAS) is frequently 
associated with emm1 isolates, with an attendant mortality of approximately 40%.  Cases 
occur in previously healthy individuals with a history of upper respiratory tract infection, 
soft tissue contusion and no obvious portal of entry. Using a new model of mild contusion 
injury, we set out to determine the impact of contusion on iGAS bacterial burden, 
phenotype and host cytokine response.   
 
Firstly invasive bioluminescent GAS strains were developed using a replicative plasmid 
pTHLK but these were unstable in vivo.  A stably bioluminescent M89 iGAS strain was 
developed using a plasmid pICL18Lux and characterised in vitro and in vivo models of 
invasive infection.  Bioluminescence measured in vivo correlated with bacterial quantity 
but practical application to produce a lower respiratory tract infection or prolonged soft 
tissue infection was limited by detection of light production during infection. The new 
isolate was attenuated in growth and virulence and it could not be used to study the 
interaction of contusion and virulence.   
 
A new model of soft tissue contusion was developed that resulted in local soft tissue 
neutrophilic inflammation, no bony injury, systemic cytokine production or weight loss. The 
model of mild contusion was used to determine the impact of trauma on emm1 iGAS. 
Surprisingly, mild contusion did not provide a focus for initiation or seeding of bacteraemic 
GAS infection, but instead provided an environment that enhanced GAS dissemination to 
local lymph nodes. Dissemination was linked to a phenotypic change with the emergence 
of mucoid GAS colonies in lymphoid tissue, bloodstream and spleen. The mucoid GAS 
colonies in the lymph node demonstrated a significant increase in production of capsular 
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hyaluronan and were not associated with covRS mutations.   Whole genome sequencing 
was applied to understand the genetic change responsible, a selection of mutations 
occurring in the spleen and lymph node were discovered.  The exact role of some of the 
mutations in the pathogenesis of dissemination of GAS and the influence of trauma is not 
entirely known and the subject of on-going investigation. 
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1 Introduction 
1.1 Group A Streptococcal Infections 
 
Streptococcus pyogenes (Group A streptococcus, GAS) is a Gram-positive bacterium 
causing diseases ranging from mild pharyngitis to severe infections such as necrotising 
fasciitis (NF) and toxic shock syndrome (TSS) (Cunningham 2000, Lamagni, Darenberg et 
al. 2008). Furthermore GAS is responsible for non-suppurative sequelae like rheumatic 
fever, rheumatic heart disease (RHD) and glomerulonephritis (Walker, Barnett et al. 2014).  
It is an important human pathogen and one of the top ten causes of mortality from an 
infectious disease, with the majority due to invasive disease and RHD (Carapetis, Steer et 
al. 2005). 
 
Humans are the only known natural reservoir for GAS and transmit the bacteria via direct 
contact, droplet spread or ingestion through contaminated fomite (Marks, Reddinger et al. 
2014) or food (Sarvghad, Naderi et al. 2005). Clinically GAS affects a diverse selection of 
tissues including the mucous membranes, tonsils, lungs, skin, fascia, muscle and blood 
causing pharyngitis, tonsillitis, pneumonia, impetigo, cellulitis, necrotizing fasciitis (NF), 
myositis, bacteraemia, toxic shock syndrome (TSS) and puerperal sepsis (Figure 1.1).  
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Figure 1.1 Diagrammatic representation of the clinical spectrum of disease caused 
by infection with Group A streptococcus (Patterson 1996) 
 
 
The worldwide mortality and morbidity of diseases associated with GAS infections is 
enormous both in developing and developed countries, with over 616 million cases of 
pharyngitis per year and 111 million prevalent cases of pyoderma (Carapetis, Steer et al. 
2005). During the mid 20th century the incidence of invasive GAS infection declined in 
parallel with the introduction of penicillin (Abraham, Chain et al. 1941, Kardos and Demain 
2011), improvements in infection control practices (Meleney 1924), surgical techniques 
(Meleney 1929) and potentially reduced expression of virulence factors by the organism 
and a changing host response (Stevens 1995). However, since the mid-1980s there have 
been an increasing number of reports of severe GAS infections including pneumonia, TSS 
and NF particularly in the developed world (Stevens, Tanner et al. 1989, Martin and Hoiby 
1990, Schwartz, Facklam et al. 1990, Stromberg, Romanus et al. 1991, Stevens 1992, 
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Hoge, Schwartz et al. 1993, Cartwright, Logan et al. 1995, Stevens 1995, 2014, Gostin, 
Hodge et al. 2014, McCarthy 2014, Nau 2014). 
 
1.1.1 Classification 
GAS was originally named in the late 19th Century as Streptococcus pyogenes 
(Rosenbach 1884, Wilson 1987) but it was not until the early 1900s that it was further 
classified as a Group A streptococcus (GAS), with the emergence of serological 
techniques to distinguish between beta-haemolytic streptococci based on differences in 
cell wall polysaccharide or lipoteichoic acids (Lancefield 1933). Lancefield provided an 
additional method based on the surface M protein to group and link the streptococci to 
particular disease, for example, certain M types were known as “throat” strains whilst 
others were designated “skin” isolates (Cunningham 2000). Following the discovery of the 
M protein, over 80 M serotypes have been described (Lancefield 1928, Facklam, Beall et 
al. 1999). Other phenotypic typing techniques rely on T (now recognised as pilus) protein 
antigens (Cunningham 2000), of which there are 30 different types, and the serum opacity 
factor (OF), which is a type specific cell surface enzyme (Hallas and Widdowson 1983). 
Today, the Lancefield serological system for M protein identification is no longer used, 
having been superseded by sequencing the 5’ variable region of the emm gene encoding 
the M protein (Beall, Facklam et al. 1996); there are now over 200 recognised emm types 
(Facklam 2002, Facklam, Martin et al. 2002) although interestingly some of these are 
serologically indistinct.  
 
The emm genotyping system is a useful epidemiological tool for characterizing GAS 
strains (Facklam, Beall et al. 1999). There is heterogeneity between the 5’variable region 
of the emm gene in different strains and, compared to traditional typing methods using 
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antisera, it is less expensive and labour intensive, plus is more easily conducted 
reproducibly by laboratories worldwide (Facklam, Beall et al. 1999). Sequences from the 
variable end are sequenced using specific emm typing primers and the sequences 
analysed on a central database. Two isolates are regarded as belonging to the same emm 
type when they share more than 95% of the same variable sequence. Today, sequencing 
the emm gene is viewed as the gold standard method for GAS typing, although more 
recently sequencing short-reads using whole genome sequence principles may offer a 
method of refining current methods.  This new approach may solve some of the 
ambiguities associated with previous typing methods and determine the presence or 
absence of certain genes (Athey, Teatero et al. 2014). 
 
Although there is geographical and socioeconomical variation in the distribution of emm 
types, many remain strongly associated with specific clinical conditions, for example, the 
association of emm types 1 and 3 with invasive diseases including necrotizing fasciitis and 
pneumonia (Olsen and Musser 2010). Further molecular work has identified virulence 
traits that are characteristic of individual emm types, such as the unique presence of the 
streptococcal inhibitor of complement-mediated lysis (SIC) that can undergo marked allelic 
variation in emm 1 isolates (Hoe, Vuopio-Varkila et al. 2001), and a phage-encoded novel 
extracellular secreted phospholipase A2, SlaA important for tissue invasion with genomic 
differences noted in emm 3 isolates (Hoe, Vuopio-Varkila et al. 2001, Beres, Sylva et al. 
2002, Johnson, Wotton et al. 2002, Beres, Carroll et al. 2010). 
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1.2 Invasive Group A Streptococcus disease (iGAS) 
Invasive Group A streptococcal disease (iGAS) is an infection defined by the isolation of 
GAS from a normal sterile site (confirmed case) (Stevens 1995, Smith, Lamagni et al. 
2005, Yee-Guardino, Kumar et al. 2008) or by GAS isolated from a non sterile site in 
combination with streptococcal toxic shock syndrome (STSS) or another severe 
manifestation like pneumonia, necrotizing fasciitis, puerperal sepsis, meningitis or septic 
arthritis (probable case). iGAS is most commonly associated with bacteraemia, cellulitis, 
necrotizing fasciitis, septic arthritis, pneumonia, meningitis, osteomyelitis and puerperal 
sepsis, which may be complicated by the development of STSS (Stevens 1995, Walker, 
Barnett et al. 2014). 
 
1.2.1 Epidemiology 
Globally, it is estimated that there are 663,000 cases of iGAS disease per year resulting in 
163,000 deaths (Carapetis, Steer et al. 2005). Although it is presumed that the incidence 
of iGAS is higher in developing countries (Carapetis, Steer et al. 2005), the past thirty 
years has seen an increased reporting of these severe infections in the developed world, 
following cases emerging from the US, Canada, Norway, Sweden, Denmark and the UK 
(Stevens, Tanner et al. 1989, Martin and Hoiby 1990, Stromberg, Romanus et al. 1991, 
Andersen and Ronne 1995, Cartwright, Logan et al. 1995, Stevens 1995, Holm 1996, 
Maganga, Kapetshi et al. 2014).  
 
The increase in cases of iGAS in the developed world has paralleled the emergence of 
emm1 (M1T1) and emm3 (M3) clones, which are commonly associated with outbreaks 
demonstrating high mortality rates (Schwartz, Facklam et al. 1990, 2014, Gostin, Hodge et 
al. 2014). The high mortality associated with iGAS is attributed to the development of TSS 
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with death occurring within the first 7 days (O'Loughlin, Roberson et al. 2007, Lamagni, 
Darenberg et al. 2008).  Of relevance to this thesis, infections have been reported to 
occur in healthy young adults with no predisposing medical conditions apart from a 
history of an upper respiratory tract infection or episode of minor non penetrating 
trauma (Stevens 1992). 
 
Within the UK, the reported incidence rate of iGAS is 3.3 per 100,000 (Lamagni, Neal et al. 
2008), with research showing that the majority of cases are caused by emm 1, 3 and 89 
genotypes in comparison to the main emm types found in symptomatic oropharyngeal 
infections (Figure 1.2). 
 
Figure 1.2 The distribution of emm types found among non-invasive and invasive 
GAS isolates.  
Shown is the distribution of non-invasive isolates (left chart, n=135 isolates from west 
London, April – November 2009, data Imperial College London) and invasive GAS isolates 
(right chart, n=124 isolates from London region, January – November 2009, data Public 
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Health England).  Emm types 1, 3 and 89 cause the majority of invasive infections, while 
emm 12 strains are the leading cause of non-invasive infections 
1.2.2 Risk Factors 
There are a number of risk factors associated with the development of iGAS specific to the 
host, environment or the pathogen (Table 1.1). Prevention of iGAS is difficult as the 
majority of cases occur spontaneously in the community (Davies, McGeer et al. 1996, 
Lamagni, Darenberg et al. 2008, Butler and Morello 2014, Gostin, Hodge et al. 2014) 
Year Geographical 
Location 
Incidence 
of iGAS in 
cases per 
100,000 
Case 
fatality 
from 
invasive 
disease (%) 
Risk factors 
for iGAS 
Common 
serotypes 
Cases of 
NF/ 
Myositis 
 (%)  
Case 
fatality 
 NF (%) 
Reference 
1982
-
1993 
Melbourne, 
Australia 
Not known 
(children) 
3 (7) Malignancy, 
diabetes, 
chronic liver 
disease 
M1, M12 1 (2) 0 (0) (Carapetis, 
Robins-
Browne et 
al. 1995) 
1987
-89 
Denmark Not known 52 (22) Debilitated 
and healthy 
(highest 
mortality) 
M1, 
remainder 
as others 
Not 
Known 
Not 
reported 
(Andersen 
and Ronne 
1995) 
1987
-
1988 
Norway 11 25 (29) Older 
children, 
middle aged 
M1 and M3 5 (6) 1 (1) (Martin and 
Hoiby 
1990, 
Bucher, 
Martin et 
al. 1992, 
Gostin, 
Hodge et 
al. 2014) 
1988
-
1999 
Sweden 2.26 
(mean over 
3 y) 
76 (18) 
over 2 y 
SSTI, 
cardiovascul
ar disease, 
alcohol, 
trauma, 
pregnancy, 
DM, IVDU 
M1, other 
M types not 
described 
Not  
Known 
31 (41) 
did not 
specific 
NF but 
SSTI foci 
(Stromberg
, Romanus 
et al. 1991) 
1992 
- 
1993 
Ontario 
Canada 
1.5 50 (15) HIV, heart 
and lung 
disease, DM, 
Cancer and 
alcohol 
M1, 3, 4, 
12 and 28 
19 (6) 9 (18) (Davies, 
McGeer et 
al. 1996) 
1995
-
1999 
5 US states: 
Georgia, 
Minnesota, 
Oregon, San 
Francisco, 
Connecticut 
3.5 1200 (12) Age (<2 and 
>65), 
African-
American, 
HIV infection 
and IVDU 
M1,28, 12, 
3, 11, 4, 
114, 89, 77 
and 33 
143 (7.1) Not 
reported 
(O'Brien, 
Beall et al. 
2002) 
1995
-
2006 
Minnesota, US 1.9 
(estimate) 
222 (12) Nursing 
home 
residents 
only and 
Age>65 
M1, M89, 
M28 and 
M3 
Not 
reported  
Not 
reported 
(Rainbow, 
Jewell et 
al. 2008) 
1996
-
2009 
Germany Not known Not reported Varicella 
zoster, 
immunosupp
ression, 
surgery, 
M1, M28, 
M3, M12 
and M89 
285 (19) Not 
reported 
(Imohl, van 
der Linden 
et al. 2011) 
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pregnancy, 
IVDU, DM, 
chronic 
diseases. 
1997
-
1999 
Atlanta 
Georgia 
USA 
1.6   18 (13) HIV, IVDU, 
household 
contact (one 
or more 
children with 
a sore 
throat), DM, 
cardiac 
disease, 
corticosteroid
s and 
cancer.  
Not known 9 (6) Not 
reported 
(Factor, 
Levine et 
al. 2003) 
 Baltimore 
Maryland 
USA 
2.0 
 Toronto-Peel 
Ontario 
Canada 
1.1 
1999
-
2004 
Calgary, 
Canada 
4.27 Not 
recorded 
Male, 
increasing 
age 
N/A 44 (19) 
SSTI 
focus did 
not 
specify 
NF 
Not 
recorded 
(Laupland, 
Ross et al. 
2006) 
2000
-
2004 
United States 3.5 735 (13.7) Elderly, 
infants, Black 
M1, M3 
and M12 
389 (7.2) 92 (23.7) (O'Loughlin
, Roberson 
et al. 2007) 
2001
-
2005 
Japan Not known 
but 137 
isolates 
Not known Not known M1, M3, 
M89, M12, 
M28 
Not 
reported 
Not 
reported 
(Ikebe, 
Hirasawa 
et al. 2007) 
2002
-
2004 
Australia 2.7 26 (7.8) Elderly >65 
years and 
young <5y 
M1, M12, 
M22, M28, 
M3 
30 (9) 5 (17) (O'Grady, 
Kelpie et 
al. 2007) 
2002
-
2010 
Utah, US 6.3 6 (7) Age 18-64, 
Hypertension
, liver 
disease, 
heart 
disease, 
pulmonary 
disease, DM 
Not known 61 (4) 8 (13.1) (Stockman
n, Ampofo 
et al. 2012) 
2003
-
2004 
UK, channel 
islands and Isle 
of Man 
3.3 413 (19) – 
in first 7 
days of 
diagnosis 
Age, trauma, 
DM and 
IVDU 
Not known 136 (5) 46 (34) 
within 7 
days of 
diagnosis 
(Lamagni, 
Neal et al. 
2008) 
2003
-
2004 
Europe: Cyprus, 
Czech republic, 
Denmark, 
Finland, France, 
Germany, 
Greece, Italy, 
Romania, 
Sweden and UK 
2.79 (crude) 643 (19) Elderly and 
skin 
infections 
Not 
described 
441 (8) 25 (8) (Lamagni, 
Darenberg 
et al. 2008) 
2005
-
2007 
Fiji 9.9 19 (32) Age<5 
or>65y.  
Chronic 
disease 
including 
diabetes and 
renal disease 
No 
particular 
dominant 
M type 
4 (7)  1 (25) (Burnouf, 
Emmanuel 
et al. 2014) 
2006
-
2009 
Norway 5 6 (10)  Chronic 
heart 
disease, 
Age>65 or 
15-40 
M1, M3, 
M12, M28, 
M82 and 
M89 
14 (23) Not 
reported 
(Kittang, 
Bruun et 
al. 2011) 
2000
-
2002 
Alberta, Canada 3.27 44 (11) Age >65 or 
<1y. Hx of 
varicella, 
winter 
months 
M1, M3 53 (12) Not 
specified 
(Tyrrell, 
Lovgren et 
al. 2005) 
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2004
-
2009 
Queensland, 
Australia 
3.5 (<18y) 
13.2 
(indigenous 
population) 
4 (4) Indigenous 
population, 
age<1y, 
male, blunt 
trauma 
M4, M1, 
M12, M49, 
M89, M41 
*(mixed 
distribution) 
1 (1) 0 (0) (Whitehea
d, Smith et 
al. 2011) 
2006
-
2009 
Canada Not known Unknown Alcohol 
abuse, 
homelessnes
s, HCV 
infection, 
illicit drug 
use, surgery, 
post partum 
infection,  
M1, M59 73 (23.1)  (Laupland, 
Ross et al. 
2006) 
2012
-
2013 
Ireland 2.66 8 (12.5) Elderly and 
young 
M1, M28 Not 
described 
Not 
describe
d 
(Meehan, 
Murchan et 
al. 2013) 
 
Table 1.1 Studies of invasive GAS disease.  
The table shows surveillance studies assessing the incidence and risk factors involved in 
the development of iGAS particularly NF.  The common M serotypes involved in iGAS are 
listed. Within the table the following are described: M= M serotype, IVDU = Intravenous 
drug user, HIV = human immunodeficiency virus, HCV = Hepatitis C virus, DM = Diabetes, 
NF = Necrotising fasciitis.  A systematic review focused on studies assessing the 
epidemiological and clinical features of iGAS performed between 1986 and September 
2014 by searching the PubMed database. Performed from 1986 to Sep 2014 searching 
PubMed were included in this table. 
 
Common to many of the studies shown in Table 1.1 is the emergence of invasive 
infections in the middle age group consisting of older children and young adults.  M1 and 
M3 have emerged as the most common serotypes involved in infections and there 
are cases of necrotizing fasciitis or myositis reported in the majority of studies. 
 
1.2.3 Host Factors 
Age has been frequently recognized as a risk factor for the development of iGAS (Factor, 
Levine et al. 2005). Infants and the elderly (particularly over 65 year olds) are at high risk 
of disease and mortality from iGAS (Martin and Hoiby 1990, Stromberg, Romanus et al. 
1991, Davies, McGeer et al. 1996, Tyrrell, Lovgren et al. 2005). In children there is a 
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reduced immune response and increased susceptibility to iGAS, although the incidence is 
low in comparison to infants under the age of 1.  iGAS in children occurs particularly in 
association with other infections such as varicella (Imohl, van der Linden et al. 2011) and 
upper respiratory tract viruses such as influenza (Wong-Chung 2012). These viruses 
disrupt anatomical barriers of skin and respiratory epithelium, providing a portal of entry, 
allowing GAS to adhere and invade deeper tissues, and additionally serve to prime the 
immune system (Okamoto, Kawabata et al. 2003, Okamoto, Kawabata et al. 2004). The 
rise in iGAS in the elderly is most likely due to a reduced immunity and increase in other 
co-morbidities (Anton 2007). However the recent upsurge in iGAS has been associated 
with the appearance of a more dominant clone of streptococci infecting healthy young 
adults aged 18 to 44 years (Stevens 1992, Factor, Levine et al. 2005). 
 
Other host factors responsible for the development of sporadic iGAS have been 
highlighted including skin trauma (penetrating or blunt) or skin infections such as varicella 
zoster, HIV infection, diabetes mellitus, cardiovascular disease, alcohol abuse, 
malignancy, use of steroids and other chronic diseases (Stevens 1992, Hoge, Schwartz et 
al. 1993, Davies, McGeer et al. 1996, Smith, Lamagni et al. 2005).  Some studies 
comment on geography and race predisposing to development of invasive disease (Mulla 
2002, Carapetis, Steer et al. 2005, 2014). 
 
Host genetic susceptibility to infection has been widely studied in relation to more chronic, 
less rapidly lethal conditions such as tuberculosis and HIV. Studies of genetic susceptibility 
to iGAS are limited by the number of patients who die from the disease, but, nonetheless, 
at least one study has linked HLA class II to protection or risk; whether this is linked to 
superantigen sensitivity is unclear (Kotb, Norrby-Teglund et al. 2002) and further in vivo 
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work supports the association (Nooh, El-Gengehi et al. 2007). There are currently at least 
two on-going studies that will examine host genetic susceptibility to rheumatic heart 
disease, and one pilot study in the UK related to iGAS (Parks 2014) .  
 
1.2.4 Environmental factors 
There is increasing concern regarding the transmission of GAS and the propensity for 
contacts of iGAS cases to develop invasive disease (PHE 2004) . The main environmental 
factors significantly associated with iGAS disease are: three or more people living in the 
house (i.e. household size) with the index case and the presence of a child with a sore 
throat (p<0.05). Work environment including number of people at work, number of hours 
worked and the presences of an ill person were not significantly associated with iGAS 
(Factor, Levine et al. 2005). 
 
 For maternal sepsis, the risk of household GAS sore throats has been highlighted, but not 
quantified, although the risk of nosocomial transmission is recognised both from infected 
healthcare workers and other patients, and through contaminated fomites (Steer, Lamagni 
et al. 2012). Indeed, roughly 10-12% of all iGAS is estimated to be nosocomial rather than 
sporadic. As invasive infection is notifiable in some countries, there are data to quantify 
the risk to household contacts of iGAS; this relative risk varies from a 200 to a 2000-fold 
increase (Carapetis, Robins-Browne et al. 1995), and may provide the basis for 
intervention in households where an iGAS case is detected (Robinson, Rothrock et al. 
2003).  
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1.2.5 Pathogen-associated factors 
It is thought that the increase in iGAS cases seen from the 1980s onwards may be 
associated with a change in virulence of the pathogen (Stevens 1992). Of particular note 
is the high proportion of M1 and 3 serotypes in cases many of which are associated 
with diseases like NF, pneumonia and TSS (Table 1.1). In contrast, developing 
countries report a mixture of M serotypes with no particular serotype being more 
dominantly represented, while there are also fewer cases of NF (Carapetis, Steer et al. 
2005).  In the UK, emm1/M1 GAS has remained the dominant cause of iGAS, at times 
causing almost 50% of cases. Although emm3, and also emm89, strains have caused 
surges in iGAS in the last decade becoming the most dominant types on occasion, such 
episodes have been short-lived (<6 months). This suggests that these pathogens may 
acquire new virulence factors in waves that favour expansion in the population, but are 
eventually countered either by population immunity, or change in environment, or 
emergence of other more dominant pathogenetic traits or strain types. It is therefore 
interesting that the emm1/M1 clone has remained dominant throughout.  
 
1.2.6 Acquisition of GAS and transmission 
GAS enters via the skin or mucous membranes and tends to cause sporadic infections, 
although person-person spread has been reported (Ramage, Green et al. 1996) and quite 
often there is no defined site of entry (Stevens 1992, Yamin, Gertler et al. 2014).  GAS has 
the unique ability to colonise and persist in within the pharynx or in skin tissue transmitting 
through droplet spread or skin contact.  However, there have been reports of outbreaks 
occurring through ingestion of food leading to tonsillitis or pharyngitis (Sarvghad, Naderi et 
al. 2005). Studies have shown an increase risk of iGAS following a rise in the carriage 
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rates of GAS (Crum, Hale et al. 2004, Crum, Russell et al. 2005) and if there are 
household contacts (Robinson, Rothrock et al. 2003).  
 
1.2.7 Clinical Features 
The clinical features of invasive GAS disease depend on the portal of entry and site of 
infection and whether there is development of bacteraemia, sepsis and streptococcal toxic 
shock syndrome (TSS).  Shown in the table are a summary of the main clinical diseases 
and how the initial site of infection dictates their presentation. 
Site of infection Clinical Diseases 
Soft tissue 
 
Respiratory 
Genital Tract 
Rare 
Cellulitis, arthritis, bursitis, NF and 
myositis 
Pneumonia, mediastinitis and empyema 
Myometritis, peritonitis 
Endocarditis, meningitis 
All of the clinical presentations may be complicated by: 
Bacteraemia 
Severe sepsis 
Toxic Shock syndrome 
Table 1.2 Summary of the clinical presentation of iGAS and complications 
 
Where possible a thorough history should be taken from patients suspected to have an 
iGAS disease, focusing on a history of injury or prior respiratory tract infection particularly 
when there is no obvious portal of entry (Stevens 1995). Patients with TSS experience flu-
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like symptoms including fever, chills, myalgia, diarrhoea and quite often nausea and 
vomiting (Stevens 1992, Stevens 2000, Ruotsalainen, Karden-Lilja et al. 2008).  Severe 
pain is reported as a presenting feature of patients with NF and/or TSS often preceding 
many physical signs.  Other areas of the history are important including a history of non-
steroidal anti-inflammatory use or contact with an individual with acute tonsillitis (Morgan 
2010). 
 
Physical findings such as fever and confusion are non-specific but occur often in patients, 
whilst skin changes like swelling, colour change and tenderness can occur later 
particularly in patients with NF (Morgan 2010). Often patients are hypothermic and, by the 
time of admission, many patients are hypotensive particularly in cases of STSS associated 
with diffuse capillary leaking and activation of the inflammatory response through the 
action of the superantigens (Hackett and Stevens 1993). 
 
1.3 Group A Streptococcal Necrotising Fasciitis 
 
Figure 1.3 Group A streptococcal necrotising fasciitis: late stages of clinical 
presentation   (Courtesy of Dr Marina Morgan, Devon and Exeter Hospital) 
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Necrotising fasciitis is colloquially known as the “flesh eating disease” (Loudon 1994, 
Cartwright, Logan et al. 1995) and is a severe GAS infection causing progressive 
destruction of the subcutaneous and deep soft tissue and in some cases muscle, often 
sparing the skin (Wilson 1952, Ruotsalainen, Karden-Lilja et al. 2008). The exact global 
burden of disease is unknown, as most epidemiological studies report on the incidence of 
invasive disease, but sporadic outbreaks have been reported (Crum, Hale et al. 2004, 
Ruotsalainen, Karden-Lilja et al. 2008). NF can be caused by a range of pathogens 
including GAS, Clostridium perfringens or septicum and other gram negative and 
anaerobic bacteria (Stevens 1995). Since its re-emergence in the 1980’s, NF and 
myonecrosis caused by GAS yielded attendant mortalities of over 40% particularly when 
associated with TSS, despite aggressive medical and intensive care support (Stevens 
1995).  Mortality is even higher in developing countries (Carapetis, Steer et al. 2005) and 
in the absence of surgical treatment (Cole, Barnett et al. 2011).  
 
There have been descriptions of GAS NF since Hippocrates (Goldsmith 1863, Jones 1923, 
Meleney 1924, Meleney 1929) with the original definition proposed by Wilson in 1952 
based on the histopathological features of the disease (Wilson 1952). Cases of GAS NF 
were commonly seen in periods of war where the infection was associated with 
penetrating trauma. However in the early 20th century, cases of GAS NF, known as 
‘haemolytic streptococcal gangrene’, were described in healthy young individuals with a 
prior history of non penetrating trauma by Meleney in China (Meleney 1924, Meleney 
1929).  Meleney reported cases whose symptoms and signs developed 24h following an 
injury and progressed over a period of 7 days whereby the clinical condition of the patient 
deteriorated and the progressive gangrene (NF) that ensued was caused by haemolytic 
streptococci and/or anaerobic bacteria. His description of cases in China occurred prior to 
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the discovery of antibiotics such as penicillin and sulphonamides, and where management 
of infections relied on disinfection and aggressive “bear claw” fasciotomies and 
debridement (Meleney 1924, Meleney 1929). Despite an absence of antibiotics, mortality 
was 20%, still lower than seen today, suggesting that both the virulence of the organism 
and host response can influence disease outcome (Stevens 1995). 
 
Following the wider use of penicillin (Bud 2007, Kardos and Demain 2011) there was a 
dramatic decline in cases of GAS NF until the late 1980s, where cases emerged in young 
healthy individuals (Adams, Gudmundsson et al. 1985, Stevens 1995).  Many patients 
presented with non-specific symptoms of severe sepsis including fever, vomiting and 
diarrhoea, and often a prior respiratory tract illness or injury was reported (Olsen and 
Musser 2010). 
 
1.3.1 Streptococcal myositis 
GAS myositis or myonecrosis is often associated with GAS NF, as the result of spread of 
bacteria and destruction of deeper muscle tissue (Hubens, Carly et al. 1989) although it 
can occur in isolation. Streptococcal myositis is rare with a higher mortality rate than NF 
alone, 80% versus 20-50% (Adams, Gudmundsson et al. 1985). Cases can be 
distinguished from NF by surgical exploration or incisional biopsy.  Other bacteria 
presenting with myositis include Clostridium perfringens and Clostridium septicum, 
demonstrating gas at the infection site.   Although historically clostridial infections and 
gangrene are associated with penetrating injury and soil-contaminated wounds, more 
recently this pathogen has been found at sites of infection occurring following 
comparatively minor trauma (Hubens, Carly et al. 1989). In some reports, the mortality of 
NF due to this pathogen appears to be lower than GAS (Morgan 2010). 
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1.3.2 Risk Factors for GAS NF 
Both the predisposition to develop GAS NF and its overall prognosis are affected by host 
factors including associated medical co-morbidities and genetics (Olsen, Shelburne et al. 
2009). NF unlike other iGAS is uncommon among babies and children, suggesting an age 
specific feature may exist, although cases of iGAS and NF do occur in children with 
varicella zoster infections (Lamagni, Neal et al. 2008). Other co-morbidities like 
intravenous drug use (IVDU), diabetes, non-steroidal inflammatory drugs (NSAIDS), 
alcoholism and malignancy predispose people to invasive disease including NF (Table 
1.1) by altering the host immune response, causing anatomical or physiological changes in 
the host and may be responsible for outbreaks in healthcare settings (Daneman, Green et 
al. 2007).  
 
1.4 Association of GAS NF and injury 
GAS NF occurs either through direct entry of GAS into tissue through a bite, injury or 
damage to the skin surface from infections like varicella zoster or burns (Stevens 1995). 
More recently, GAS NF has been found in patients with a non penetrating injury or muscle 
strain (Table 1.3) and in some no obvious portal of entry with many patients report a 
history of a upper respiratory tract (URTI) infection (Olsen and Musser 2010). It is 
hypothesised that, following a GAS URTI, there is a transient GAS bacteraemia allowing 
the pathogen to travel from the throat to a site of injury, although this has not been 
categorically demonstrated (Stevens 1995, Hamilton, Bayer et al. 2008, Seki, Saito et al. 
2008).  It is further hypothesised that the bacteraemic seeding of injured tissue arises 
because of specific interactions between GAS and injured host tissue in particular the 
increased expression of vimentin by muscle cells (Bryant, Bayer et al. 2006, Hamilton, 
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Bayer et al. 2008). Consequently, there are many factors crucial to GAS dissemination in 
NF including virulence factors (illustrated in Figure 1.6) and gene regulatory systems 
affecting the ability of GAS to adapt to the environment and the host response. The 
central aim of this thesis is to develop the models and systems to explain the 
observed link between iGAS and blunt trauma. 
1.4.1 Epidemiological evidence   
History is replete with descriptions of GAS NF being associated with trauma particularly 
due to penetrating wounds. More recently GAS NF has been reported to develop at sites 
of previous non penetrating minor trauma (Lamb, Sriskandan et al. 2015), for example a 
muscle strain or contusion (Adams, Gudmundsson et al. 1985, Svensson, Brookstone et 
al. 1985, Hird and Byrne 1994, Sellers, Woods et al. 1996, Nothwang and Ulrich 1998, 
Jallali 2004, Raffoul, Fournier et al. 2010, Heinze, Puschel et al. 2011, Radovan, Ilic et al. 
2011, Baker 2012).  These are summarised in Table 1.3.  Larger studies from North 
America and the UK report that nearly 25% of GAS NF is associated with non-penetrating 
trauma (Kaul, McGeer et al. 1997, Monnickendam, McEvoy et al. 1997).    
 
To determine if there was a recall bias in patients with iGAS reporting antecedent trauma, 
a prospective population-based study was undertaken, that showed a significant 
association between non-penetrating trauma and GAS NF but not GAS cellulitis 
(Nuwayhid, Aronoff et al. 2007). The study involved a secondary analysis of patients who 
were hospitalised in Florida for iGAS (n=211) between August 1996 and 2000. From this 
cohort, two case series were used, patients with severe cellulitis (n=63) or GAS NF (n=37).  
The prevalence of blunt trauma was higher among the GAS NF compared to controls 
(patients with iGAS but no cellulitis or NF, n=111); 10.8% versus 3.6% respectively, with 
cases six times as likely to have blunt trauma as a predisposing factor (adjusted OR=5.97, 
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p=0.04). In comparison the prevalence of blunt trauma in the severe cellulitis group was 
4.8% with there being reduced risk of blunt trauma being a predisposing factor (adjusted 
OR=1.13, p=0.07).   Thus, although many cases of NF arise spontaneously, and without 
reported or recalled antecedent trauma, there does appear to be an association between 
the two conditions, although this epidemiological study may have been underpowered to 
detect an association between GAS cellulitis and trauma (Nuwayhid, Aronoff et al. 2007). 
 
1.4.2 Genome Analysis 
More recently the publication of whole genome sequences of many different serotypes of 
GAS provides further information linking the particular serotypes to cause different clinical 
diseases enhancing our understanding of epidemics of iGAS (Beres, Sylva et al. 2004). 
The majority of the GAS genome is homologous between serotypes, however about 10% 
is variable and attributed to differences in mobile genetic elements or prophages which 
encode virulence factors such as the two component regulatory systems as previously 
described (Olsen and Musser 2010). Many GAS strains vary by single nucleotide 
polymorphisms (SNPs) and analysis of SNPs has revealed specific virulence axis 
important in the molecular pathogenesis of GAS NF, like mtsR-prsA-SpeB (described later 
in this section).   
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Ta
ble 1.3 Case reports demonstrating the association between non-penetrating 
traumatic injury and GAS NF.  
The table illustrates case reports of patients developing GAS NF following a muscle strain 
or contusion injury.  The age, sex, country, site of injury/GAS NF and any predisposing 
factors are described.  A large number of the reports demonstrate the high mortality 
associated with GAS NF. Adapted from (Lamb, Sriskandan et al. 2015). 
 
 
Age Sex Country Site Risk factors Trauma Mortality Reference 
58, 
40 
Male, 
Female 
USA Limb Nil Skin injury 100% (Adams, 
Gudmunds
son et al. 
1985) 
38, 
29, 
43, 
41 
1 Male, 
3 
Female  
South 
Africa 
Arm Obesity Contusion of 
arm 
50% of 
GAS 
cases 
(Svensson, 
Brookstone 
et al. 1985) 
17 Male USA Thigh Nil Bruise from 
sport 
100%  (Hird and 
Byrne 
1994) 
46 6 Male, 
2 
Female 
USA Limb 5/8 history of 
chronic 
illness 
Blunt trauma, 
bee sting and 
ulcer 
25%  (Sellers, 
Woods et 
al. 1996) 
19  Male Germany Thigh Nil Fall on side 0% (Nothwang 
and Ulrich 
1998) 
36 Female Japan Right hip Nil Injury to right 
hip 
100% (Hirose, 
Shibuya et 
al. 2001) 
61, 
32 
Male USA Hand Rheumatoid 
arthritis 
(61 year old) 
Blunt trauma 
to the hand 
50% (Dahl, 
Perniciaro 
et al. 2002) 
42 Male UK Anterior 
chest 
Wall 
Epilepsy and 
heavy 
alcohol 
intake 
Collapse 
following 
convulsion 
0% (Jallali, 
Gebru et al. 
2004) 
46 Female France Hand/arm Nil Contusion  0% (Raffoul, 
Fournier et 
al. 2010) 
47 Male Germany Leg Likely NSAID 
injection 
Minor trauma 
to left leg 
during tennis 
100% (Heinze, 
Pschel et 
al. 2011) 
48, 
57 
Female 
Male 
Serbia Chest 
wall, 
upper 
limb and 
trunk 
NSAIDs - 
naproxen, 
aspirin and 
diclofenac 
Injury, Fall 100% (Radovan, 
Ilic et al. 
2011) 
33 Male UK Hamstring Nil Muscle strain 100% (Baker 
2012) 
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1.4.3 Laboratory Investigations and Management 
1.4.3.1 iGAS  
Laboratory investigations are most useful in the early part of the infection to help make a 
diagnosis.  Biochemical changes such as early renal impairment, hypoalbuminaemia, a 
rise in creatinine kinase and C-reactive protein occur often with invasive disease (Stevens 
1992).  Further microbiological investigations including blood, sputum, cerebrospinal fluid, 
fluid and tissue cultures can confirm the diagnosis of iGAS (Morgan 2010). Radiology 
including X-ray, ultrasound and CT or MRI can be used to locate the site of infection, 
confirm a presumed diagnosis and allow monitoring of the extent of disease. Most 
importantly, radiology can identify a source of sepsis that may be amenable to removal.  
 
Patients are managed according to the cause and severity of infection, although many 
patients present late, as signs of disease occur late, when the prognosis is extremely poor 
(Morgan 2010). Patients with associated TSS have a high mortality (Stevens 1995) and 
can deteriorate rapidly. The management of these patients usually takes place in a high 
dependency or intensive care setting where appropriate supportive care can be provided 
(Olsen and Musser 2010).  
 
Isolation and disinfection of patients and wounds was introduced in the late 19th Century 
during Civil war outbreaks of hospital gangrene (Goldsmith 1863, Manring, Hawk et al. 
2009) and forms an important part of preventing nosocomial outbreaks of iGAS disease 
(Ramage, Green et al. 1996). Surgical debridement and fasciotomy techniques from the 
early 20th Century have proved to be vital in the appropriate management of iGAS disease 
particularly those due to NF or myositis (Meleney 1924, Meleney 1929)  The discovery and 
manufacture of penicillin was influential to the treatment of patients with invasive GAS 
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infections and may be partially responsible for the decline in infections seen post World 
War 2 (Abraham, Chain et al. 1941, 1943, Bud 2007, Kardos and Demain 2011)  Other 
adjunctive antibiotics like clindamycin have been shown to be important in managing 
patients with iGAS particularly those with TSS (Stevens, Gibbons et al. 1988, Morgan 
2010).  Clindamycin has been shown to be beneficial in the inhibition of GAS toxin 
production through reducing protein synthesis (Stevens, Gibbons et al. 1988), although 
there is recent concern regarding an increase in resistance to clindamycin amongst GAS 
clinical isolates (Pesola, Sihvonen et al. 2015). 
 
The high mortality associated with iGAS is often due to TSS and, in certain cases, 
intravenous pooled immunoglobulin (IVIG) is recommended (Raithatha and Bryden 2012). 
It is thought that IVIG augments the humoral response, dampening the effect of 
superantigens produced by GAS and enhances bacterial clearance (Darenberg, 
Ihendyane et al. 2003, Norrby-Teglund, Ihendyane et al. 2003, Sriskandan, Ferguson et al. 
2006, Raithatha and Bryden 2012, Tan and Sriskandan 2014).  However much of the data 
supporting the use of IVIG is anecdotal and controlled trials have been limited by patient 
numbers; for this reason, use of IVIG in the UK for iGAS is permitted where patients fail to 
respond to first line therapy.   
 
1.4.3.2 Necrotising fasciitis 
It is vital that an early diagnosis of GAS NF is considered and investigated promptly as any 
delay can be life threatening even with intensive supportive care, surgery and 
antimicrobials.  Biochemical and radiological tests aid diagnosis but a tissue biopsy of 
infected tissue is required during surgical debridement, particularly as NF is a 
 
 
47 
histopathological diagnosis (Wilson 1952).  Samples of tissue obtained from a suspected 
case are sent for microscopy, culture and sensitivity and histological analysis.   
 
 
Figure 1.4 H&E histology slide from the tissue of a young girl with GAS NF of the 
lower leg.  
From the Atlas of Infectious Disease Pathology, Tsutsumi, 2000. The slide shows massive 
necrosis of the skin and subcutaneous tissue with an inflammatory infiltrate in a the thigh 
tissue of a young girl with NF. 
 
 
Sections of tissue from patients with NF show a marked inflammatory infiltrate containing 
degenerate white blood cells in particular neutrophils and organisms distributed along the 
fascial planes (Olsen and Musser 2010). Often the necrosis can lead to the inflammatory 
cell infiltrate being visualized beyond the fascial planes into the muscle leading to a 
myositis. There may be elevated acute phase cytokines including IL-6, IL-1β, TNF-α and 
IFN-ϒ (Rodriguez, Abdullah et al. 2006, Sjogren and Anderson 2009). More lethal 
necrotizing infections are characterized by a paucity of neutrophils at the site of bacterial 
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growth and this has been seen in fatal human cases and a baboon NF model (Taylor, 
Bryant et al. 1999, Edwards, Taylor et al. 2005, Goodman 2014).  
 
NF cases often require extensive surgical debridement and fasciotomies, aggressive 
antibiotic use, immunoglobulin and intensive care support (Morgan 2010) As seen in the 
management of iGAS, clindamycin can be important in preventing further tissue 
destruction, inhibiting the production of TSS which leads to deterioration of the patient and 
increased mortality (Olsen and Musser 2010). Similarly, intravenous immunoglobulin has 
been indicated as adjunct therapy to treat severely unwell patients with iGAS NF (Health 
2011, Raithatha and Bryden 2012). 
 
1.4.4 Prevention of iGAS 
 
An outbreak of iGAS is defined by two or more cases of culture confirmed symptomatic 
iGAS linked in time and place.  Despite the spread of GAS through contact with infected 
patients, there is little evidence in the UK to justify the use of chemoprophylaxis for 
contacts unless they develop symptoms (Smith, Lamagni et al. 2005). There is some 
evidence to suggest that most secondary cases of iGAS occur within 7 days following the 
presentation of the index case, although this is a rare event (Allen and Moore 2010). The 
UK approach differs from other countries approach to contact management probably as a 
consequence of experience of iGAS infections and attributable strains (Lamagni, 
Darenberg et al. 2008). Other preventative strategies including controlling the spread of 
infection through isolation of cases in hospital environments, disinfection of the 
environment and the thorough investigation of contacts of index cases (Steer, Lamagni et 
al. 2012). 
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1.5 Molecular basis of iGAS 
 
 
Figure 1.5 Molecular basis of iGAS. (Adapted from Cole et al, 2011)  
Shown above is a pictorial display of virulence factors upregulated by GAS during invasive 
disease.  Specifically resistance to neutrophil-mediated killing occurs by producing Dnase 
(Sda 1) leading to NET (neutrophil extracellular trap) destruction; streptolysin O (SLO) 
causing apoptosis of neutrophils, SpyCEP degrading IL-8 (interleukin 8), and streptococcal 
inhibitor of complement (SIC) and hyaluronic capsule reducing resistance to antimicrobial 
peptides. Bacterial streptokinase aids the production of plasmin, which enables the 
colonisation of host tissues. The majority of virulence factors are upregulated by a 
mutation in the covRS operon. 
 
As previously described, GAS is a human specific pathogen causing infection by 
colonizing the human host through the nasopharynx or skin. Following colonization, GAS 
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adapts to many different tissue sites in the human host by altering the transcription of key 
virulence factors allowing the destruction of local tissue barriers to facilitate dissemination. 
Further adaptation by the pathogen promotes evasion of the immune system allowing the 
production of other molecules essential to promote further invasion and soft tissue 
damage (Olsen, Shelburne et al. 2009). Survival of the pathogen relies on its ability to 
continually evolve to different environments through the production and regulation of 
virulence factors.  
 
It is likely that the horizontal acquisition of new virulence factors could partially explain the 
genetic basis for the increase in reporting of iGAS infections seen more recently.  
Consequently, emm 1 and 3 have been commonly associated with increasing iGAS 
(Beres, Sylva et al. 2002, 2014). Clones of certain emm types that have acquired phages 
encoding superantigens such as SPEA and SPEC have also been associated with TSS 
(Stanley, Linton et al. 1995). However despite the emergence of new virulent clones of 
GAS, there have been few outbreaks and it is thought that host factors like immunity make 
certain individuals more or less susceptible to develop iGAS (Stevens 2000, Johnson, 
Wotton et al. 2002, Ruotsalainen, Karden-Lilja et al. 2008).  
 
1.5.1 Gene regulators 
GAS possess a variety of gene regulators responsible for the activation and repression of 
gene expression enabling the pathogen to survive in the human host (Churchward 2007).  
Examples include “stand alone” transcriptional regulators like mga (multiple gene activator 
of GAS) or two component systems like the control of virulence regulatory system, covRS 
(Cole, Barnett et al. 2011).  Specifically, the two component sensor-regulatory systems 
 
 
51 
allow GAS to adapt to changes in its environmental surroundings by controlling the 
expression of particular virulence factors (Federle, McIver et al. 1999).  
1.5.1.1  The Control of virulence regulatory system (CovRS)  
 
One of the most common two component regulatory system is covRS, responsible for 
regulating 10-15% of the GAS genome, normally represses the expression of virulence 
factors, like for example the regulation of genes controlling the expression and production 
of capsule (Walker, Barnett et al. 2014). This system is essential to GAS survival in 
different environmental conditions including an elevated temperature, high salt 
concentration, low pH, presence of LL37 and iron starvation (Gryllos, Tran-Winkler et al. 
2008). It is the acquisition of mutations that seem to enhance further survival of GAS, 
enhancing the production of virulence factors needed for resistance to phagocytic killing 
and invasive infection (Cole, Barnett et al. 2011). 
 
CovRS encodes a membrane bound sensor kinase (CovS) and a response regulator 
(CovR) (Levin and Wessels 1998, Bernish and van de Rijn 1999, Federle, McIver et al. 
1999) allowing GAS to adapt to different environments as seen in invasive GAS disease 
(Dalton and Scott 2004). Following autophosphorylation of covS, there is transfer of a 
phosphate group to its response regular, covR that increases its affinity to various DNA 
binding sites (Dalton and Scott 2004, Dalton, Hobb et al. 2006, Churchward 2007).  Unlike 
many other response regulators, phosphorylation of covR leads to the repression of many 
promoter systems and gene systems many of which are important in GAS virulence. 
Examples include hasABC operon (responsible for the production of hyaluronic capsule), 
ska (streptokinase), sagA (streptolysin S), rivR (transcriptional regulator RivR of M 
protein), Streptococcal inhibitor of complement (SIC) and cepA (SpyCEP) (Churchward, 
Bates et al. 2009, Turner, Kurupati et al. 2009, Cole, Barnett et al. 2011).  In some cases, 
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phosphorylation of covR can reduce the repression of other virulence genes including 
speB (Cole, Barnett et al. 2011) with mutants of covS and covR decreasing levels of this 
protease (Mayfield, Liang et al. 2014). 
 
It is thought that covRS plays an important role in the dissemination of GAS systemically 
from a local source of infection.  Spontaneous mutations have been demonstrated in 
genes encoding covRS in M1T1 GAS strains (Sumby, Whitney et al. 2006, Walker, 
Hollands et al. 2007) allowing the de-repression of multiple virulence-associated genes 
(Cole, Barnett et al. 2011). More recently mutations of covS have been reported in in 
invasive M3 isolates (Shea, Beres et al. 2011)   
 
Mutations in covR or covS can affect the virulence of GAS in mouse models (Gryllos, 
Cywes et al. 2001, Engleberg, Heath et al. 2004, Dalton, Hobb et al. 2006, Graham, 
Virtaneva et al. 2006, Mayfield, Liang et al. 2014). In some cases mutations led to reduced 
virulence (Dalton, Hobb et al. 2006), whilst others showed increased virulence of GAS 
(Graham, Virtaneva et al. 2006, Sumby, Whitney et al. 2006).  Importantly, the M protein 
and hyaluronic capsule were integral to the selection of covRS mutations seen in vivo in 
mouse models of invasive disease, through the upregulation of the DNAase gene, sda1. 
Sda1 is a virulence factor involved in preventing the phagocytosis of GAS through the 
destruction of neutrophil extracellular traps (NETs) (Walker, Hollands et al. 2007). 
 
1.5.1.2 Regulator of Cov (RocA) 
Little is known about the regulation of CovR, although it has been shown that CovR can 
negatively regulate its own transcription, de-repressing its effect on virulence gene 
expression (Lynskey, Goulding et al. 2013). RocA is a gene which positively regulates 
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covR expression and is present in all sequenced GAS strains, including M1 and M3 
(Biswas and Scott 2003). RocA mutants are “mucoid” showing increased has transcription 
and markedly enhanced capsular hyauronan production compared with wildtype strains, 
through the de-repression of hasABC and enzymes controlling cell wall synthesis.  
Analysis of the sequence of rocA originally suggested that that it is unlikely to directly act 
on promoters as there are no obvious DNA binding motifs, therefore RocA was believed to 
affect transcription indirectly through covR which has been shown to be unique to GAS 
(Biswas and Scott 2003). More recent studies have shown rocA to be a metabolic 
regulator with actions reaching beyond the covR/S regulatory system, possibly acting as a 
kinase (Lynskey, Goulding et al. 2013).  Proteins affected included those involved in cell 
wall synthesis as well as the hasABC locus. The production of the hyaluronan capsule 
requires not only hasABC (to provide hyaluronan synthetase and glucuronan) but also a 
plentiful supply of N-acetyl glucosamine (GlcNAc) derived from cell wall synthesis. This 
may explain why GAS strains that do not produce a functional RocA, for example the 
entire M18 serotype that is characterised by hyperencapsulation, have a characteristic 
hypermucoid appearance that goes beyond any phenotype observed for covRS mutants 
(Lynskey, Goulding et al. 2013). 
 
1.5.1.3 Multiple-Gene Regulator (Mga) 
Unlike the covRS regulatory system, the multiple-gene regulator of GAS (mga) is a 
standalone regulator controlling 10% of the GAS genome, particularly genes involved in 
virulence, metabolism and sugar utilisation. The core regulon affects the production of M 
protein, C5a peptidase and Sic (Hondorp and McIver 2007) and the secondary mga 
regulon activates genes involved in carbohydrate and metabolic metabolism (Hause and 
McIver 2012). Mga has been found in all GAS strains examined so far and the two alleles 
mga1 and mga2 are associated with particular infections, throat (mga1) and skin (mga2) 
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and positively affect emm transcription and M protein production (Hondorp and McIver 
2007) particularly during exponential growth phase.  
 
During infection there is a change in sugar status of the environment leading to the 
expression of virulence genes by mga (Hondorp, Hou et al. 2013). In carbohydrate poor 
environments there is increased phosphorylation of Mga leading to down regulation of 
colonizing factors and dissemination systemically (Hondorp and McIver 2007). The 
inhibition of mga phosphorylation in a mouse model of invasive infection led to reduced 
invasion by GAS (Hondorp, Hou et al. 2013).  
 
1.5.1.4 The ihk-irr two component regulatory system 
This system regulates approximately 20% of the GAS genome (Ruotsalainen, Karden-Lilja 
et al. 2008) and has a sensor kinase, isp-histidine kinase (ihk) and isp-adjacent response 
regulator (irr) which respond to reactive oxidative species (ROS) produced by neutrophils 
in response to damaged host tissue (Peake and Suzuki 2004). Tissue damage may occur 
during exercise, injury or thermal stress (Butterfield, Best et al. 2006).  Inactivation of this 
two-component system in a mouse model reduces the virulence of GAS due to increased 
phagocytosis of strains lacking irr, with GAS becomes more susceptible to neutrophil 
killing (Voyich, Braughton et al. 2004).  
 
More recent studies have illustrated the ability of GAS to survive intracellularly within 
macrophages through M protein-dependant mechanisms, which rely on the inhibition of 
maturation of phagosomes (Hertzen, Johansson et al. 2010). Recent work using 
microarray analysis has shown there is a change in gene expression over time following 
an infection.  The ihk-irr TCS was critical in the earlier time points allowing GAS to persist 
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intracellularly in macrophages, whilst at 6h post infection, the covRS TCS is upregulated, 
enabling the bacteria which have migrated from the cells to infect further cells (Hertzen, 
Johansson et al. 2012).The ihk-irr TCS has been important in other Streptococcal related 
pathogens such as Streptococcus suis, whereby a mutation in the TCS contributes to an 
attenuation in virulence, reducing the ability of the pathogen to survive in an acidic or 
oxidative stressed environment (Han, Liu et al. 2012). 
 
1.5.2 RofA-like protein IV (RivR) 
RivR is a member of the RofA-like protein family of transcriptional regulators which is 
unique to GAS and plays an important role in gene expression (Roberts, Churchward et al. 
2007). RivR functions through dependent and independent covR pathways (Trevino, Liu et 
al. 2013) and has been shown to be particularly important in GAS colonisation. In 
colonisation RivR is a negative transcriptional regulator of hyaluronic acid capsule 
synthesis, allowing GAS to produce proteins for optimal adherence.  Consequently, rivR 
mutants show enhanced capsule production and, therefore, reduced adherence to 
keratinocyte cells with the affect being abolished through the addition of hyaluronidase. 
Furthermore rivR mutants showed attenuation in a mouse model of bacteraemia (Trevino, 
Liu et al. 2013). 
 
1.5.3 Resistance to the Immune Response 
 
GAS possesses virulence factors involved in the evasion of the host immune response. 
Examples include the anti-phagocytic M protein, hyaluronan capsule, SIC (streptococcal 
inhibitor of complement), enzymes such as cysteine protease (SpeB) and IdeS that can 
cleave immunoglobulin, and the chemokine cleaving protease SpyCEP. 
 
 
56 
1.5.3.1 M Protein 
Following its classification at the beginning of the 20th century, over 100 M serotypes have 
been described; M1 and 3 serotypes predominating among cases of iGAS. (Table 1.2)  
The M protein is expressed on the surface of all GAS strains and during invasive GAS 
infections promotes survival by resisting phagocytosis and enhancing GAS binding to 
extracellular matrix promoting further invasion (Smeesters, McMillan et al. 2010). Although 
many complement inhibitory proteins such as factor H and C4 binding proteins attach to M 
protein theoretically preventing the deposition of complement, a definite role for FH binding 
has yet to be proven (Horstmann, Sievertsen et al. 1988, Persson, Beall et al. 2006) 
Fibrinogen and plasminogen bind to M protein and through inhibition of C3 convertase and 
C3b deposition prevent further phagocytosis by neutrophils (Carlsson, Sandin et al. 2005, 
Ly, Taylor et al. 2014).  Indeed, the binding of fibrinogen by M protein may in fact outweigh 
any other binding activities demonstrated.  
 
The M protein is a fibrillar protein, in which the mature form is attached to the 
peptidoglycan cell wall through the action of the sortases and LPXTG motif.  Like other M 
proteins it shares the common framework, which includes a conserved signal peptide, a 
hypervariable region and a conserved C terminus.  Specifically M1 protein contains no A 
repeats (unlike M6) but contains 2 B repeats thought to be involved in the binding of 
fibrinogen allowing the formation of the M1-fibrinogen complex, one of the key pro-
inflammatory properties of M1 (Macheboeuf, Buffalo et al. 2011).  The binding of 
fibrinogen to M proteins will depend on whether the M protein is anchored or released. 
Released M protein-fibrinogen complex binds to β2 integrins activates neutrophils and 
leads to vascular leakage (Smeesters, McMillan et al. 2010) and activation of the 
inflammatory response (Pahlman, Morgelin et al. 2006).  
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1.5.3.2 Capsule 
The hyaluronic capsule surrounds the majority of GAS strains and plays an important role 
in virulence and adaptation of GAS to changing environments (Gryllos, Cywes et al. 2001). 
Often GAS strains associated with invasive disease are highly encapsulated or “mucoid” 
(Martin and Hoiby 1990, Johnson, Stevens et al. 1992). The enzymes required for capsule 
synthesis are controlled by the expression of the hasABC synthase operon present in all 
strains except M4 and M22 (Crater and van de Rijn 1995, Flores, Jewell et al. 2012).  
Capsule production requires only hasA encoding hyaluronate synthase.  The other genes 
hasB and hasC encode two enzymes involved in the biosynthesis of activated sugars.  
Previously it has been shown that expression of the has operon is under the control of a 
single promoter P1 which is located upstream of hasA (Dougherty and van de Rijn 1994) 
and affected by growth phase with the majority of capsule being  produced in mid to late 
log phase, declining in stationary phase (Crater and van de Rijn 1995). Furthermore, 
transcription of the hasABC operon is regulated by the covRS regulatory system, with the 
response regulator CovR binding to AT rich DNA regions surrounding P1 promoter 
(Federle and Scott 2002).  Spontaneous mutations in CovRS genes arise during in vivo 
infections and result in capsule overproduction and hypervirulence (Sumby, Whitney et al. 
2006).  Although, many of the GAS isolates arising with a functioning CovRS system also 
produce large amounts of capsule suggesting another mechanism may be involved (Cao, 
Liu et al. 2014).  More recently, a complex novel regulatory region upstream of P1 has 
been identified and acts to control transcription of the has operon and contains two 
promoters and a transcriptional terminator contributing to GAS virulence, as deletions 
within this region has a positive effect on has operon transcription and capsule 
biosynthesis (Falaleeva, Zurek et al. 2014).  Furthermore the new mutant has been shown 
to be resistant to neutrophil killing and virulent in a mouse model of iGAS. 
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Capsule contributes to the virulence of GAS by providing the bacteria with a mechanism of 
resistance to complement-mediated phagocytosis by blocking the binding of antibody to 
surface epitopes (Dale, Washburn et al. 1996), known as molecular mimicry.  Capsule 
promotes GAS survival within neutrophil extracellular traps by inhibiting the human 
antimicrobial peptide cathelicidin (Cole, Pence et al. 2010).   
 
In mouse models of invasive infection capsular strains were more virulent than acapsular 
strains (Gryllos, Cywes et al. 2001, Engleberg, Heath et al. 2004, Cole, Pence et al. 2010). 
Further work illustrated the importance of capsule in enhancing virulence following an 
initial viral respiratory tract infection (Okamoto, Kawabata et al. 2004). Interestingly, M4 
and M22 GAS strains have been shown to survive and resist phagocytosis in human 
whole blood despite a genetic absence of capsule (Ruotsalainen, Karden-Lilja et al. 2008, 
Flores, Jewell et al. 2012) suggesting that other virulence mechanisms may compensate 
during invasion by these strains.    
 
Capsule is important to carriage longevity; it was recently shown that the highly 
encapsulated M18 GAS serotype (a result of a RocA mutation) was shed for long periods 
in a mouse model of nasopharyngeal infection (Lynskey, Goulding et al. 2013). However, 
capsule can also inhibit adhesion to proteins such as collagen and fibronectin hence may 
impede tighter attachment that can result in true carriage or invasive infection.  
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Figure 1.6 A picture illustrating the positive and negative regulators of capsule 
synthesis in GAS.  
Positive regulation of the hyaluronic capsule of GAS is by ccpA (catabolite control protein 
A).  Other factors including CovRS, rgg, rivR and rocA negatively regulate the production 
of hyaluronic capsule. 
 
1.5.3.3 Streptococcal inhibitor of complement (SIC) 
Streptococcal inhibitor of complement (SIC) is a secreted virulence factor produced 
predominantly by emm1 strains (Akesson, Sjoholm et al. 1996). SIC affects the innate 
immune response by binding to the membrane attack complex, preventing complement 
mediated lysis and inactivates a number of antimicrobial peptides including alpha-defensin 
and LL-37 (Frick, Akesson et al. 2003, Sagar, Kumar et al. 2008). SIC enhances bacterial 
dissemination and efficient colonisation of the mucosal surface (Lukomski, Hoe et al. 
2000), which may explain the increased frequency of invasive GAS infections due to the 
M1 serotype (Mylvaganam, Bjorvatn et al. 2001, Frick, Shannon et al. 2011). More 
recently SIC has been shown to inhibit the actions of common commensals such as 
streptococcus salivarus, a prominent colonizer of mucosal surfaces of the oropharynx 
(Frick, Akesson et al. 2003, Minami, Ohmori et al. 2009), underlining the potential of this 
protein to advance the dominance of the emm1 GAS clonal type. 
 
Negative 
regulation 
covRS 
rgg 
rivR 
Positive 
regulation 
ccpA 
rocA 
!
Hyaluronic Capsule of 
GAS 
 
 
60 
1.5.4 Antimicrobial peptides  
Antimicrobial peptides (AMPs) are small but important components of the innate host 
defence (Walker, Barnett et al. 2014), originating from plants or animals and range in size 
from 2 to 5kDa (Gryllos, Tran-Winkler et al. 2008). AMPs have antimicrobial activity 
against a wide range of pathogens including viruses, bacteria and fungi (Jenssen, Hamill 
et al. 2006). Examples of AMPs include LL-37, α-defensins, β-defensins and Θ-defensins. 
Neutrophils, epithelial cells and keratinocytes produce AMPs as a response to infection or 
injury (Dorschner, Pestonjamasp et al. 2001).  Lower concentrations of AMPs may act as 
signalling molecules activating certain bacterial pathways or regulatory systems, whilst at 
higher concentrations they cause bacterial damage (Gryllos, Tran-Winkler et al. 2008). 
 
1.5.4.1 Cathelicidins 
Cathelicidins are produced by neutrophils in response to injury or infection.  There is only 
one cathelicidin described in humans called human cationic antimicrobial peptide of 18kDa 
(hCAP18) (Gordon, Huang et al. 2005). This peptide is upregulated by inflammation and 
injury and then cleaved to produce LL-37 (a 27-amino acid antimicrobial peptide) and 103-
amino acid cathelin domain. LL-37 is a cationic AMP with antibacterial activity (disrupting 
cell membranes) and is chemotactic for many inflammatory cells like neutrophils 
(Johansson, Thulin et al. 2008) and stimulates IL-8 secretion. The equivalent to LL-37 in 
mice is cRAMP (Gallo, Kim et al. 1997, Wallis 2014) and both are encoded by similar 
genes, having similar proteins structures (alpha helical), spectra of antimicrobial activity 
and tissue distribution (Nizet, Ohtake et al. 2001). This murine variant of LL 37 has been 
involved in iGAS, as cRAMP deficient mice were more likely to succumb to invasive GAS 
disease in comparison to wildtype mice (Nizet, Ohtake et al. 2001).  Although more 
recently sub inhibitory concentrations of LL-37 has been shown to have a paradoxical 
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effect of enhancing GAS pathogenicity through de-repressing covRS, increasing the 
expression of virulence factors, which include capsule (Gryllos, Tran-Winkler et al. 2008). 
In this work, 100nM of LL-37 was shown to stimulate increase in capsule, 200 times lower 
than previously required to inhibit growth.  Further work from this group have shown 
increased capsule production through this mechanism can occur in M-types 1, 4, 5 and 29 
and it requires a functional covS, resulting in resistance to phagocytosis. 
 
As previously described, injury to human and mouse skin increases the expression of 
cathelicidins, LL-37 and cRAMP in sections of tissue evaluated by immunohistochemistry 
at various time points following injury (Dorschner, Pestonjamasp et al. 2001). In this work it 
was shown that cRAMP was expressed following a cutaneous infection with GAS.  In 
many cases these antimicrobial peptides can protect against murine necrotic skin 
infections due to GAS but higher concentrations of cRAMP and LL-37 were used.   
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1.6 Molecular basis of Necrotising Fasciitis  
 
 
Figure 1.7 Bacterial virulence factors associated with invasive streptococcal 
disease enabling it to establish a deep tissue infection (Lamb, Sriskandan et al. 
2015).  
GAS possesses a number of virulence factors, which enable the bacteria to evade the 
host innate and adaptive immune defences and establish a deep tissue infection.  Surface 
expressed proteins such as the M protein and C5a peptidase are involved in complement 
evasion, whilst SpyCEP influences neutrophil activation and migration. The secreted  
protein SpeB is involved in the tissue necrosis in NF and phenotypic switching of bacteria 
in invasive infection.  Other secreted proteins include; SIC which aids complement 
evasion, the DNAase Sda1 that acts on neutrophil derived extracellular traps and the 
immunoglobulin degrading protein, IdeS. The two component regulatory system, CovR/S 
is involved in the regulation of some of these virulence factors and may be associated with 
more invasive bacterial phenotypes. 
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1.6.1 Streptococcus pyogenes cell envelope protease (SpyCEP) 
In many patients with lethal NF there is a paradoxical paucity of neutrophils at the site of 
infection, and primate animal models of iGAS have replicated this finding (Taylor, Bryant et 
al. 1999, Edwards, Taylor et al. 2005, Turner, Kurupati et al. 2009, Goodman 2014). IL-8 is 
the main chemokine involved in recruiting human neutrophils to the site of infection or 
injury. This chemokine is produced by a variety of cells including epithelial cells, fibroblasts 
and macrophages mainly found in the interstitial tissues.  It passes to the luminal surface 
of the endothelium where it interacts and activates neutrophils through CXCR1/2 binding.  
GAS secretes a proteinase, SpyCEP that enables the bacteria to evade the immune 
response through cleavage of IL-8 at its C terminus.  The activity of SpyCEP is higher in 
invasive rather than pharyngeal isolates (Edwards, Taylor et al. 2005). Specifically cleaved 
IL-8 at the C terminus results in reduced activation and migration of neutrophils (Edwards, 
Taylor et al. 2005). SpyCEP has been shown in mouse models to be important in 
dissemination from a soft tissue focus and to the draining lymphatics or into the respiratory 
tract (Kurupati, Turner et al. 2010). SpyCEP also plays an important part in neutrophil 
regulation across the vascular endothelium.  Further work highlighted the N terminus to be 
specifically involved in mediating the uptake of SpyCEP through an endosomal pathway 
into endothelial cells (Kaur, Nerlich et al. 2010).  
 
CovRS is responsible for the regulation of transcription of cepA (the gene that encodes the 
proteinase SpyCEP) and the activity of SpyCEP in invasive and pharyngeal isolates 
(Turner, Kurupati et al. 2009). For example, a mutation in CovR results in the over-
expression of SpyCEP in a lethal invasive isolate, whilst in other M1 isolates, CovS 
mutations have been responsible for the potential of modern isolates to invade (Sumby, 
Whitney et al. 2006, Walker, Hollands et al. 2007). However unlike CovR, CovS mutations 
can be found in both invasive and non-invasive isolates and not necessarily associated 
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with increased expression of cepA. Further work has shown that the M1T1 clone linked to 
the recent increase in NF and TSS isolates (Aziz, Pabst et al. 2004) possesses a 
bacteriophage-encoded DNAase (sda1) that may be solely responsible for driving 
mutations in covRS (Turner and Sriskandan 2007, Walker, Hollands et al. 2007). 
Mutations in CovRS allow isolates to become invasive through the de-repression of a 
number of virulence factors and hence the reduced expression of SpeB, allowing GAS to 
disseminate.   
 
The use of SpyCEP as a vaccine candidate to protect against iGAS has been explored 
(Rodriguez-Ortega, Norais et al. 2006, Moss and Patel 2014).  The N terminal part of 
SpyCEP was expressed and purified, antibodies against this part neutralized the IL-8 
cleaving activity of SpyCEP, reducing dissemination in a mouse model of NF and 
intranasal model of infection (Turner, Kurupati et al. 2009). 
 
1.6.2 Streptococcal Cysteine Protease (SpeB)  
This is a cysteine protease regulated by a number of control mechanisms including the 
two-component system covRS.  It is involved in the cleavage of host molecules including 
the extracellular matrix, cytokines, chemokines, complement, immunoglobulins and serum 
protease inhibitors (Nelson, Garbe et al. 2011). SpeB also activates host 
metalloproteinases involved in GAS destruction and dissemination, particularly MMP-2 
and MMP-9 (Olsen and Musser 2010). The expression of SpeB varies at different phases 
of growth (Olsen and Musser 2010) allows other virulence factors including M protein to be 
expressed to allow for adherence and proliferation.  During later growth, SpeB expression 
is enhanced to allow dissemination through tissues into the blood stream. Once in the 
blood, expression is reduced to allow the expression of virulence factors facilitating 
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survival in blood.  In necrotising fasciitis, speB is upregulated to promote tissue destruction 
(Johansson, Thulin et al. 2008) and has been implicated in the inactivation of LL-37 at the 
bacterial surface which may explain the massive bacterial loads seen in the tissues of 
patients with NF.  
 
Despite the wealth of literature on speB, there is much controversy regarding its function, 
however it has been demonstrated that speB is critical for the pathogenesis of iGAS and 
NF (Carroll and Musser 2011), as genetic inactivation results in reduced virulence in a 
mouse model of iGAS. Transcription and translation of speB is complex, involving multiple 
promoters, transcription factors, regulators and catalytic processes. Throughout 
production, there is strict control by a variety of regulatory mechanisms, including the 
covRS system.  Factors involved in processing speB, include ropA (regulator of protease) 
trigger factor and prsA.    PrsA has been shown to be important in the maturation of SpeB, 
and decreased prsA activity led to reduce virulence in patients with NF (Olsen, Sitkiewicz 
et al. 2010).  Environmental factors play a part in the regulation of speB and they include 
nutrient availability, pH, growth phase, salt concentration are important, for example, a 
reduction in pH, as occurs during the development of an abscess, triggers the expression 
of speB (Loughman and Caparon 2006).  
 
1.6.2.1 Regulation of SpeB 
SpeB is regulated by a number of transcription factors. The most well known is RopB 
(regulator of SpeB or Rgg), although expression of SpeB is not solely dependant on RopB.  
Mutations of RopB lead to a reduced or complete lack of SpeB expression and this has 
occurred in M1 and M3 GAS isolates, (Hollands, Aziz et al. 2008, Beres, Carroll et al. 
2010) although the isolates have been subsequently been able to produce SpeB under 
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different growth conditions (Olsen, Sitkiewicz et al. 2010). CovRS affects expression of 
SpeB; mutations in covS in general lead to decreased SpeB expression both in vitro and in 
vivo, with CovR thought to repress transcription either directly by binding upstream of the 
SpeB promoter or indirectly through the repression of RopB (Graham, Smoot et al. 2002). 
There are many more regulators not discussed but referenced in a detailed review by 
Carroll et al, 2011 (Carroll and Musser 2011). 
 
1.6.3 The mts-prsA-SpeB Virulence Axis 
In Canada, an upsurge in M3 iGAS emerged over several years, and some M3 GAS 
clades showed a reduced propensity to be associated with NF (Olsen, Watkins et al. 
2011). The clade was typified by a single nucleotide mutation in the mts-R (metal 
transporter of streptococcus regulator) resulting in premature termination of the protein. 
Further work showed that this disrupted a virulence axis responsible for the secretion of 
SpeB, through the overexpression of prsA, a peptidyl-isomerase resulting in a less virulent 
GAS strain that had reduced ability to cause NF (Olsen, Sitkiewicz et al. 2010). 
Intriguingly, mutations in this regulator only seem to impact on morbidity of NF infections 
and do not have an effect on other invasive GAS diseases (Beres, Richter et al. 2006). 
 
1.6.4 Streptococcal C5a Peptidase 
C5a peptidase is a serine protease located on the cell surface of all GAS strains which 
cleaves C5a, another mechanism whereby GAS can evade phagocytosis (Cleary, Prahbu 
et al. 1992). Consequently, there is impaired chemotaxis by C5a and reduced recruitment 
of neutrophils at the site of infection (Cleary, Prahbu et al. 1992). The gene ScpA encoding 
the C5a peptidase is very similar to that found within group B and G streptococcal isolates 
(Cleary, Handley et al. 1992).  
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Much work has been done in the US regarding using C5a peptidase or surface- bound 
C5a peptidase as a vaccination candidate particularly as it is highly conserved amongst all 
serotypes.   Preparations of C5a peptidase (scpA) protein were immunogenic in a mouse 
intranasal model, the protease is required for efficient colonization of the nasopharynx, 
and colonization was significantly reduced through effective vaccination.  The 
administration of anti-scpA serum provided added protection against intranasal infection 
(Cleary, Matsuka et al. 2004, Park and Cleary 2005). 
 
1.6.5 Summary 
In summary, GAS has acquired a number of virulence factors including regulators, which 
enhances its ability to evade, disseminate and persist within the human host.  Of particular 
interest in this project is the influence of trauma on the dissemination of GAS and the 
change in its virulence repetitoire.  The remainder of the introduction will discuss the 
clinical aspects of contusion and its impact on the inflammatory response, leading onto a 
final section describing the modelling of GAS infection and trauma.  This last section will 
describe the use of Biophotonic imaging (BPI) to refine models of infection. 
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1.7 Contusion Injuries 
This section will describe the clinical aspects of contusion and its impact on the acute 
inflammatory response. 
1.7.1 Clinical presentation 
Amongst the many types of muscle and soft tissue injuries, contusion is the most common 
and occurs when muscle tissue is exposed to an impact force or a crush injury (Smith, 
Kruger et al. 2008). Muscle contusions occur in daily life as the result of accidents or 
simple falls, but are commonly seen in contact sports where they represent 10-55% of all 
injuries (Hawkins and Fuller 1999, Beiner and Jokl 2002, Souza and Gottfried 2013, 
Trojian 2013).  These muscle injuries are often difficult to manage as patients present with 
varied symptoms and signs (Jarvinen, Jarvinen et al. 2005). Injury to the muscle leads to 
damage to the muscle tissue, including bleeding and the formation of a haematoma and 
the activation of the acute inflammatory response (Souza and Gottfried 2013). Common 
sites of injury include the thigh and upper arm.  Complications include haematoma which 
may lead to compartment syndrome, infection and myositis ossificans (an inflammatory 
pseudo-tumour) (Kary 2010). Shown in table 1.4 are descriptive terms of different injuries 
to skeletal muscle. 
Method of Injury Description Reference 
Contusion Damage to the muscle through 
direct impact 
(Beiner and Jokl 2001) 
Eccentric contraction During an eccentric contraction 
(lengthening contraction), the 
muscle elongates while under 
tension due to an opposing force 
greater than the muscle generates. 
(Barash, Mathew et al. 2004) 
Isometric contraction There is no change in the length of 
the muscle during this contraction 
and the joint does not move 
(McMaster, Gill et al. 2014) 
Passive stretch An exercise whereby an external 
force is exerted to move the limb 
into a new position 
(Prabhu, Swaminathan et al. 
2013) 
 
Table 1.4 Descriptive terms of different injuries to the skeletal muscle 
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1.7.2 Diagnosis and Management 
Imaging is used to assist in diagnosing muscle contusion injuries, which includes X-ray, 
ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI).  X-ray is 
used to detect a bony injury and may give an indication of the amount of oedema present 
in the muscle tissue. Ultrasound is used to compare soft tissue swelling including bleeding 
and haematomas (Aspelin, Ekberg et al. 1992, Koh and McNally 2007, Woodhouse and 
McNally 2011). MRI is more sensitive than CT for the detection of haemorrhage, 
distinguishing blood from other tissue fluid  
 
There has been little change in the treatment of muscle injuries (Kary 2010) with 
conservative medical management being the central focus, with surgery being used for 
more complex cases  (Beiner and Jokl 2001, Bleakley, McDonough et al. 2004). Other 
modalities such as therapeutic ultrasound are thought to provide benefit to muscle 
contusions, although animal data are conflicting (Fisher, Baracos et al. 1991, Rantanen, 
Thorsson et al. 1999, Woodhouse and McNally 2011).  There have been many studies on 
the use of other agents including corticosteroids and growth factors designed to reduce 
inflammation or improve healing (Beiner and Jokl 2001). 
 
1.7.3  Inflammatory response in humans following injury 
The innate immune system provides the initial host response to injury comprising of cells 
including mast cells, neutrophils, monocytes, macrophages, dendritic and natural killer 
(NK) cells, signalling pathways and cytokines.   
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1.7.3.1 Neutrophils and Macrophages 
Acute inflammation is a dynamic process occurring within the first 3 days following injury. 
Both neutrophils and macrophages are involved in the initial inflammatory response.  
Following a contusion injury there is an increase in the number of circulating neutrophils, 
which remain high for 24 hours following injury, presumably due to mobilisation from the 
bone marrow (Bhatia, Pallister et al. 2005). Of particular importance is the margination of 
neutrophils to the endothelial wall, allowing cells to communicate and promoting the efflux 
of neutrophils from the circulation into the extracellular matrix (ECM), next to damaged 
myocytes.  Cytokines released following muscle injury activate neutrophils so that they 
produce reactive oxygen species (ROS) responsible for the initial damage (Pizza, 
Peterson et al. 2005).    
 
Macrophages are involved during acute inflammation but generally contribute to 
regeneration and healing of damaged tissue.  There are two groups of macrophages, 
those circulating as monocytes in the peripheral blood system and are elevated acutely 
within 3h up to 3 days post injury, involved in removing injured debris and those that are 
resident in skeletal muscle and are mainly involved in repair rather than infiltration of 
damaged tissue (Butterfield, Best et al. 2006). 
 
1.7.3.2 Cytokines and chemokines in muscle contusion 
Following muscle injury, myocytes and the endothelium release cytokines such as IL-1β, 
IL-6, IL-8 and TNF-α, which actively recruit neutrophils and encourage margination of the 
neutrophils along the endothelial wall. IL-6 and IL-8 have been found in high levels in the 
plasma in patients following major trauma and in the skin dermis following sterile injury 
(Botha, Moore et al. 1996, Bhatia, Pallister et al. 2005, Sjogren and Anderson 2009).  
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Other cytokines including IL-1β and TNF-α recruit macrophages involved in tissue repair 
and regeneration.  There is a pro-inflammatory loop promulgated through IL-1β stimulating 
macrophages which produce more pro inflammatory cytokines, which in turn activate and 
recruit more neutrophils (Butterfield, Best et al. 2006). Septic patients have shown a 
similar IL-8 mediated chemotaxis loop that, as with trauma, is associated with upregulation 
of the neutrophil CXC chemokine receptor, CXCR1(Cummings, Martin et al. 1999).  
1.7.4 PAMPs and DAMPs in the Inflammatory Response 
Injury can cause a systemic inflammatory response syndrome (SIRs) similar to that seen 
in sepsis (Zhang, Raoof et al. 2010) In comparison to pathogen-associated molecular 
patterns (PAMPs) seen in sepsis, cellular injury due to trauma releases endogenous 
damage-associated molecular patterns DAMPs (Calfee and Matthay 2010)  Previous 
research has suggested that injury releases mitochondrial DAMPs into the circulation 
which activates neutrophils through a similar mechanism to PAMPs, using formyl-peptide 
receptor 1 and toll-like receptor 9 (TLR-9), the result is neutrophil-mediated organ injury, 
liked acute lung injury.  It was proposed that the two processes are similar because of the 
molecular similarity between mitochondrial DNA and bacterial DNA. 
 
1.7.5 Histological changes seen following contusion injury 
Much of the clinical work describing the histological changes seen following contusion 
injury relies on case reports (Smith, Kruger et al. 2008). There have been some 
experimental human studies evaluating the effect of eccentric contraction on muscle 
damage (Friden, Seger et al. 1983). Other studies rely heavily on animal models (Table 
1.5), mainly involving rodents and rabbits either using contusion or eccentric contraction. It 
was not until the 1980s that direct evidence of muscle fibre injury and necrosis was 
demonstrated through light and electron microscopy (Tiidus 2008).  This work revealed 
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local changes to the injured muscle including myofibrillar disruption, extracellular matrix 
disturbances and capillary damage leading to haemorrhage.  There was evidence of 
inflammation at the site, with neutrophil infiltration, and increased local cytokine production 
(particularly IL-6, IL-1β, and TNF-α) (Tiidus 2008).  Table 1.5 describes the animal models 
of muscle injury designed to assess different responses following injury.   
 
Previously, a simple model of muscle contusion injury was developed, using a dropped 
mass technique to deliver a single impact to the gastrocnemius muscle of Wistar rats.  
Histological examination of the injured tissue demonstrated disruption to the muscle fibres 
and oedema of the tissue.  Associated with this change was an increase in staining of the 
intermediate filament protein, vimentin, in damaged but not regenerating tissue (Crisco, 
Jokl et al. 1994). Vimentin is found in a variety of cell types (Bryant, Bayer et al. 2006) and 
upregulation of this intermediate filament protein occurs in cells undergoing epithelial-to-
mesenchymal transition (EMT) like those involved in wound healing or metastatic 
transformation of malignant cells (Ivaska 2011). 
 
1.8 Animal models of trauma and infection 
Mice have been used as models of infectious diseases as they may be used to identify 
genes involved in susceptibility or resistance to infection through the use of targeted gene 
knock out mice (Buer and Balling 2003), and the reagents to study immunological 
responses are readily available. Unlike primate models of infection, there are a wide 
variety of different strains, genetic backgrounds and colours easily available and 
maintained.  Despite the widespread use of mice to model human disease, there are many 
conditions for which mouse models are yet to be developed.  
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There has been increasing debate regarding the use of mouse models to investigate the 
pathogenesis of inflammatory diseases including burns, trauma and sepsis, epitomised by 
the conflicting findings of two groups studying transcriptomic responses in mice compared 
with humans (Seok, Warren et al. 2013, Takao and Miyakawa 2014).    
 
Two groups have studied the impact of trauma on the development of GAS NF in mice 
models and these models will be discussed later in this section (Bryant, Bayer et al. 2006, 
Hamilton, Bayer et al. 2008, Seki, Saito et al. 2008).  Producing a model of GAS NF in 
association with trauma requires choosing an appropriate model of both contusion and 
iGAS.  This section will describe animal models of contusion and invasive GAS disease 
particularly models of necrotizing fasciitis. Finally, the two existing models of GAS NF and 
injury will be described and their role in enhancing our knowledge into the pathogenesis of 
GAS NF. 
 
1.8.1 Animal models of traumatic injury 
Experimental models of skeletal muscle injury are varied and diverse both in methods 
used to produce the trauma and the severity of the damage inflicted.  They can roughly be 
divided into models of contusion including crush and blunt force models (Table 1.5).  Other 
models include ischaemia-reperfusion, injection of venom, freezing, laceration or eccentric 
contraction (Goetsch, Hawke et al. 2003, Peters, Barash et al. 2003, Pachori, Melo et al. 
2004, Warren, O'Farrell et al. 2004, Hamilton, Bayer et al. 2008, Mu, Peng et al. 2011). 
For this project the model necessitates a mild/moderate muscle injury with no break in the 
bone, for humane reasons, or damage to the skin of the animal (thereby preventing a 
contiguous portal of entry for GAS). It is now recognized that GAS is easily seeded by 
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grooming and in-fighting in particular affecting previous sterile sites of injection (Alam, 
Bateman et al. 2013). 
 
1.8.1.1 Models of contusion 
Animals have been used to model injury for the past 100 years allowing researchers to 
investigate the mechanisms behind muscle injuries, the inflammatory response and trial 
different treatment regimens (Allbrook 1962, Allbrook, Baker Wde et al. 1966). There are 
many models of contusion injury varying from a simple contusion device to a more 
complex crush model (Table 1.5). 
Study 
Year 
Type 
of 
Model 
Device Animal Open 
surgery 
Outcomes Presumed 
Severity  
Limit 
Reference 
1962 Crush Forceps held 
on open 
muscle for 2 
minutes 
Mice and rats Yes Muscle 
injury 
Histology 
Moderate (Allbrook 
1962) 
1966 Blunt 
force 
Weight 
Drop/Hammer 
Vervet 
monkeys 
No  Fracture and 
muscle 
injury 
Histology 
Substantial (Allbrook, 
Baker Wde et 
al. 1966) 
1975 Crush Spring-loaded 
hammer 
Rat No Histology 
and impact 
of 
mobilisation 
Moderate (Jarvinen and 
Sorvari 1975) 
1984 Blunt 
force 
Drop Mass 
technique 
Rat 
Gastrocnemius 
No Histology 
and the 
effect of 
ultrasound 
Moderate (Stratton, 
Heckmann et 
al. 1984) 
1990 Blunt 
force 
Drop Mass 
technique 
Male Sprague – 
Dawley rats - 
gastrocnemius 
 
No Histological 
changes 
following 
injury  
Moderate (Fisher, 
Baracos et al. 
1990) 
1994 Blunt 
force 
Drop Mass 
technique 
Rat 
Gastrocnemius-
soleus 
No Contractile 
function, 
energy and 
histology 
Moderate (Crisco, Jokl 
et al. 1994) 
1997 Crush Battery 
operated 
crush machine 
Male MF1 mice 
Tibialis anterior 
Yes  Model and 
histology 
Moderate (Rushton, 
Davies et al. 
1997) 
1999 Blunt 
force 
Drop Mass 
technique 
Rats tibialis 
anterior 
No Histology Moderate (Minamoto, 
Grazziano et 
al. 1999) 
1999 Blunt 
force 
Drop Mass 
technique 
Rat  No Effect of 
steroids on 
muscle 
injury 
Moderate (Beiner, Jokl 
et al. 1999) 
2004 Crush Weight drop CFLP mice  Yes Histology Moderate (Bunn, 
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on open 
muscle belly 
and 
immunocyto-
chemistry 
 
Canning et 
al. 2004) 
2003 Crush Forceps Wistar Rats Yes Assessing 
metabolic 
recovery 
Moderate (Fink, Fortin 
et al. 2003) 
2005 Blunt 
force 
Drop mass 
technique 
Male Wistar 
rats 
gastrocnemius 
No Effect of 
ultrasound 
on healing 
Moderate (Markert, 
Merrick et al. 
2005) 
2007 Blunt 
force 
Drop mass 
technique 
Male Wistar 
rats 
No Effect of 
ultrasound 
on healing 
Moderate (McBrier, 
Lekan et al. 
2007) 
2009 Blunt 
force 
Drop mass 
technique 
Male Wistar 
rats 
No  MRI 
evaluating a 
novel 
contusion 
device 
Moderate (McBrier, 
Neuberger et 
al. 2009) 
2009 Blunt 
force 
Drop Mass 
technique 
Male Sprague-
Dawley rats 
thigh femoral 
vessels 
No Measuring 
cytokines 
using micro 
dialysis 
Unclassified (Farnebo, 
Lars-Erik et 
al. 2009) 
2010 Crush Aneurysm clip 
– Tibialis 
anterior 
F1 Hybrid male 
rats 
Yes Effect of 
ischaemia-
reperfusion 
on 
inflammation 
Moderate (Ghaly and 
Marsh 2010) 
2011 Crush Forceps – left 
soleus 
Sprague 
Dawley male 
rats 
Yes MRI and 
histology 
Moderate (Winkler, von 
Roth et al. 
2011) 
2011 Blunt 
force 
Drop mass 
technique - 
gastrocnemius 
Male Wistar 
rats 
No The effect of 
therapeutic 
cold 
Moderate (Puntel, 
Carvalho et 
al. 2011) 
2013 Blunt 
force 
Drop Mass 
technique 
Sprague-
Dawley Male 
rats 
No Time 
dependent 
expression 
of Egr-1 
Moderate (Winkler, von 
Roth et al. 
2011, Fan, 
Ye et al. 
2013) 
2013 Blunt 
force 
Drop Mass 
technique 
New Zealand 
White rabbits 
No Histology of 
vastus 
lateralis 
Moderate (Deane, 
Gregory et al. 
2013) 
  
Table 1.5 Animals Models of Contusion.  
The table summarises the main models involving a blunt force or crush injury.  The 
presumed severity limits are based on the UK system of severity classification and 
directive 2010/63: unclassified = protocols performed under general anaesthetic where the 
animal does not recover from consciousness; mild = protocols where the animal suffers 
minor adverse effects; moderate = protocols where the animal may experience a degree of 
pain, suffering, distress or harm (most surgical procedures); substantial = protocols 
causing significant or prolonged animal suffering (major surgery, sepsis syndromes and 
vaccine challenge studies). 
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The majority of experimental animal models of contusion use rodents, particularly rats, and 
are divided into models of crush or blunt non-penetrating impact  (Table 1.5). Within these 
models a variety of techniques are used to produce an injury to the muscle to mimic 
contusion, examples include dropping a mass or ball onto the muscle, surgically exposing 
the muscle and applying a force or pinching the muscle with forceps.  In comparison to 
models of crush injury, models of blunt non-penetrating impact provide a more accurate 
representation of the injury seen in human patients.  These models tend to cause limited 
damage to the skin surface unlike many of the crush models. Often the cytokine response 
can differ between models and injury to the skin can cause further alteration (Smith, 
Kruger et al. 2008). The majority of models are likely to be classified as moderate severity 
limit, with one classified substantial and one unclassified.  
 
The work in my thesis concentrates on using the blunt impact models, as there was a 
need to provide a trauma model with no skin penetration.  The models are designed to 
cause an injury to the hind limb of the animal, as the majority of injuries occur in the lower 
limb muscles in humans (Dallinga, Benjaminse et al. 2012) and this is also the most 
common site for iGAS NF. Within the rat model, the gastrocnemius muscle is often used 
(Wang and Kernell 2000) with other models using the tibialis anterior, extensor digitorum 
longus or soleus muscle. Other factors considered when producing a contusion model 
include the shape, weight of the mass used and the height from which it is dropped. Many 
models are refined by using imaging such as MRI (McBrier, Neuberger et al. 2009), and 
characterized through histology or by monitoring the inflammatory response (Bunn, 
Canning et al. 2004).  
 
 
 
77 
1.8.1.2 Other models of muscle injury 
Other models of muscle injury include eccentric contraction (model of strain), laceration, 
ischaemia-reperfusion, freezing, injecting anaesthetic or toxins (Goetsch, Hawke et al. 
2003, Warren, O'Farrell et al. 2004, Hamilton, Bayer et al. 2008). To mimic a muscle strain 
a force can be applied to a stretched muscle, via so-called “eccentric contraction” (Peters, 
Barash et al. 2003, Barash, Mathew et al. 2004). In comparison to contusion models, 
where the impact force affects the muscle belly leading to haemorrhage and inflammation 
at a specific site, strain models tend to involve processes occurring at the myotendinous 
junction (Pratt, Lawlor et al. 2012).  Models representing strain injury are produced using 
electric muscle stimulation (Mishra, Friden et al. 1995, Pratt, Lawlor et al. 2012) or traction 
of the muscle tendon (Ramos, Leal Junior et al. 2012) and usually require exposure of the 
muscle and open surgery hence not suitable for this project.  
 
Laceration models were designed to mimic injuries occurring during road traffic accidents, 
where there is often a break in the skin surface (Menetrey, Kasemkijwattana et al. 1999). 
Laceration models tend to be more similar in their methodology in comparison to contusion 
or strain models.  The majority either involve a complete or incomplete transection of the 
muscle belly of the animal and tend to only vary by the type of cut (Souza and Gottfried 
2013). Unlike contusion models, where there is variation in the use of the model, the 
majority of laceration models are used to assess the scarring that occurs post injury (Park, 
Ki et al. 2012). Other models involve injecting a toxin to the muscle or inducing a freezing 
injury (Souza and Gottfried 2013).   Ischaemic-reperfusion models have also been used to 
provide models of major trauma (Ghaly and Marsh 2010). 
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1.8.1.3 The Acute Inflammatory response in animal models of trauma  
Little is known about the local inflammatory or cytokine response to muscle injury in animal 
models. A recent study in rats illustrated a widespread pro-inflammatory response 
following major blunt trauma with significant increases in cytokines IL 6 and IL 8 (Farnebo, 
Lars-Erik et al. 2009). This study looked specifically at local responses to severe injury by 
measuring key cytokines using micro-dialysis catheters inserted into gracilis muscle of the 
rat thigh on both the injured and uninjured side (control leg).  The cytokines were 
quantified using a standard ELISA kit.  There was a generalised rather than local cytokine 
response to major injury involving an increase in IL-6 and IL-8 but not TNFα. However 
consideration should be paid to rise in IL-6 and IL-8 as a result of the insertion of the 
micro-dialysis catheter, particularly as these cytokines are abundant in this tissue type 
(Smith, Kruger et al. 2008, Farnebo, Lars-Erik et al. 2009).  
 
1.8.1.4 Imaging in animal models of trauma  
Non-invasive imaging assesses disease processes on live animals without significantly 
affecting the physiology or well being of the animal (Balaban and Hampshire 2001) though 
live animal imaging poses difficulties due to long anaesthetic times, monitoring and motion 
artefacts. Imaging can be used to assess and refine animal models, the main types used 
in small animals being Faxitron X-ray, computerized tomography with and without positron 
emission tomography (CT-PET), magnetic resonance imaging (MRI) and biophotonic 
imaging (discussed as a separate section). 
 
X-rays provide a quick and simple tool to assess bony changes and any gas formation 
within tissues but provide little information on damage to muscle structure.  Muscle injuries 
including contusions are best assessed using MRI, offering excellent tissue contrast, being 
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sensitive to haemorrhage and oedema.  Conventionally T2 weighted MRI images provide 
the optimal view for imaging muscle injuries, while MRI provides a tool to refine animal 
models, allowing longitudinal imaging of injuries rather than a requirement to cull animals 
at specific time points for histology (Kanapathipillai, Restrepo et al. 2014). 
 
1.8.1.5 Faxitron Imaging 
This sensitive, cost effective and well developed system provides a method to assess the 
mineral content of bone from a post-mortem specimen using a Faxitron point projection 
digital micro-radiography machine (Bassett, van der Spek et al. 2012). In the context of 
this project it allows the injury models to be assessed for bony damage prior to sending 
samples for histological assessment. 
 
1.8.2 Animal Models of Infection 
Humanised transgenic mice were developed to overcome pitfalls associated with 
modelling complex human infections in mice. In the case of GAS, specific HLA class II and 
human plasminogen transgenic models have been developed to illustrate the contribution 
of superantigens and streptokinase respectively (Sriskandan, Unnikrishnan et al. 2001, 
Welcher, Carra et al. 2002, McArthur, Cook et al. 2012). 
 
1.8.3 Animal models of invasive GAS disease 
Non-human primate models provide the closest in vivo system for studying iGAS disease 
like NF and GAS pharyngitis (Sumby, Tart et al. 2008), although there is controversy to the 
appropriateness of such models for studying pathogenesis as opposed to vaccine 
evaluation (Stevens, Bryant et al. 1996, Taylor, Bryant et al. 1999, Olsen, Sitkiewicz et al. 
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2010). Mice have been widely to study iGAS, through inoculation of bacteria into different 
sterile sites and observing the differences between strains or treatment groups. Table 1.6 
shows the wide variation of methods used to model invasive GAS disease and systemic 
invasion is confirmed by detection of GAS in the blood, lymph nodes, spleen or liver 
tissue.  The majority of the studies did not comment on the spread of GAS to local 
lymphatics. 
Year Model Vol Strain Sex M 
type 
CFU/ 
Animal 
Tissue 
sampled 
LN 
spread 
Reference 
 
1996 IV  Baboon  
Papio 
cynocephalus 
M/F M3 1-3x10 
10cfu/ml 
Blood 
Serum 
Post-
mortem 
NS (Stevens, 
Bryant et al. 
1996) 
1997 IT/IN NA C3HeB/FeJ 
C57BL/10SnJ 
F 24 1x107  Blood, 
Spleen, 
Liver 
NS (Husmann, 
Dillehay et al. 
1996, 
Husmann, 
Yung et al. 
1997) 
1999 IT/SC  50µl 
100 µl 
CD1 
Crl: SKH1-hBR 
M 3 107-108 Blood, 
Heart, 
Lung, 
Spleen, 
Liver 
NS (Lukomski, 
Montgomery 
et al. 1999) 
2000 SC 100 µl CD1  F 3 1x 108 Lesion 
sites, 
spleen 
NS (Limbago, 
Penumalli et 
al. 2000) 
2001 IP/SC NA (ip) 
or 50µl 
SC 
 
CD1 F 3 1x104 
(expon) or 
1x107 ip 
or 1x107 
or 1x 108 
Spleen NS (Ashbaugh 
and Wessels 
2001) 
2001 IP NA CD1 F 3 2x 10 7 Blood, 
spleen, 
lavage of 
peritoneal 
cavity 
NS (Gryllos, 
Cywes et al. 
2001) 
2002 SC 100 µl Crl:SKH1-hrBR M 1 3x107 Skin 
lesions 
NS (Graham, 
Smoot et al. 
2002) 
2003 SC NA CD1 NA 1 1x 109  Kidney, 
spleen, 
blood 
NS (Smith, 
Sledjeski et 
al. 2003) 
2005 SC/IP 50µl ICR  F 3 1x108 
900 (IP) 
Blood, 
spleen 
and lesion 
NS (Bricker, 
Carey et al. 
2005) 
2008 IM NA ddY M NA 1x107 Muscle 
and blood 
NS (Seki, Saito 
et al. 2008) 
2008 IV 50µl Swiss webster NA 3 8.2x105 – 
1.3x107 
Blood, 
spleen 
and 
muscle 
NS (Hamilton, 
Bayer et al. 
2008) 
2010 IM NA CD1  F 81 
M3 
1x108 (for 
both) 
Blood, 
spleen, 
Inguinal 
LN 
(Kurupati, 
Turner et al. 
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liver and 
muscle 
2010) 
2010 IP NA BALB(c) NA 49 NA Spleen 
and liver 
NS (Sheel, 
Pandey et al. 
2010) 
2013 IP 250 µl CD1 F M1 6x107 Survival NS (Trevino, Liu 
et al. 2013) 
2014 IM 100 µl CD1 F M3 1x107 Liver, 
spleen, 
lesion 
NS (Li, Liu et al. 
2014) 
 
Table 1.6 Animal models of Invasive GAS disease  
Shown in the table are some of the animal models of invasive GAS disease which require 
different methods of infection: IV= intravenous, IP= intraperitoneal, IN = Intranasal, IT = 
intratracheal, SC = subcutaneous and IM=  intramuscular.* NS = Not specified. 
 
1.8.4 Modelling GAS NF and injury 
Few studies have specifically investigated the link between injury and the development of 
GAS NF.  Bryant et al, 2006, suggested that the major skeletal GAS binding protein is 
vimentin, and that GAS seed skeletal muscle following trauma by binding to vimentin 
(Bryant, Bayer et al. 2006). As previously mentioned, vimentin is an intermediate filament 
protein of the cytoskeleton of many cell types including immature skeletal muscle and 
satellite cells.  There are also reports of a cell surface form of vimentin on platelets, 
endothelial cells and lymphocytes.  Bryant et al demonstrated that (1) intact, immature 
skeletal muscle cells express vimentin on their surface, (2) vimentin surface expression 
increases with modest cell injury (reduction in pH using lactic acid) and (3) intracellular 
vimentin becomes accessible with severe injury.  In contrast to immature skeletal muscle 
cells, mature skeletal muscle cells do not express vimentin except during regeneration 
after injury (Bornemann and Schmalbruch 1992, Vater, Cullen et al. 1994, Vaittinen, Lukka 
et al. 1999, Vaittinen, Lukka et al. 2001). Their work was supported by an in vivo eccentric 
contraction model of injury that showed the up regulation of vimentin after modest injury at 
12 hours and maximally at 48 hours (Peters, Barash et al. 2003). Consequently it was 
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suggested by Bryant et al that these findings corresponded to similar timings reported 
clinically when patients normally present 24-48 hours post injury with GAS NF. GAS 
bacteria were shown in vitro to bind vimentin although the responsible GAS ligand was not 
identified.  
 
Two groups have demonstrated the acceleration of STSS and myonecrosis by a traumatic 
injury in murine models (Hamilton, Bayer et al. 2008, Seki, Saito et al. 2008).  However, 
neither group demonstrated how the infection occurs when there is an undefined portal of 
entry, as both required the introduction of GAS bacteraemia by an intramuscular infection 
into the forelimb or intravenous injection into the lateral tail vein.  
 
Seki et al (Seki, Saito et al. 2008) showed, using their animal model of STSS (Iida, Seki et 
al. 2006), that mice inoculated intramuscularly into the forelimb with GAS (of an unknown 
emm type) develop a short illness, then recover and remain healthy for about 20 days, and 
then incur a sudden death in the presence of an artificial bruise distant from the primary 
GAS infection site (Seki, Saito et al. 2008).   The death in these animals was facilitated by 
artificially bruising the right hind limb by pinching with forceps, at 20 days the bacterial 
burden was higher in the bruised site in comparison to the non-bruised control leg.  In a 
separate experiment they demonstrated that amputation of the infected leg prior to 
bacteraemia enhanced survival and prevented STSS.  There were several limitations to 
their work which included experiments containing a small number of animals, the trauma 
method was crude, not calibrated or characterized, an unknown serotype of GAS was 
used and it was not clear whether the infection simply resulted from contiguous extension 
of a pre-existing infection. 
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Hamilton et al delivered between 8.2x105 – 1.3x107 cfu/50µl of serotype M3 GAS 
intravenously via the lateral tail vein 48 hours after an eccentric contraction (EC) induced 
injury of the murine hind limb muscles (Hamilton, Bayer et al. 2008).  Following on from 
their in vitro work on vimentin, the group showed that vimentin was up regulated 8 fold 48 
h after EC.  Significantly more GAS were found in moderately injured muscles than 
uninjured contralateral control legs They showed that NSAIDs augmented the number of 
GAS in injured muscles.  This group focused on vimentin as the main filament protein 
involved in binding GAS post injury and did not investigate other proteins.  In all these 
studies, a link between GAS and blunt trauma was apparent but did not appear specific 
and, crucially, GAS was found in non-injured muscle as well.  Furthermore, the EC model 
required insertion of electrodes through the skin at the site of the infection hence it is 
conceivable that GAS entered the injured muscle via a contiguous portal of entry.  We 
have established that GAS is easily seeded by grooming and in-fighting at otherwise 
sterile sites of injection, underlining the importance of ensuring skin breaks are avoided in 
these models (Alam, Bateman et al. 2013). A key aim of the thesis was therefore to 
develop a humane and reproducible model of contusion in which the progression of 
iGAS could be monitored.  
 
1.9 Modeling GAS disease using Biophotonic Imaging (BPI) 
All of the aforementioned models of iGAS require quantification of GAS bacteria or 
severity scoring at defined time points, often necessitating culling of animals and 
uncertainty as to whether a key pathophysiological event has been missed. Non-invasive 
biophotonic in vivo imaging of bioluminescent bacteria can circumvent the need to cull 
animals at defined time points, and refine the ability to monitor pathogenesis longitudinally. 
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Biophotonic imaging is an imaging technique which is based on the detection of light 
produced from the excitation of a fluorescent protein (FP), fluorescence or through an 
enzyme (luciferase) reaction in the presence of oxygen, bioluminescence (Andreu, Zelmer 
et al. 2011). Gene(s) encoding the luciferase or fluorescent protein are introduced into 
cells containing a promoter controlling their expression and the light produced monitored 
using a luminometer or fluorometer.  The bioluminescent or fluorescent cells can be 
introduced into an animal model, usually the mouse to monitor a disease process, a 
technique referred to as “in vivo biophotonic imaging”.  More importantly, it relies on the 
ability of light produced by genetically modified organisms to pass through mammalian 
tissue at certain depths and be detected (Rice, Cable et al. 2001).  The light produced by 
the cells is dim and specialized photon detectors commonly known as “charge coupled 
cameras” (CCD) are required for its detection, many of which are commercially produced, 
for example the so called ‘In Vivo Imaging System’ (IVIS) (Rice, Cable et al. 2001). It is 
also possible to monitor multiple biological events through the ability of different 
luciferases and fluorescent proteins to emit light at different wavelengths (Andreu, Zelmer 
et al. 2011). 
 
When compared to other imaging modalities such as CT or MRI, BPI tends to cost less, 
provide shorter imaging times with no exposure to radiation, and allows the opportunity to 
image more than one animal at a time (Francis 2005). Furthermore it allows biological 
processes to be located and quantified with an improved accuracy to MRI/CT, which tend 
to provide structural information (Contag and Ross 2002). In essence, BPI has evolved to 
allow refinement and reduction of animals used in experiments through the monitoring of 
animals longitudinally, supporting the work of the National Centre for Refinement, 
replacement and reduction, NC3Rs (Francis 2005).  BPI models negate the requirement 
for large groups of animals to be sacrificed in order to provide information for different time 
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points allowing the host-pathogen interaction to be followed more closely, providing 
information on the pathogenesis and leading to the discovery of novel niches of infection 
which may have been missed by conventional methods (Burgos 2009). Importantly 
however, BPI has been used most successfully for Gram-negative bacteria which tolerate 
production of luciferases and retain multi copy plasmids more readily that some Gram-
positive pathogens.  
 
BPI has nonetheless been used to trial therapeutics and vaccines, in different in vivo GAS 
models (Francis, Joh et al. 2000, Park and Cleary 2005, Sheel, Pandey et al. 2010).  
However BPI is not without its pitfalls and problems, with it becoming increasingly 
apparent that the models produced should be characterized and validated appropriately 
(Bose, Rosenberg et al. 2008, Alam, Turner et al. 2013). To date an M49 GAS and an 
M75 GAS have been developed to express bioluminescence, though both are non-
invasive isolates (Sheel, Pandey et al. 2010, Alam, Bateman et al. 2013).  One aim of the 
project was to exploit the technology to develop a bioluminescent GAS strain that 
could be used to longitudinally monitor invasive GAS and NF in a mouse model of 
trauma. 
 
Bioluminescence should be distinguished from fluorescent imaging, whereby a fluorescent 
compound is irradiated with a specific wavelength of light causing light of a specific 
wavelength to be emitted when excited electrons returns to a lower energy level. A large 
majority of available fluorescent proteins emit light signals in the red-spectrum allowing 
improved detection through mammalian tissues.  Unlike bioluminescence imaging, 
fluorescent imaging is subject to a greater signal to noise ratio which can make modelling 
certain disease are more difficult (Andreu, Zelmer et al. 2011). Tissue autofluorescence 
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occurs because of the production of endogenous fluorophores such as keratin, elastin, 
porphyrins and collagen. Diets containing chlorophyll increase the tissue autofluorescence 
seen in small animal models and it is important to image animals prior to the administration 
of a reporter to get background images and hence appropriate controls. For this project, 
bioluminescence was chosen as the appropriate reporter system for our animal 
models. 
 
1.9.1 Luciferases used in BPI 
There are a variety of luciferases that have been cloned to a point that they may be used 
in the laboratory and potentially in animal models of infection: bacteria (Photorhabdus 
luminescens and Vibrio spp), jelly fish and sea pansy (cnidaria including renilla reniformis) 
and insects (firefly, photinus pyralis) (Contag and Bachmann 2002, Doyle, Burns et al. 
2004, Prescher and Contag 2010). The production of light occurs from the interaction 
between an enzyme, luciferase and a substrate, luciferin in the presence of energy and 
oxygen. The wavelength that light is emitted varies amongst the luciferase-luciferin 
groups, with the firefly being the most efficient producer of light and is the choice or 
reporter for research involving eukaryotic cells. 
	    
Figure 1.8 The adapted bacterial luciferase system.  
This is an example of how light production occurs in the soil bacterium, Photorhabdus 
luminescens and how the lux operon has been rearranged so that it may be optimally 
expressed in Gram positive bacteria. 
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For my thesis, I have focused on using the reporter system from the soil bacterium, 
Photorhabdus luminescens. This gram negative bacterium contains genes that encode 
a luciferase (LuxAB) and enzymes (fatty acid reductase) for regeneration of the substrate 
(LuxCDE) on a single operon which can be optimally expressed at 37 degrees (Doyle, 
Burns et al. 2004). Other lux genes have been identified but only luxABCDE are essential 
for the synthesis of light. The LuxCDABE operon has been successfully used in studying 
variety gram-negative infections since the publication of Contag’s seminal paper in 1995 
on Salmonella typhi (Contag, Contag et al. 1995).  More recently the lux operon has been 
redesigned so that it can be used in gram positive organisms through the incorporation of 
optimal gram positive ribosomal binding sites (Shine-Dalgarno sites) and the change in 
gene order to luxABCDE to distinguish it from the native operon luxCDABE (Francis, Joh 
et al. 2000).  
 
1.9.2 Considerations when using BPI to model infection 
BPI has been particularly useful in infectious disease modelling by monitoring the bacterial 
burden within mammalian tissues, discovering novel niches of infections previously 
unknown (Hardy, Francis et al. 2004), monitoring the response to therapeutics and 
understanding the host immune response (Andreu, Zelmer et al. 2011). The first use of 
BPI in monitoring gram positive infections in vivo was performed using strains of 
Staphylococcus aureus transformed with a shuttle vector, pMK4 containing the rearranged 
operon, luxABCDE, which allowed constitutive bioluminescence at 37 degrees (Francis, 
Joh et al. 2000). This work demonstrated the use of BPI in monitoring the effect of 
therapeutics such as antibiotics on the course of infection.  However as BPI addresses the 
metabolic state of microorganisms, limitations of this technique are related to difficulties in 
differentiating between bacteriostatic and bactericidal treatments (Andreu, Zelmer et al. 
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2011). BPI has been useful to discover novel niches of infection as exemplified by the 
discovery that the Peyer’s patches are the primary site of growth for Bacillus anthracis post 
ingestion (Glomski, Corre et al. 2007) and the importance of the gallbladder in infection 
with Listeria monocytogenes (Hardy, Francis et al. 2004).   
 
A variety of factors need to be considered when optimising a bioluminescent model which 
include the sensitivity of the reporter system, assessing any attenuation of bacterial 
growth, continued stability despite passage in vitro and in vivo, and whether there is good 
correlation between bacterial burden and emission of light. It is well known that 
mammalian tissue impacts the diffusion of light and as a result it is important to consider 
this when producing an infection model.  Photons diffusing through tissue can be scattered 
and absorbed depending on the depth of infection within the cells or tissues, oxygen and 
wavelength of light (Cheong, Prahl et al. 1990, Contag and Bachmann 2002).  Some of the 
factors affecting function of a BLI model are considered below.   
 
1.9.2.1 Biological tissue attenuates light propagation 
Photons of light emitted by bacterial cells get scattered or absorbed by the complex, turbid 
environment within mammalian tissue (Troy, Jekic-McMullen et al. 2004) in particular by 
cell membranes, nuclei and collagen (Rice, Cable et al. 2001, Virostko and Jansen 2009).  
Other molecules such as haemoglobin and melanin are chromophores that absorb light. 
The depth of infection and sensitivity of detection ultimately will also influence the 
detection of the signal produced (Contag and Bachmann 2002).  For example, a 
subcutaneous model of infection using bioluminescent cells will provide high sensitivity of 
detection compared to a deep tissue model, as there is a 10 fold loss in photon intensity 
for each centimetre of tissue (Contag, Contag et al. 1995).  In such a model, light emitted 
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at the surface of the animal will be in the blue part of the spectrum as the minimal depth 
reduces absorption. However, from deeper tissue levels, light becomes increasingly 
absorbed by haemoglobin and melanin, particularly in the blue and green part of the 
visible spectrum, thereby only allowing the passage of light with a wavelength above 
600nm i.e. in the red part of the spectrum.   The BLI signal can therefore be adversely 
affected by diseases that result in increased blood flow or haemorrhage (Virostko and 
Jansen 2009). Furthermore the pigment in the spleen and liver attenuate the signal 
produced by the bioluminescent organism (Hutchens and Luker 2007). 
 
Nude or severe immunodeficient (SCID) mice are effective models of bioluminescent 
infections as there is little or no pigment available to absorb the light admitted (Doyle, 
Burns et al. 2004). Animals with dark fur pose a specific problem, as the melanin pigment 
absorbs a large proportion of the light emitted from bioluminescent cells and the signal is 
attenuated.  This affects studies of bacterial-host pathogenesis as many genetically 
engineered mice are developed on a C57BL/6 background.  Shaving of these animals can 
reduce the attenuation or they may be bred onto an albino C57BL/6 background. This also 
applies to using bioluminescent cells in animals other than mice like rats, rabbits or 
primates.  The larger size of the animal causes difficulty in detecting the signal from deep 
within the body.  There are of course added complications of anaesthetising larger animals 
and fitting animals into the imaging system. 
 
1.9.2.2 Requirement for Oxygen in BPI 
Certain infectious diseases produces an anaerobic microenvironment within the tissue 
infected; this was evident in Contag’s paper with Salmonella typhi, where there was a 
reduced bioluminescent signal in the lumen of the intestine post infection until air was 
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injected into the ileum and colon (Contag, Contag et al. 1995, Hutchens and Luker 2007).  
In cases where there is likely to be anaerobic environment, organs that require imaging 
like the colon are dissected and put in a container like a petri dish prior to imaging (Wiles, 
Clare et al. 2004). 
 
1.9.2.3 Wavelength of light 
Blue/green light of a short wavelength does not transmit through tissue as well as red light 
(Doyle, Burns et al. 2004).  Reporter systems utilize different wavelengths of light, for 
example the firefly luciferase emits light in the spectrum above 600nm allowing it to be 
easily detectable. In contrast, Renilla luciferase does not emit above 590nm and so is 
rarely used for deeper infection models.  In this project the bacterial luciferase system has 
been used, which emits a small amount of its bioluminescent signal above 600nm and is a 
unique system, which has the ability to constitutively express light. 
 
1.9.3 Modelling Group A Streptococcal disease using BPI 
Bioluminescence has been used to model infections due to GAS, although there has been 
limited use in iGAS (Sheel, Pandey et al. 2010). Some of the initial work used a 
bioluminescent M49 (Xen 20) S.pyogenes skin isolate to demonstrate that membranous 
cells in nasal-associated lymphoid tissue (NALT) provide a portal of entry for GAS in an 
intranasal infection model in mice (Park, Francis et al. 2003). NALT is lymphoid tissue 
located along the lateral nasopharyngeal wall.  BPI provided a tool for longitudinally 
monitoring the spread of infection and a mechanism to localize the main site of infection by 
analysing harvested organs.  Further work used the model to demonstrate that intranasal 
immunization of mice with C5a peptidase, a surface-bound protein on Group a 
streptococci enhanced clearance of streptococci from NALT following an intranasal 
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infection.  Persistence of streptococci in the NALT was monitored using BPI measuring 
total photon emission from the nose region of the mouse (Park and Cleary 2005). 
 
The M49 strain is now commercially available from Perkin Elmer and has been used by 
another group to determine the efficacy of an M protein peptide vaccine on invasive GAS 
infection (Sheel, Pandey et al. 2010). Recent work in this laboratory using BPI for 
S.pyogenes research has focused on the pathogenesis of nasopharyngeal infections and 
the development of a reproducible model of suppurative pharyngeal infection that could 
emulate human disease and allow study of transmission. Using a known M75 
nasopharyngeal isolate (Alam, Turner et al. 2013), the impact of virulence factors , for 
example covRS mutation on nasopharyngeal  infection was  assessed.  Having developed 
a suitable model, the group has developed a bioluminescent derivative of the M75 strain, 
M75lux, that was then used to assess SpyCEP as a vaccine candidate by comparing 
photon emission in vaccinated and sham-vaccinated animals, the results showing a 
reduced bacterial burden in the vaccinated group (Alam, Bateman et al. 2013). 
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2 Hypothesis and Aims 
The recent upsurge in invasive Group A streptococcal infections including necrotizing 
fasciitis has been associated with healthy young individuals, a proportion of which have no 
defined portal of entry or report a minor injury or prior respiratory tract illness. Previous 
work has attempted to model this process, highlighting a protein vimentin as a likely 
candidate involved in binding GAS to injured tissue.  However, past models require 
refining and validating.  The initial hypothesis is that a following an injury, GAS found 
colonizing the oropharynx causes a transient bacteraemia which then localizes at the site 
of injury. 
 
This hypothesis led to the following aims. 
1. To produce and characterise a model of mild contusion injury  
2. To produce a bioluminescent strain of an invasive GAS isolate 
3. To characterize the bioluminescent strain in lower respiratory tract, bacteraemia and 
muscle models of infection 
4. To produce a model of invasive GAS infection and contusion  
5. To evaluate the impact of trauma on GAS infection  
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3  Methods 
The main techniques used in this project are first described and then followed by a 
comprehensive list of bacterial strains, plasmids, materials and kits used in the project at 
the end of the Chapter. 
 
3.1 Bacterial strains and media 
GAS strains used in the project were clinical strains isolated from invasive GAS infections, 
the majority of which were from patients referred to the Hammersmith Hospital Infectious 
Diseases service (Table 3.1).  The isolates were grown overnight in Todd-Hewitt broth 
(THB) and then placed in 20% glycerol before storage at -80°C further use.  When 
required for use in experiments the isolates were plated from glycerol stocks onto 
Columbia horse blood agar (CHB) and then grown in THB at 37°C with 5% CO2.  All 
isolates were emm typed by standard molecular methods (Facklam, Beall et al. 1999). 
Plasmids were propagated in Escherichia coli (E.coli) strain DH5α (Invitrogen) and grown 
in Luria-Bertani (LB) broth at 37°C shaking at 200-220rpm.  Growth media were 
supplemented with antibiotics when required (GAS: kanamycin (400µg/ml); E.coli 
(kanamycin 50µg/ml), spectinomycin (50µg/ml)). 
 
3.2 Genomic techniques 
3.2.1 Genomic DNA preparation from GAS 
Streptococcal DNA was extracted using a method developed by Pospeich et al. (Pospiech 
and Neumann 1995). 50ml overnight cultures of GAS were grown in THB and centrifuged 
at 1000g for 10 minutes at 4°C.  The supernatant was removed and the pellet re-
suspended in 1ml sterile PBS, 20µl mutanolysin (10,000 units/ml) and 20µl of lysozyme 
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(100mg/ml) and incubated at 37°C for 10 minutes.  Samples were centrifuged at 200g for 
10 minutes and re-suspended in lysis buffer (500µl SET buffer, 50µl of 1% SDS and 5µl 
proteinase K (0.5mg/ml). Samples were incubated at 55°C in a water bath for 2 hours with 
occasional mixing.   
 
Following incubation, 175µl of 5M NaCl and 500µl of chloroform were added, and the 
samples were incubated for 30 minutes at room temperature before being centrifuged at 
16,000xg for fifteen minutes.  Following centrifugation, the aqueous phase was removed 
and transferred to a new tube and 500µl of isopropanol was added to precipitate the DNA.  
The DNA was pelleted by centrifugation at 16,000xg for 5 minutes and the supernatant 
was removed. The pellet was re-suspended in 70% ethanol and the centrifugation step 
repeated for a further 3 minutes.  The ethanol was discarded, and the DNA pellet was air-
dried and then resuspended in 200µl of molecular grade H2O. 
 
3.2.2 Polymerase chain reaction (PCR)  
All the primers used for PCR are referenced in Table 3.2.  The gene of interest was 
amplified using a polymerase from Megamix Blue mastermix, Go Taq Long Polymerase 
mastermix or Go Taq polymerase mastermix.  Each PCR reaction (50-100µl) constituted 
2µl DNA sample (10ng) added to the Megamix blue, Go Taq Long or Go Taq mastermix 
(quantities specified at the end of this chapter) with forward and reverse primers added 
(each at 100µM).  Samples were prepared on ice and placed in a Hybaid Touchdown 
Thermo cycler.  Standard PCR reactions were amplified using the following protocol: 
Samples were heated to 95°C for two minutes for initial denaturation.  Amplification 
included 30 cycles of denaturation at 95°C for 1 minutes, primer annealing at an optimum 
temperature for 1 minute and primer extension at 72°C for 1 minute.  Samples were 
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incubated at 72°C for 10 minutes for final extension and soaked indefinitely at 4°C to 
prevent DNA degradation. 
 
3.2.3 Electrophoresis of DNA (Agarose Gel Electrophoresis) 
2% agarose gels were made to analyse DNA products from PCR reactions.  The gels were 
made with TAE buffer (1x) with SybrSafe (1µl/10ml).  Following 5-10µl of sample being 
loaded and 7µl (0.7µg) of 1kbPlus ladder being added, gels were run in TAE buffer (x1) at 
100V for 30 minutes.  Products were visualized under UV light using a GelDoc-it imaging 
system and size of bands inferred from the ladder. 
 
3.2.4 Preparation of samples for sequencing  
3.2.4.1 PCR Purification 
Samples were cleaned using the QiaQuick PCR purification Kit to remove traces of dNTP, 
salts and primers from the PCR reaction, which could affect the PCR reaction.  One 
volume of each PCR product was added to 5 volumes of buffer PB (binding buffer).  The 
samples were transferred to a column and a collection tube.  The samples were 
centrifuged at 16,000xg for 1 minute and the follow through discarded.  Samples were 
washed with 0.75ml buffer PE (with ethanol added) and centrifuged for 1 minute at 
16,000xg and the follow through discarded.  Samples were centrifuged for a further minute 
at 16,000xg and the follow through discarded to remove the excess ethanol.  The spin 
columns were transferred to collection tubes (1.5ml eppendorfs) and 50µl ddH2O added to 
the centre of the column.  The DNA was eluted following centrifugation at 16,000xg for 1 
minute. 
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3.2.4.2 Sequencing and whole genome sequencing 
The concentration of PCR product was estimated from analysis of the electrophoresis gel 
and diluted in molecular grade water to an approximate concentration of 10ng per 100bp.  
A total volume of 7µl of appropriately diluted purified PCR product was added to a clean 
tube twice and 3µl of diluted primer (1pmole), forward and reverse was added to obtain 
forward and reverse sequences.  The MRC CSC Core genomics laboratory, Imperial 
College London, Hammersmith Campus, performed automated-fluorescent sequencing of 
products. In some cases, GAS strains underwent Illumina whole genome sequencing; the 
CSC core genomics laboratory prepared libraries from genomic DNA prepared as above. 
 
3.2.4.3 Analysis of sequences 
Bioedit software (www.mbio.ncsu.edu/BioEdit/bioedit.html) was used to view the sequence 
traces and sequences.  Analysis was carried out using clustalW multiple sequence 
alignment tool within BioEdit with the appropriate reference sequence traces. 
 
3.3 Plasmid constructs and electroporation of GAS 
3.3.1 Construction of plasmids pICL18Lux and pTHLK 
Two plasmids were used to derive bioluminescent strains by electroporation of GAS 
(Figure A and B): pTHLK (Alam, Bateman et al. 2013) derived from theta based vectors 
(Biswas, Jha et al. 2008) and pICL18Lux. pTHLK is a replicative shuttle plasmid carrying 
the luxABCDE construct with both Gram negative and positive origins of replication.  
pICL18Lux has only the pUC18 gram negative origin of replication and survival of the 
plasmid in GAS therefore requires integration into the chromosome via intentional 
homologous recombination.  The site for homologous recombination is the chromosomal 
 
 
97 
locus Spy0535 that encodes part of an extinct bacteriophage; an 839bp fragment from 
Spy0535 has been cloned into the construct upstream of the lux operon to allow targeted 
integration into this part of the genome, which is thought to be inert. Previous studies have 
demonstrated no functional effect of plasmid insertion at this locus (Alam, Bateman et al).  
Both constructs incorporate the Listeria monocytogenes Phelp  promoter (Riedel, Monk et 
al. 2007) upstream of the luxABCDE operon and both require kanamycin for selection in E. 
coli.  pICL18lux only requires kanamycin in S. pyogenes whilst pTHLK requires 
erythromycin selection in Gram-positive bacterial hosts.   Notably the ampicillin resistance 
gene of pUC has been removed from pICLmut. Both constructs were used previously to 
transform M75 GAS.  
 
Figure 3.1 Schematic diagrams of plasmids.  
Shown are the two plasmids used in this project with arrows indicating locations and 
orientations of open reading frames. Shown are the replicating plasmid construct pTHLK 
(A) and integrating plasmid pICL18Lux (B). Adapted from Alam et al, 2013 (Alam, Bateman 
et al. 2013) 
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3.3.2 Plasmid DNA extraction from E. coli by miniprep 
Plasmid DNA from E.coli was prepared using QIAprep Spin Miniprep Kit (Qiagen) using a 
modified protocol to account for the >10kB size of the plasmids.  This technique ensured 
the production of high quality and effective concentration of plasmid DNA. 5ml of each 
E.coli containing the desired plasmid was cultured overnight in LB supplemented with the 
appropriate antibiotic (pTHLK/pICL18mut - kanamycin 50µl, pDL - spectinomycin 50µl). 
Cultures were centrifuged at room temperature for 10 minutes and the supernatant 
removed.  250µl of Buffer P1 (with RNAase added) was used to resuspend the pellet and 
the tube was vortexed.  250µl of Buffer P2 was added to lyse the bacteria under alkaline 
conditions and the tube was inverted 4-6 times.  The samples were neutralized and 
adjusted for high salt binding conditions by adding 350µl of buffer N3.  Samples were 
centrifuged at 16,000xg for 10 minutes at room temperature.   
 
The supernatant was added to the Qiaprep Spin Column and spun for 1 minute to allow 
the adsorption of bacterial DNA onto the column membrane and the follow through 
discarded.  Samples were washed with 0.5ml or Buffer PB and 0.75ml of Buffer PE (with 
ethanol added) and centrifuged for 1 minute at 16,000xg and the follow through discarded.  
It was centrifuged at 16,000xg for a further minute to remove any excess alcohol and the 
follow through discarded.  The spin column was transferred to a clean 1.5ml eppendorf 
and 50µl of ddH2O added to the centre of the column and left to stand for 1 minute.  The 
DNA was eluted following centrifugation at 16,000xg for 1 minute.  The plasmid DNA 
obtained was stored at -20°C for further use. 
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3.3.3 Electroporation of Group A streptococci 
The electroporation of GAS was optimized and the protocol shown was used to produce 
the bioluminescent GAS strains (Kimoto and Taketo 2003). The empty replicative pDL278 
plasmid (LeBlanc, Lee et al. 1992) was used as a positive control and to assess the 
efficiency of the GAS transformation process; pDL278 requires spectinomycin selection.  
The GAS strains used in the study are shown at the end of this Chapter and these were 
transformed with either pTHLK or pICL18lux, as well as with control plasmid pDL278.    
 
3.3.3.1 Preparation of competent cells: 
10ml of overnight culture of the chosen GAS strain was inoculated into 100mls THB and 
incubated at 37°C.  The Optical Density (OD) at 600nm was measured at frequent 
intervals.  The cells were harvested by centrifuging at 3500g (Beckman Centrifuge, JA-20 
rotor) for 10 minutes at 4°C when the OD600 reaches 0.15-0.175.  The THB was removed 
completely after centrifuging and cells kept on ice, then washed twice with ice cold 
electroporation (1mM MgCl2, 272mM Glucose) by centrifuged at 3500g for 10 minutes at 
4°C.  After the last wash, the supernatant was decanted completely and the pellet re-
suspended in 750µl of electroporation medium and stored on ice for electroporation. 
 
3.3.3.2 Electroporation 
75µl of competent cells were mixed with 5µl plasmid DNA with pDL 278 as the positive 
control (LeBlanc, Lee et al. 1992), transferred to a chilled sterile electroporation cuvettes 
(1mm) and electroporated using the following settings: voltage, 1KV; resistance 128 ohms; 
capacitance 50µf (Gene Pulser Xcell, BioRad) aiming for a time constant between 3-4.5.  
1ml Todd-Hewitt Yeast 0.2% (THY) was added to each cuvette after electroporation and 
the sample transferred to 9ml THY and incubated at 37°C for 2.5-3 hours for recovery.  
 
 
100 
Post recovery the cells were centrifuged at 2500g at 4°C (RTH 750 Rotor, Sorvall) for 10 
minutes at 4°C and the supernatant decanted.  The cells were re-suspended in 500µl THY 
broth and 100µl plated onto 5 TH agar plates containing appropriate antibiotic and 
incubated for 24-48 hours at 37°C at 4.5-5% CO2.  Clones were screened for 
bioluminescence using an IVIS (Xenogen) and by growth in LB with antibiotic selection to 
measure Relative Light Units (RLU) using a luminometer (Modulus).   
 
Bioluminescent strains produced were grown in overnight in LB medium with antibiotic 
selection and then aliquoted into bead or glycerol stocks and stored at -80°C. 
 
3.4 In vitro GAS phenotypic analyses 
3.4.1 Growth kinetics of the bioluminescent strains  
Bioluminescent and parent strains were plated onto THY kanamycin (400mcgml-1) 
selective and CBA plates respectively.  Bioluminescent and parent strains were grown 
overnight in THB, with kanamycin for the bioluminescent strains.  A new culture was 
started from the overnight culture at a 1/10 dilution by inoculating 5mls of the overnight 
culture into 45mls of THB and this was performed in triplicate. At half hourly intervals 100µl 
of culture was removed from each replicate and the RLU measured using a modulus 
single tube luminometer either neat or diluted 1:10 in 1xPBS.  At hourly intervals, 1ml of 
culture was removed and the OD600 measured and a 10µl sample removed to assess 
bacterial counts (colony forming units, CFU) by serial dilution using the Miles and Misra 
method (Hasle 2014). 
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3.4.2 Light production of bioluminescent strains  
Overnight cultures of the bioluminescent strains were made and supplemented with 
kanamycin (400mcg/ml) if a pTHLK transformed strain.  100µl of neat culture was added in 
triplicate to a specialized blacked out 96 well plate (VWR) and then 1/10 dilutions were 
made from the neat culture (in triplicate).   For each dilution in triplicate the CFU, RLU and 
total flux (photons/second) using an IVIS was measured. 
 
3.4.3 Stability of bioluminescence expression in vitro  
The stability of the bioluminescent strains over 96 hours with and without antibiotic 
selection using kanamycin was assessed in vitro.  The strains were grown overnight in 
THB supplemented with kanamycin (400mcgml-1) and then 1ml of the culture was 
inoculated into 49ml of fresh THB with and without kanamycin and this was performed in 
triplicate.  Every 24 hours at a specific time points, samples were taken for plating onto 
antibiotic (kanamycin) selective and non-selective plates to assess the number of bacteria 
with and without the plasmid construct. 
 
3.5 Biochemical techniques 
3.5.1 Extraction of GAS cell wall associated proteins 
50ml of THB containing 30µl/ml of hyaluronidase was inoculated with chosen strain and 
grown overnight to stationary phase.  The cultures were centrifuged at 3000 rpm for 10 
minutes and the supernatant removed for further concentration using an ultrafiltration 
system.  The pellet was re-suspended in 1ml of 30%(w/v) raffinose and the sample 
transferred to an eppendorf tube and centrifuged at 10,000 rpm for 5 minutes.  The pellet 
was re-suspended in 1ml of cell-wall extraction buffer and incubated for 3h at 37°C turning 
occasionally.  Following incubation, the samples were centrifuged at 13,000 rpm for 10 
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minutes.  The supernatant (cell wall extract) was aspirated and filtered then concentrated 
as required. 
 
3.5.2 Western Blotting 
3.5.2.1 Vimentin in muscle 
10µl of supernatants from homogenized injured and control muscle tissues were 
denatured by incubating with LDS and DTT at 75°C for 10 minutes.  The protein samples 
were fractionated by running on a 10% Nu Page Tris gel (Invitrogen) in MES (1:20 dilution) 
at 200V constant for 35 minutes with a standard (Seeblue).  The proteins on the gel were 
transferred onto a Hybond-P membrane (Amersham) pre-soaked in methanol in cold 1% 
transfer buffer and run at 60V (300 Amps) for 1 hour at 4°C (using a Mini Trans-blot cell, 
Bio-Rad).  Once the transfer was complete the membrane is washed four times with PBS 
combined with 0.1% Tween and then it was incubated overnight in 5% milk (or for at least 
an hour). 
 
Following the incubation period, the milk was removed and then the membrane washed 
four times for at least 20 minutes on the rotator.  The wash solution was removed and 
0.5µl of the Vimentin primary antibody (Thermo Scientific) was added to 5ml of 1% milk 
(1:10000) and incubated on the rotator for 2 hours.  Following the incubation period the 
membrane was washed four times with PBS and 0.1% Tween for at least 20 minutes and 
then 0.25µl of HRP-conjugated goat anti-chicken antibody was added to 1% milk 
(1:20000) and then incubated for at least 45 minutes on the rotator.  Following the 
incubation period the membrane is washed four times for at least 20 minutes.  The 
membrane is removed and the sensitivity of the assay was improved by incubation with 
ECL  (enhanced chemiluminescence) Advance Western Blotting Detection Kit (GE 
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Healthcare).  The membrane was then exposed to X-ray film for 30 seconds and 1 minute 
and developed using an AGFA developer. 
3.6 Capsule measurement 
3.6.1 Preparation of GAS capsular hyaluronic capsule 
GAS isolates were grown on CBA from glycerol stocks.  A sterile loop was used to transfer 
colonies from each strain into 1.5ml eppendorf tubes with 600µl of sterile PBS (x1) to a 
final OD600 of 0.3-0.4.  Serial dilutions of the samples were plated for colony counts. The 
samples were spun at 16,000xg for 5 minutes and the supernatant discarded.  The pellets 
were washed twice in 300µl Tris-HCL (10mM, pH 7.5).  The samples were spun at 
16,000xg for 5 minutes in between washes.  Following the last wash, the pellets were 
resuspended in 300µl Tris-HCL.  An equal volume (300µl) of chloroform was added and 
the tubes vortexed for 30 minutes and then left to stand at room temperature for 1 hour.  
The samples were centrifuged at 16,000xg for 10 minutes.  The aqueous layer containing 
the hyaluronic acid was removed into a new tube. 
 
3.6.2 Quantification of GAS capsular hyaluronic acid 
The amount of capsule was quantified by using a Hyaluronan ELISA DuoSet (R&D 
systems). 100µl of diluted capture antibody was added to each well of a 96-well 
microplate, sealed and then incubated at room temperature overnight.  Following 
incubation, the wells were washed three times with Wash buffer and then each well was 
blocked with reagent diluent and then incubated for a further hour.  Following incubation, 
the wells were washed and the 100µl of samples and standards added and incubated at 2 
hours at room temperature.  Following incubation, the samples were washed and then 
100µl of the Detection antibody diluted in reagent diluent were added and incubated for a 
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further 2 hours.  Following the incubation, the plate was washed and 100µl of the working 
dilution of Streptavidin-HRP was added to each well and the plate covered and incubated 
for 20 minutes at room temperature, avoid placing in direct light.  The wash step is 
repeated and 100µl of substrate solution is added and incubated for 20 minutes at room 
temperature (avoiding direct light).  Following incubation, 50µl of Stop solution (H2SO4) 
was added and the optical density of each well was estimated using an ELISA plate reader 
(MQuant, Bio-Tek Instruments inc.) at 540nm absorbance.  The sample concentrations 
were calculated from the standard curve (using KcQuant software).   Capsule production 
was measured in fg/cfu. 
 
3.7 Assays of GAS fitness in tissue culture 
3.7.1  Galleria mellonella fitness assay 
To determine fitness of GAS strains in a system with live innate immune system, Galleria 
mellonella were obtained from a single vendor (Live foods) and infected (Olsen, Watkins et 
al. 2011, Loh, Adenwalla et al. 2013).  After receipt, the larvae were allowed to equilibrate 
for 24 hours by storage in the dark at 10-12°C and then used within 2 weeks of purchase.  
Prior to experimental work, the larvae were inspected for any discoloration or black 
speckling.  Larvae were injected with 10µl GAS or PBS (control) into the left hindmost 
proleg as per previously described models (Olsen, Watkins et al. 2011, Loh, Adenwalla et 
al. 2013). Following inoculation, the infected larvae were incubated at 37°C in 5% CO2 in 
petri dishes.  The wax worm larvae were infected in groups of 20 and observed for survival 
with mortality of the wax worm shown by rapid melanisation (dark pigmentation) and no 
movement. 
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Figure 3.2 Wax worm alive and dead. 
 A photograph of the appearance of a healthy wax worm prior to inoculation and dead wax 
worm illustrating dark melanisation that occurs.(Hoenen, Watt et al. 2014) 
 
 
3.8 Murine models of invasive GAS infection and injury 
The next section will describe the maintenance, housing and anaesthesia used in animal 
experiments.  The techniques used to infect the mice to produce an invasive GAS infection 
(iGAS) will be described.  For each model the bacterial burden of each tissue was 
calculated and the host cytokine response measured using a mouse 20-plex luminex kit. 
Biophotonic imaging using an IVIS was used to refine the iGAS model. A new murine 
model of injury was produced using the weight drop device and the extent of injury 
characterized by comparing histopathology and the host response through the use of the 
mouse 20-plex Luminex assay. 
 
3.8.1 Animal maintenance and anaesthesia 
Animal studies were approved by the Home Office and conducted according to the Animal 
and Scientific Procedures Act 1986 and approved by the local Ethical Review Process.  
Adult female mice (approximately 20-30g, aged 6-8 weeks) of CD1 or FVB (n) strain were 
used (Charles River UK Ltd, Harlan Olac Ltd) and were maintained in individually HEPA 
filtered cages with sterile bedding and free access to food and water. GLP Mini Fun 
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Tunnels (Lillico), or Des. Res. Mini Mouse Houses were provided for environmental 
enrichment.  Food and water were provided ad libitum, and the facility was maintained on 
a 12 hour light-dark cycle. 
 
Mice were maintained in cage densities between 3-8 mice per cage depending on 
individual mouse weights.  Mice were anaesthetised briefly with 2% isofluorane for 
intranasal and intravenous infection and contusion experiments.  Following non-terminal 
experiments was animals were allowed to recover from anaesthesia and return to their 
cage.  Anaesthetic was used to allow control of the animal during infection and muscle 
injury and limit discomfort.  Isofluorane was chosen, as fluorane-based anaesthetics have 
been shown to have the least effect on muscle contractility although little is known 
regarding injury (Ingalls, Warren et al. 1996) and administration does not require an 
external injection, which would interfere with the development of the model. 
 
3.8.2 Murine model of lower respiratory tract infection 
Female CD1 or FVB/n mice aged 6 to 8 weeks (Charles River, Margate, UK) were used to 
model a lower respiratory tract infection.  Following gaseous anaesthesia with isofluorane, 
mice were challenged intranasally with between 1x107-1x108 cfu per mouse, administered 
in volume of 25µl. Pilot work has shown that this volume and bacterial load to be sufficient 
to cause a reproducible lower respiratory tract infection and pneumonia. The inocula for 
infection were prepared from overnight cultures of THB inoculated with parent or 
bioluminescent GAS strains with or without antibiotic selection (kanamycin 400µml -1).  
Following incubation, cultures were spun at 2500rpm at 4°C for 10 minutes, the 
supernatant discarded and the pellet re-suspended in PBS (x1) to wash away any 
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remaining THB.  A600 was adjusted to between 0.8 - 1, using a 1:100 dilution of the final 
inoculum so that a 25µl sample would give approximately 1x107 - 1x108 CFU per mouse.  
 
The number of viable bacteria within each inoculum was assessed by serial dilutions and 
plated using the Miles and Misra method.  The animals were observed according to the 
experimental protocol on the project licence and the animals culled at day 2 following 
infection, unless they reached a defined end point prior to this. Bacterial burden in the 
nose, lung, spleen, liver, blood, muscle and inguinal lymph node (ILN) were estimated and 
the method of dissection will be described at a later point in this chapter.  To directly 
evaluate the ability of bioluminescent GAS to be non-invasively detected in the thoracic 
cavity in vivo bioluminescent GAS were injected directly through the chest wall of a group 
of 6 mice, on both sides, immediately after being culled. 
 
3.8.3 Murine intramuscular infection 
Female CD1 or FVB/n mice aged 6 to 8 weeks were intramuscularly infected with 
approximately 1x108 cfu in a 50µl volume by injection directly into the thigh (Kurupati, 
Turner et al. 2010). Following infection the animal was allowed to recover and move freely 
in the cage.  The number of viable bacteria within the inoculum was assessed by serial 
dilutions.  The animals were observed for 24 hours following infection.  The animals were 
culled at the defined end point and the infected muscle, inguinal lymph node, spleen and 
liver dissected for bacterial burden.  The blood was plated for CFU and serum spun for a 
cytokine luminex panel. 
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3.8.4 Intravenous Infection 
Female CD1 and FVB/n mice were infected with 1x107– 6x107 cfu/mouse (volume of 50µl) 
of washed GAS (process previously described) intravenously via the lateral tail vein 
(Hamilton, Bayer et al. 2008) and monitored.  Mice were culled when they reached a 
critical end point.  24h following infection, mice were culled and spleen, liver, lung, muscle 
and inguinal lymph node harvested.  Blood was plated for CFU and serum spun for a 
cytokine Luminex panel to assess the host response. 
 
3.8.5 Dissection 
At the end of the experiment, all the animals were culled using CO2 inhalation, blood 
removed for serum and bacterial counts by cardiac puncture.  To remove the organs the 
peritoneum was exposed, the spleen and a small portion of liver removed through an 
incision on the left side. The inguinal lymph nodes were localized on the peeled skin and 
dissected, following which the thigh tissue was removed.  The lungs were removed by 
dissecting through the diaphragm, carefully removing the heart.  The nasopharynx was 
dissected by exposing the cranium and removing the orbits as previously described (Alam, 
Bateman et al. 2013) .  The dissecting equipment was cleaned in between dissections by 
placing in microsol, followed by water and then 70% ethanol.  All organ tissues were 
placed in a pre weighed container and PBS (x1) was added and the tissue homogenized.  
The samples were plated onto CBA either neat or serially diluted depending on type of 
infection. 
 
3.8.6 Histopathology 
Samples of tissue were formalin fixed and sent for routine processing, decalcification and 
sectioning to produce Haematoxylin and Eosin (H&E) stained sections and Gram-stained 
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sections (where tissue was infected). Injured and control legs were orientated so that 
longitudinal sections including the surface skin, injured muscle and bone could be 
visualized.  The sections were examined by Professor Cheryl Scudamore (Chair of the 
SAC in Veterinary pathology) and the degree of muscle damage and inflammation was 
scored using a semi-quantitative grading scheme (Shackelford, Long et al. 2002).scores 
were semi-quantitative, allowing estimates of severity rather than actual measurements.  
The severity grades were determined by the extent or estimate of the percentage of tissue 
involved i.e. damaged and the magnitude of the damage i.e. severe myo-degeneration.  
For this project a numerical value was assigned to the histological findings reported. And a 
median value was calculated.  
Numerical Severity grading Qualitative description of 
histology 
Percentage of tissue involved 
0 Not present  
1 Minimal <1% This corresponds to a change that 
may be barely noticeable. 
2 Slight 1-25% This corresponds to a histological 
change that is noticeable but not a 
prominent feature of the tissue. 
3 Moderate 26-50% This corresponds to a 
histological change that is a prominent 
feature of the tissue.   
4 Moderately severe/high 51-75% This corresponds to a 
histological change that is an 
overwhelming feature of the tissue. 
5 Severe/high 76-100% This corresponds to a 
histological change that is the main 
feature of the tissue. 
 
Table 3.1 Severity grading system for the histological analysis of injured tissue 
samples.  
Shown in the table are the histological grading scores for the assessment of injured tissue 
samples (Shackelford, Long et al. 2002). 
 
3.8.7 Colony identification 
 
Colonies of GAS were visualized on CBA plates 24h following serial dilutions and plating.  
The plates were examined for the presence of GAS by evidence of beta-haemolysis.  
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Confirmation of GAS was performed by Gram-staining and/or Lancefield grouping 
(Facklam 2002). GAS are Gram-positive bacteria appearing purple under the microscope 
and are usually in pairs or chains. Following the addition of Grouping reagent A, the 
sample will agglutinate similar to the positive control.    
 
3.8.8 Luminex cytokine assays 
Serum and muscle tissue obtained from experiments were assessed for cytokine 
responses using a mouse cytokine 20-plex kit (Invitrogen) according to the manufacturers’ 
instructions.  The kit is designed to detect the following cytokines and chemokines: FGF 
basic, GM-CSF, IFNϒ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IP-10, 
KC, MCP, MIG, MIPα, TNFα and VEGF in serum or tissue culture supernatant.  
 
Following the samples being defrosted, they are spun and the supernatant removed.  The 
standard and solutions for the standard curved are prepared.  Before use, the plate is 
washed with working wash solution and antibody detection beads are added to each well 
of the 96 well plate and then the plate washed again. The standard is added to the wells, 
along with a blank.  Samples and controls are added to the remaining 80 wells with 
Incubation buffer and assay diluent.  The plate is incubated out of direct sunlight on a 
shaker for 2 hours.  Prior to the end of the incubation, 1xbiotenylated antibody is added 
and then left on the shaker under cover for a further hour.  During this step, the luminex 
system is prepared and calibrated ready for analysis.  At the end of the incubation period, 
streptavidin is added and the plate covered and incubated on the shaker for a further 30 
minutes.  Following the incubation period, the plate is washed and the liquid extracted.  
The plate is incubated with working wash and then drained and analysed. 
 
 
 
111 
3.9   Imaging 
3.9.1 Biophotonic Imaging 
Groups of infected mice were subjected to bioluminescence analysis under isofluorane 
anaesthetic using an IVIS 100, Spectrum or Lumina System (Perkin Elmer).  The mice 
were imaged, at most three times in the same day.  Following imaging, the animals were 
allowed to recover in their cages with free access to food and water.  Background images 
were obtained prior to infection experiments.  During imaging, a reference image was 
obtained of the animal under low illumination prior to quantification of photons emitted from 
bioluminescent GAS strains at a binning of 4 over 60 seconds.  Photon emission was 
determined with Xenogen’s Living Image Software Package (Version 3.2).  A pseudo 
colour image representing the light intensity was generated using the software and 
superimposed over the grayscale reference image, this allowed localization of the signal to 
a particular anatomical site.  Light intensity on the reference image was presented as total 
flux (photons/second).  Bioluminescent signals were quantified by measuring a region of 
interest (ROI) over a specific organ site using the Living Image Software 3.2 programme 
and displayed as total flux.  The total flux was then compared to bacterial counts in the 
same organ tissue. 
 
3.9.2 Faxitron Imaging 
The faxitron point project digital micro-radiography machine was used to assess the bones 
of the injured limbs prior to histological analysis. This imaging technique was also used to 
refine the modelling of injury to the muscle and identify any inadvertent fracture causation.  
The limitation of the technique is that it is only used on cadavers.  Injured female CD1 
cadavers aged 6 to 8 were placed in the Faxitron machine (Bassett, van der Spek et al. 
2012). The following equipment and computer software was available: Faxitron MX20 
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variable kV point projection X-ray source and digital image system (Qadas, Cross 
Technologies plc, Berkshire, UK); Image J 1.43n software; Adobe Photo stop 7.0.1 
software. 
 
Prior to imaging the machine was calibrated by running images at 15s with a voltage at 
26kV.  The animal was placed on the image area on a sample tray and inserted into the x5 
magnification slot and the door is closed.  The exposure is started and the image 
displayed on the computer screen.  The image is saved as a DICOM file.  Image J was 
used to analysed the images. 
 
3.10    Statistics 
Statistics were performed using Prism Graph pad version 6.0.  Data are presented as 
median plus range.  Power and sample size calculations were performed to determine 
number of animals used in experiments: n=6 for intramuscular infection experiments and 
n=8 for intranasal lower respiratory tract infection experiments.  The different statistical 
tests used for experiments are shown below: 
 
3.10.1 Regression Analysis 
Regression analysis was used as the relationship between data and to fit data to the 
appropriate linear, logistic or decay model.  The data was deemed a good fit when the r2 
>0.95 and a p value of less than 0.05 was defined as significant. 
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3.10.2 Mantel-Cox Log-rank test 
To analyse the survival distributions of groups, the log-rank test was used.  It is a non-
parametric test and p values of less than 0.05 were defined as significant. 
 
3.10.3 Mann-Whitney U  
The non-parametric Mann-Whitney U test was used to compare colony counts and 
cytokine responses in different organs between the injured and control groups.   A p value 
of less than 0.05 was defined as significant. 
3.10.4 Chi-Square Test 
 
The chi-squared test was used to determine whether there is a significant difference 
between the expected frequencies and the observed frequencies in one or more 
categories. A p value of less than 0.05 was defined as significant. 
 
3.10.5 Kruskal-Wallis Test 
The non-parametric test was used to compare colony counts and cytokine responses in 
three or more unmatched groups.  In the majority of cases a post Dunn’s test was 
performed.  A p value of less than 0.05 was defined as significant. 
 
3.10.6 Power Calculations 
Power calculations were performed to calculate the minimum number of animals required 
to detect an effect of a given size. PS (Power and sample size) was the computer 
programme used to perform statistical power and sample size calculations 
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3.11   New Techniques 
3.11.1 Model of Contusion 
The Home Office approved the administration of a controlled contusion to the hind limb of 
the mouse.  Contusion of the hind limb was undertaken using the weight drop device 
(WDD) (Figure 3.4) as pilot experiments showed no histological evidence of soft tissue 
damage following compression by calibrated forceps.  The device used is a modification of 
a standardised fracture device used in rats (Bonnarens and Einhorn 1984), which has 
been subsequently amended (Macdonald, Skirving et al. 1988).  
 
 
Figure 3.3 Weight Drop Device.  
This device consists of a blunt nosed impactor which is a straight bar of 10 mm width and 
5 mm radius rested against the skin. The Impactor is in turn driven by a falling weight of 
mass 125 g, which is dropped a distance of 13 cm on to the anvil connected to the 
impactor, imparting a total energy of 15.7 mJ to the tissue, (157000 ergs). 
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Two models of injury were produced using the WDD method and these were adapted from 
a previous crush model by Bunn et al, 2004 (Bunn, Canning et al. 2004) by changing the 
weights administered, (250g and 123g) and adjusting the height of the weight drop to 
13cm.  The model was further adapted following histopathology reports to include 
screening with Faxitron X-ray using a weight of 123g, height 13cm to ensure no bony 
injury to the animal.  To produce the mild contusion in the mouse hind limb the animal was 
positioned ventrally under isofluorane anaesthetic and injured using the 123g weight 
dropped at a height of 13cm on to the left thigh.  Following injury the animal was allowed 
to recover freely in its cage.  Buprenorphine was administered as advised by the 
Veterinary service to animals receiving the higher weight, but not those receiving the lower 
weight.  Control animals (i.e. not injured) were anesthetised using isofluorane only.  
 
Following contusion animals were monitored for change in weight or signs of distress.  The 
animals were culled at specific time points and the leg muscles removed and stored in 
formalin.  Samples were decorticated then; longitudinal sections were made and stained 
with Haematoxylin and Eosin.  Professor Cheryl Scudamore at MRC Harwell, Oxford, 
reviewed histopathological slides. 
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3.12  GAS strains 
 
M Type 
 
Strain 
 
Disease Focus 
 
Source 
Reference/Year 
Sample acquired 
1 H305 Scarlet Fever Reference 
Strain 
1880s 
1 H584 Puerperal 
sepsis, STSS 
Blood 2007 
1 H758 Necrotising 
fasciitis 
Tissue isolate 2010 
1 H800 Unknown Throat isolate 2010 
3 H325 Necrotising 
fasciitis 
Blood 1998 
75 H347 Pharyngitis Throat 1998 
75 H347Lux Pharyngitis Throat – 
bioluminescent 
strain 
2013 
89 H293 Necrotising 
fasciitis 
Muscle 1995 
 
Table 3.2 GAS Strains used in this study.  
A number of clinical GAS isolates obtained from an Imperial College London collection 
were used in this project and are shown in the above table. 
 
3.12.1 Primers 
Target gene Primer Primer Sequence 
Diagnostic primers 
to detect targeted 
integration of 
pICLLux 
 LF CAAAAGATGATGTTGTCCTAATTCA 
 RR 
 
GCTTTTCTATACTATCCCCTTCTTTC 
CovR sequencing covRS  1F 
 
CTTGCAAGGGTTGTTTGATG 
covRS 1R 
 
TTGAACTATATGGCAATCAGTG 
covRS 2F   
 
ATATCCAAACAGTGCGTGGC 
covRS 2R 
 
CGTTGTAAGAGACCAATATGC 
covS sequencing covRS 3F 
 
CGCTCAGATATTTCGTCAGG 
covRS 3R 
 
ATCGCGATTGACAGTATTTC 
 
Table 3.3 Primers used in this study.  
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3.13  Materials 
3.13.1 Chemicals 
 
Chemicals were obtained from Sigma-Aldrich (Dorset, UK), VWR (Lutterworth, UK), 
Fisher-Scientific, GE Healthcare or Invitrogen.  A list of specific chemicals is shown below: 
ECL system (GE Healthcare, Chalfont St Giles, UK) 
EDTA (Sigma-Aldrich) 
Ethanol (Fisher) 
Glucose (VWR) 
Formalin (VWR) 
Hyaluronic acid (Sigma-Aldrich) 
NaCl (VWR) 
Sodium dodecyl sulphate (Sigma-Aldrich) 
3, 3’, 5, 5’-tetramethylbenzine (TMB)(Sigma) 
Tween 20 (Sigma-Aldrich) 
Calbiochem protease inhibitor III (Calbiochem, Nottingham, UK) 
Primers were obtained from Sigma-Aldrich (Dorset, UK) 
 
3.13.2 Enzymes 
GoTaq® Hot Start DNA Polymerase 
Hyaluronidase (Sigma-Aldrich) 
Lysozyme (Sigma-Aldrich) 
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Mutanolysin (Sigma-Aldrich) 
Proteinase K (Sigma-Aldrich) 
Phusion DNA Polymerase (Finnzymes) 
Taq Polymerase (recombinant) 
 
3.13.3 PCR Mastermix combinations 
 
GoTaq® Long PCR Mastermix 
 GoTaq® Hot Start DNA Polymerase 
 Proofreading DNA Polymerase 
 dNTPs 
 MgCl2 
MegaMix-Blue Mastermix 
 Taq Polymerase (recombinant) 
1.1x reaction buffer (2.75mM MgCl2) 
 220µM dNTPs 
  
3.13.4 Standard solutions and buffers 
DNA Loading Buffer 
0.25% w/v bromophenol blue (Sigma-Aldrich) 
0.25% w/v xylene cyanole (Sigma-Aldrich) 
30% glycerol (AlalaR, Fisher Scientific, Loughborough, UK) 
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Electroporation Media 
450mls 1mM autoclaved MgCl2 
24.5g D-Glucose filter sterilized into 50mls sterile distilled water 
Preserved at 4°C  
Phosphate buffered saline (PBS) 
137mM NaCl 
2.7mM KCl 
10mM Na2HPO4 
2mM KH2PO4 
Protein sample treatment buffer 
NuPAGE LDS Sample Buffer (4X) (Invitrogen, UK) – to  1X 
1M Dithiothreitol (DTT)(10X) – 1X 
ddH2O – to the required volume 
SET 
750µl of 5M NaCl 
2.5ml 0.5M EDTA 
1ml of Tris pH 7.5 
Made up to 50mls with sterile distilled H2O 
MES Buffer  
Made by adding 25ml of MES Buffer (x20) to 475ml water 
200ml placed in the top of tank with NuPage antioxidant for running membrane 
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Western blot transfer buffer (10x) 
0.25M Tris (Sigma-Aldrich, UK) 
1.92M glycine (VWR) 
Western blot blocking solution (1xPBS) 
5% w/v skimmed milk powder (Marvel milk, Tesco, Herts, UK) 
0.1% Tween20 
Western blot, Luminex and ELISA washing solution 
0.05% Tween20 
Made up in PBS(1X) 
 
3.13.5 Antibodies 
Goat anti-rabbit HRP conjugated (Sigma-Aldrich) 
Mouse Vimentin antibody (PA1759, Thermo scientific) 
Goat anti-chicken HRP conjugated (Abcam) 
 
3.13.6 Antibiotics 
Kanamycin 50µg/ml (E.coli) and 400µg/ml (GAS) (Sigma-Aldrich, UK) 
Spectinomycin 50µgl/ml (Sigma-Aldrich, UK) 
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3.13.7 Broths and agars 
Columbia blood agar (Oxoid) 
Luria Bertani (LB) broth 
10g/L NaCl 
10g/L Typtone (MERK, Germany) 
5g/L Yeast extract Oxoid 
Luria Bertani (LB) Agar 
15g/L Bacteriological agar (Oxoid) added to make LB Agar 
Todd Hewitt Broth (THB) (Oxoid, Basingstoke, UK) 
Todd Hewitt Yeast (THY) Broth 
0.2% w/v Yeast extract (Oxoid) 
Todd Hewitt Yeast Agar 
2% w/v Bacteriological agar (Oxoid) 
 
3.13.8 Kits 
QIAprep Spin Miniprep Kit (Qiagen) 
Buffer P1 plus RNaseA 
Buffer P2 
Buffer N3 
Buffer PB 
Buffer PE 
Elute in EB 
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QIAquick PCR purification Kit (Qiagen) 
Buffer PB 
Buffer PE 
Elute in water 
Mouse cytokine 20-plex Panel (Luminex)(Invitrogen) 
Mouse 20-plex antibody bead solution (1x) contains 7.5mM sodium azide 
Mouse 20-plex Biotinylated Antibody concentrate (10x) (contains 0.1% sodium azide) 
Mouse 20-plex Lyophilized Standard (contains 0.1% sodium azide) 
Wash Solution Concentrate (20X) (contains 0.1% sodium azide) 
Assay Diluent (contains 0.1% sodium azide) 
Incubation Buffer (contains 0.05% sodium azide) 
Biotin Diluent (contains 3.3mM thymol) 
Streptavidin-RPE Concentrate (10X) (contains 0.1% sodium azide) 
Streptavidin-RPE Diluent (contains 3.3mM thymol)  
96-well filter plate 
SDS-PAGE 
NuPAGE Gel (12% BisTris gel)(Invitrogen) 
NuPAGE MES running buffer (1x) – (0.5x)(Invitrogen) 
NuPAGE antioxidant (Invitrogen) 
SeeBluePlus2 Pre-Stained Standard (Invitrogen) 
Streptococcal grouping Kit (Oxoid)  
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4 Characterizing a mouse model of mild contusion 
4.1 Introduction 
Experimental models of injury are used to replicate processes occurring during mechanical 
injury seen in humans (Souza and Gottfried 2013). The models are diverse both in 
methods used to produce the trauma and the severity of the damage inflicted.  Models 
mimic contusion, laceration or strain injury through a variety of methods: contusion by 
blunt force or crush, laceration, eccentric contraction, ischaemic-reperfusion, toxin or 
injection of local anaesthetic. Rodents, particularly rats are commonly used in models and 
histology often monitors the impact of the injury to the skeletal muscle (Souza and 
Gottfried 2013). Two models of injury have been previously used in modelling GAS NF 
and trauma: a crush contusion model (Seki, Saito et al. 2008) and a known eccentric 
contraction model (Peters, Barash et al. 2003, Hamilton, Bayer et al. 2008, Seki, Saito et 
al. 2008).  
 
The eccentric contraction (EC) model requires electrodes to be inserted through the skin to 
stimulate a nerve to cause muscle contraction (Peters, Barash et al. 2003, Hamilton, Bayer 
et al. 2008).  The EC model was not chosen to mimic muscle injury in this project because 
there is potential for GAS to enter the injured muscle through the insertion site of the 
electrodes.  Previous work has shown that GAS can seed sites of injury through grooming 
or in fighting, (Alam, Turner et al. 2013, Walker, Barnett et al. 2014) underlining the 
importance of ensuring skin breaks are avoided in these models.  The other model used a 
“crush”contusion, which was crude and not characterized appropriately (Seki, Saito et al. 
2008). 
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The aim of this chapter is to develop a characterised murine model of muscle contusion 
producing muscle injury with no bony injury or break in the skin of the mouse.  The model 
will mimic the contusion injury reported in cases of GAS NF and trauma.  This project 
produced two models of contusion, one mild and one moderate in female CD1 mice, 
characterized by comparing the histological response seen in the soft tissue and muscle. 
The cytokine response was assessed in the serum of both models. To refine and hopefully 
reduce numbers used, the model was then extended to an inbred strain of mouse that has 
recently been used for bioluminescence imaging, the FVB/n mouse; cytokine response 
was assessed in the serum and muscle of using the mild contusion model. The mild 
contusion model was chosen as the new injury model for the further infection 
models as it produced muscle inflammation with no bony involvement (i.e. no 
fracture).  
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4.2 Results 
4.2.1 The moderate contusion model produces severe myo-degeneration and 
fracture to the bone at the site of injury 
In initial experiments, 6-8 week old female CD1 mice were injured with the weight drop 
device (WDD) using a 250g weight at a height of 13cm (n=8).  Following injury the mice 
were observed for symptoms or signs of distress and weighed daily. Published work had 
reported that this weight produces a severe muscle injury but no bony injury, although in 
this case the muscle belly was isolated using surgical techniques (Bunn, Canning et al. 
2004).  There was no significant change in weight at 24 and 48h following injury with mice 
showing no external sign of distress (Figure 4.1 A). Mice were culled at 24 and 48 hours 
following injury (n=4 per group).  
 
Histopathological examination of the thigh tissue revealed subclinical fractures of the 
femur in the injured leg of some animals (3/8 mice) at both time points (Figure 4.1 C-D, E-
F).  There was no difference in the overall histological score (Shackelford, Long et al. 
2002) at 24 and 48h following injury and the median score was 3 (Figure 4.1B). 
Histopathological changes consisted of myo-degeneration (characterised by muscle 
necrosis) graded moderate (grade 3 out of 5) or moderately severe (grade 4 out of 5) seen 
at both time points with associated inflammation (seen in 7/8 mice) which tended to be 
acute (neutrophils predominating at 24 hours, Figure 4.1C and D) becoming mixed 
(neutrophils and macrophages) at 48 hours (Figure 4.1 E and F).  Inflammation was 
present at the fracture site and in muscles cranial and caudal to the femur.  For each time 
point there are two images showing two different magnifications, each with a control slide 
(right leg of the animal) showing no evidence of tissue or bony change.  
 
 
 
126 
 
 
 
 
127 
C 
 
  
 
 
128 
D 
 
 
 
 
 
 
 
129 
E 
 
 
 
 
 
 
 
 
 
130 
F 
 
 
 
 
 
131 
 
Figure 4.1 Characterization of the moderate contusion model.  
Following a contusion to the thigh muscle using the modified WDD with a weight of 250g 
and height of 13cm the weight of mice, grade of histological damage and cytokine 
response was recorded at two time points, 24 and 48h.  This model is known in the text as 
the moderate contusion model.  A There was no weight loss following injury and no 
difference in weight between the time points (p>0.05 Mann Whitney U test). B   There was 
no change in histological grading score between the time points (p>0.05 Mann Whitney U 
Test) although the grading indicated moderately severe inflammation. C and D Low and 
high power photomicrographs (H&E stained) of injured and uninjured legs. C and D 
images show a fracture site in an injured leg at 24 hours following injury. F= fracture site, 
M = myodegneration, N= normal muscle tissue.   At 24 hours the fractures are associated 
with acute muscle damage and inflammation. The right control (uninjured) leg shows no 
evidence of tissue or bony change. E and F Low and high power photomicrographs (H&E 
stained) of injured and uninjured legs.  E and F images show a fracture site in an injured 
leg at 48 hours following injury.  
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4.2.2 Significant rise in keratinocyte derived chemokine (KC) following injury 
using the moderate contusion model 
To determine the host response to severe injury, cytokines and chemokines were 
analysed in the serum of female CD1 mice at three time points: 0, 24 and 48h following 
injury (n=4 mice per time point). Following injury at 48h there was a significant increase in 
KC (Figure 4.2); the chemokine was detected 24h after injury. 
 
  
 
 
 
 
Figure 4.2 Significant rise in KC following injury with the moderate model.  
Serum obtained from 6-8 week old female CD1 females was analysed using a mouse 20-
plex Luminex kit at three time points 0, 24 and 48h following injury with the severe 
contusion model.  The time points are divided because the serum was taken and analysed 
at different times (indicated by ----). There was a significant increase in KC (p<0.01) at 48h 
following injury.  
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4.2.3 Many cytokines show a significant decrease following injury with the 
moderate model. 
Following injury with the severe contusion model, cytokines were measured using a 20-
plex mouse luminex kit. There was a significant decrease in IL-alpha, VEGF, IL-12, MIP-
1A, MCP-1, IL-2 and IL-beta concentration compared to uninjured mice (Figure 4.3). The 
remaining cytokines analysed (FGF basic, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, GM-CSF, 
TNF-α, IFN-ϒ, IP-10 and MIG) showed no change following injury with this model  (data 
not shown).  Although there appears to be a significant decrease in many cytokines 
following injury, this could be artefactual as the serum at 0h was analysed separately from 
time points 24 and 48h.  
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Figure 4.3 Cytokine responses in sera to Moderate Contusion  
Graphs representing the response of the following cytokines IL-1 alpha, IL-1 beta, IL-2, 
MCP-1, MIP-1A, IL-12 and VEGF to injury with the moderate contusion model.  
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4.2.4 The mild contusion model produces mild inflammatory changes to the 
muscle and surrounding tissue with no fracture. 
The model of moderate contusion was adapted in female CD1 mice aged 6 to 8 weeks to 
produce a mild injury with no fracture by adjusting the drop weight to 123g and keeping the 
drop height at 13cm. Faxitron x-ray was used to screen cadavers to optimise the weight 
used to cause an injury and to ensure no fracture (Figure 4.4).  The x-ray was 
subsequently used to screen all the animals following injury at both time points prior to the 
muscle being submitted for decalfication and sectioning.  
 
 
 
 
Figure 4.4 Faxitron x-ray of a mouse injured with weight drop device to produce a 
mild contusion injury.   
Female mouse cadavers were used to optimize the WDD to produce a muscle injury with 
no fracture.  Following injury female CD1 mice were imaged using the Faxitron machine 
prior to the muscle being sent for histopathological analysis.  There was no evidence of 
fracture to the bone in this model using either CD1 or C57BL/6, DQ8, FVB/n mice.  This is 
an image from a female CD1 mouse at 24h following an injury with the mild contusion 
model.  
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Following injury with the new model the mice were observed for symptoms or signs of 
distress and weighed daily. There was no change in weight in the mice or histological 
score seen between the two time points (Figure 4.5 A-B). There was histopathological 
damage to the injured tissue showing mild inflammatory changes variably to the muscle, 
fascia and skin and surrounding tissue at both time points with a median score of 2  
(Figure 4.5 C-D, E-F). 
 
Histopathological examination of the thigh tissue revealed no fractures in the injured leg 
at both time points.  Histopathological changes consisted of focal inflammation of the 
subcutis with infiltration of neutrophils at 24h (Figure 4.5 C-D) and a mixed inflammatory 
response of neutrophils and macrophages at 48h (Figure 4.5 E-F) following injury. 
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Figure 4.5 Characterization of the mild contusion model.  
Following a contusion to the thigh muscle using a weight of 123g and height of 13cm with 
the WDD, mice were observed at two time points 24 and 48h (n= 12 per group).  Following 
injury the mice were weighed, the histological damage, grade and score recorded.  This 
model is known as the mild contusion model. A There was no significant difference in 
weight between the two groups. B There was no difference in histological score between 
the two time points. C-F Photomicrographs of H&E stained tissue sections.  C and D 
Images shows focal inflammation in the subcutis of the injured leg in an animal 24 hours 
after injury at low (C) and high (D) magnifications (scale bars recorded).  Tissues in the 
control animal are normal. E and F Images show an example of injured muscle at 48 
hours with loss of myofibres and replacement by a mixed inflammatory response of 
neutrophils and macrophages at low (E) and high (F) magnification.  Tissues in the control 
animal are normal.  N = Normal muscle tissue, arrow represents the area of injury with an 
inflammatory response. 
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4.2.5 Minimal inflammatory systemic response observed in the mild 
contusion model except for an acute rise in IL-6. 
To determine the host response to mild injury, cytokines were analysed in the serum of 
female CD1 mice at four time points: before injury, 1, 24 and 48 hours following injury (n= 
6 mice for 0 and 1 hours; n=12 for 24 and 48 hours). At 1 hour post injury there was a 
significant increase in IL-6 in the serum of mice (p<0.05) following injury consistent with a 
transient acute phase response (Figure 4.6).  
 
 
 
 
 
 
 
Figure 4.6 Significant increase in IL-6 immediately following injury with the mild 
contusion model.   
Serum obtained from 6-8 week old female CD1 females was analysed at before injury, 1, 
24 and 48h following injury using a 20-plex mouse luminex kit with the mild contusion 
model.  The time points are divided because the serum was taken and analysed at 
different times (indicated by ----).  There was a significant increase in IL-6 following injury 
(p<0.05) that was short lived and not observed at subsequent time points. 
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4.2.6 There was minimal response in other cytokines analysed. 
Cytokines KC, IL-1α, IL-2, IL-5, IL-12, IL-17, MCP-1, MIP-1A, FGF and VEGF decreased 
following injury at variable time points from 1 to 48 hours (Figure 4.7). There was no 
change other cytokines: IL-1β, IL-4, IL-5, IL-10, IL-13, GM-CSF, TNF alpha, IFN-ϒ, IP-10 
and MIG (data not shown). 
 
 
Figure 4.7 Cytokine and chemokine response in the serum of female CD1 mice 
following injury with the mild contusion model.   
Serum obtained from 6-8 week old female CD1 females was analysed at 0, 1, 24 and 48h 
following injury with the mild contusion model.  The time points are divided because the 
serum was taken and analysed at different times (indicated by ----). IL-1α, IL-2, IL-5, IL-12, 
IL-17, MCP-1, MIP-1A, FGF and VEGF decrease following injury with the mild contusion 
model.  There was no change in the other cytokines: KC,  IL-1β,  IL-4, IL-5, IL-10, IL-13, 
GM-CSF, TNF alpha, IFN-ϒ, IP-10 and MIG (data not shown).  
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4.2.7 Gaseous anaesthesia with isofluorane does not affect the host cytokine 
response to injury. 
Having developed the trauma contusion model in CD1 mice, it was desirable to transfer 
the model to an inbred, white furred strain that was susceptible to GAS infection. Previous 
work had indicated that FVB/n mice would be suitable, thus the impact of mild injury on 
host cytokine response was re-evaluated in female FVB/n mice aged 6-8 weeks using the 
same 20-plex mouse luminex kit.  Having established the pattern of histopathology that 
results from the mild contusion, the injured muscle was dissected and homogenised in 
PBS to determine the local cytokine response to mild injury.  The homogenized tissue was 
stored in a freezer at -20 degrees with protease inhibitors (to prevent degradation) prior to 
centrifugation and analysis with a mouse 20-plex luminex kit. There was no difference in 
weight change at 1h, 24h, and 48h after contusion (data not shown).  Similar to findings in 
the CD1 mice, there was minimal inflammatory response detected in FVB/n mice following 
the contusion with the majority of cytokines measured in serum and muscle remaining at 
the minimal limit of detection.   There was no effect from isofluorane anaesthetic given 
during the administration of the injury.  In contrast to findings in the CD1 mice that 
sustained a moderate contusion or mild contusion respectively, there was no change in 
KC or IL-6 systemically in the blood, or in the local muscle tissue.  In contrast to the 
moderate contusion model, cytokines IL 6 and KC tended to decrease following injury.   All 
samples of blood and tissue for cytokine analysis were obtained by similar methods. 
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Figure 4.8 Cytokine response by FVB/n mice following anaesthesia and mild 
contusion in muscle and serum.   
Serum and muscle tissue were obtained from 6-8 week old female FVB/n mice and IL-6 
and KC response were analysed at three time points following injury (1, 24 and 48 hours) 
and compared against mice who were only given an anaesthetic or with control mice.  
There was minimal IL-6 and KC response to a mild contusion injury both in the muscle 
tissue and serum. 
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4.2.8 Western blot shows that the mild contusion model can produce 
upregulation of vimentin  
To determine if mild contusion had any detectable effect on muscle cell activity, injured 
and control muscle tissue were extracted at different time points following injury in FVB/n 
female mice aged 6 to 8 weeks.  In particular previous work had shown an increase in 
expression and production of a cytoskeletal protein called vimentin following injury using 
the EC model (Peters, Barash et al. 2003, Bryant, Bayer et al. 2006, Hamilton, Bayer et al. 
2008). The muscle tissue was homogenized and then stored at -20°C with protease 
inhibitors.   The samples were run on a standard Western blot using an anti-vimentin 
antibody to visualize vimentin production.   
 
The western blot identified a 58kDa protein, likely to represent vimentin at 1, 24 and 48 
hours following injury (Lanes 7-12). This protein was not seen in the control groups and 
the uninjured muscle at 1 hour following injury (Lanes 1-6).  A truncated form of vimentin is 
isolated in the control group measuring 40kDa. Human vimentin was used as a positive 
control as mouse vimentin was not available, although the former bears 96% homology to 
the later (Capetanaki, Kuisk et al. 1990). 
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Figure 4.9 Standard Western blot illustrating vimentin produced following injury 
with the mild contusion model.    
Two proteins were visualised at 40kDa and 50kDa.  The lanes are numbered 1-12 with a 
positive control in lane 13 (human vimentin). 1-2 Control (no injury); 3-4 Post anaesthetic 
(no injury); 5-6 1h post injury (control leg); 7-8 1h post injury (injured leg); 9-10 24h post 
injury (injured leg); 11-12 48h post injury (injured leg); + postive control (human vimentin 
protein). 
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4.3 Discussion 
In this chapter, two simple models of contusion have been produced and characterized 
using histology. Both of the models can be reproduced with no external surgery to the 
mouse.  The moderate contusion model produces a fracture in the cortex of the femur with 
associated severe myodegeneration in the muscle tissue. There is an acute infiltration of 
neutrophils into the site of injury in the first 24 hours which progresses to a mixed 
inflammatory response (with neutrophils and macrophages) at 48 hours as previously 
seen in other animal models of injury and in human cases (Walden, McCutchan et al. 
1990, Crinnion, Homer-Vanniasinkam et al. 1996, Bhatia, Pallister et al. 2005, Toumi, 
F'Guyer et al. 2006).  
 
There is a systemic inflammatory response seen in the moderate model, shown by an 
increase in KC over 48 hours, which has been observed in human cases and animal 
models of blunt trauma (Bhatia, Pallister et al. 2005, Tsivitse, Mylona et al. 2005, Sjogren 
and Anderson 2009, Martines, Ng et al. 2014). KC is a murine homologue of IL-8 and, like 
IL-8, ligates CXCR1/2 on neutrophils.  IL-8 mediated neutrophil migration has been shown 
to increase following major trauma in humans (Bhatia, Pallister et al. 2005).  In this 
particular model there was little change in other cytokines analysed. 
 
A mild contusion model was developed which produced less severe inflammation in the 
muscle and subcutaneous tissue with no bony injury at 24 and 48 hours following injury. At 
48 hours the injured muscle showed loss of myofibres and replacement by a mixed 
inflammatory response.  In the CD1 mice, a significant rise in IL-6 was seen 1 hour 
following injury, replicating previous work from analyzing human cytokine responses 
(Sjogren and Anderson 2009).  However, there was little systemic or local muscle tissue 
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cytokine response seen in the female FVB/n mice; indeed, many of the cytokines 
decreased following injury (although this change was small).  These results are different 
from previous models that have shown a more pronounced pro-inflammatory response 
with a rise in IL-6, IL-1beta, TNFalpha and IL-8 (Sjogren and Anderson 2009) but this may 
simply be due to the findings may be a consequence of the injury being so benign. 
 
Previous work has demonstrated an increased binding of GAS to injured muscle cells in 
vitro (Bryant, Bayer et al. 2006). Vimentin was identified and isolated as the protein 
expressed on injured skeletal muscle cells.  Vimentin has been shown to be up-regulated 
after moderate muscle injury in a rat model of muscle strain (Peters, Barash et al. 2003).  
In the mild contusion model, an up regulation of vimentin was demonstrated 1, 24 and 48 
hours following injury by Western blot with a truncated form seen in the control groups. 
Although the truncated isoform cannot at present be explained, it may represent a non-
specific band (that requires use of control preimmune sera).  The histopathological findings 
coupled with the low grade upregulation of vimentin demonstrate that the model is a truly 
local model of contusion without detectable systemic effect or adverse clinical effect. As 
such, it was used to develop a model of co-infection with GAS and explore the relation 
between iGAS and trauma.   
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5 Using Bioluminescent imaging to model invasive GAS disease 
5.1 Introduction 
In the previous chapter a murine model of mild contusion was developed and 
characterized by histopathology and the inflammatory response assessed by measuring 
the cytokines in serum and muscle tissue following injury.  This new contusion model will 
be used to assess the effect of trauma on a systemic GAS infection and to investigate the 
hypothesis that infection locates to the site of injury. The purpose of the current chapter 
was to develop a bioluminescent GAS strain that could be used in conjunction with 
trauma to model invasive infection.   
 
Bioluminescent imaging (BLI) has refined animal models, allowing infections to be 
monitored in vivo and followed in real time reducing the number of animals in experiments 
and giving further information on the development of diseases (Andreu, Zelmer et al. 
2011). However models using bioluminescent bacteria must be carefully characterized as 
often bioluminescent bacteria are attenuated following transformation with a reporter 
containing the lux operon (Alam, Turner et al. 2013). Although a commercially available 
M49 bioluminescent GAS strain exists (Sheel, Pandey et al. 2010), the main serotypes of 
GAS strains causing invasive disease in the UK are M1, M3 and M89 (Lamagni, Efstratiou 
et al. 2009), hence it would therefore be useful to have bioluminescent derivatives of these 
strains to refine animal models of iGAS.   
 
Critical to the design of a suitable model using BLI is the development of bioluminescent 
strains able to produce enough light to be detected in vivo in different models of infection.  
Furthermore they should not be attenuated in comparison to their parent wildtype strain 
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and they should remain stable within GAS (Andreu, Zelmer et al. 2010, Alam, Turner et al. 
2013).  
 
In this project, two plasmids pTHLK and pICL18Lux containing the luxABCDE operon were 
used to produce bioluminescent GAS strains. pTHLK is a replicative shuttle plasmid 
requiring antibiotics to maintain its stability while pICL18Lux requires integration into the 
GAS chromosome via homologous recombination. Both plasmids have been previously 
successfully used to transform an M75 GAS pharyngitis strain (Alam, Bateman et al. 
2013). The aim of this chapter was to derive and then characterize invasive 
bioluminescent GAS strains both in vitro and in animals models of infection so that 
they may be used to model different routes of iGAS disease. 
  
 
 
153 
5.2 Results 
5.2.1 In vitro light production and growth of bioluminescent M1, M3 and M89 
GAS strains containing the replicative pTHLK plasmid 
M1, M3 and M89 GAS strains were transformed using the replicative plasmid pTHLK.  The 
growth of each bioluminescent strain in THB supplemented with kanamycin (400µg/ml) 
was compared with the appropriate parent strain over 8 hours and the growth data fitted to 
a logistic curve through regression (Figure 5.1) Overall there was no significant difference 
between the growth of the bioluminescent strains and parent strains (Figure 5.1A-C).  
Luminescence (relative light units, RLU) of the bioluminescent strains was measured at 
half hourly time points on a bench top luminometer.  There was minimal light production by 
the transformed M1pTHLK strain throughout the entire growth phase.  The M3 and M89 
bioluminescent strains showed maximal light production at 5 and 6 hours respectively 
(Figure 5.1 B-C).  The M89pTHLK was brighter than the M3pTHLK strain in vitro.  The light 
production (measured in RLU) correlated with optical density in the bioluminescent 
M3pTHLK ( r2= 0.92, p<0.01) but not in M89pTHLK (r2=0.58, p=0.1). 
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Figure 5.1 Growth kinetics and light production of M1pTHLK, M3pTHLK and M89pTHLK.  
The growth of A M1pTHLK, B M3pTHLK and C M89pTHLK was compared with wild type parental 
strains over 8 hours (n=3 separate cultures per group) and a logistic curve was fitted to the 
growth data. (r2>0.90) The light produced by M1pTHLK, M3pTHLK and M89pTHLK was 
measured using a luminometer and recorded (green dotted line) as relative light units 
(RLU).  Error bars indicate median and range.   
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5.2.2 Attenuation of light production by M1pTHLK is unlikely to be due to a 
mutation in the BLI construct 
The M1 bioluminescent strain failed to produce light in vitro when grown in THB with 
antibiotic selection.  The reduction in light production by the strain was not due to 
instability of the plasmid as the new bioluminescent strain retained antimicrobial 
resistance.  To assess whether there was mutation in the construct, the plasmid was 
retrieved from the M1pTHLK  by genomic DNA extraction and then transformation of E.coli. 
The new transformed E.coli strains exhibited bioluminescence when visualised on LB Agar 
under the IVIS (Figure 5.2).  Furthermore restriction digests of E.coli transformed with 
M1pTHLK and E.coli pTHLK  appeared similar (data not shown). 
 
 
  
 
 
 
 
 
Figure 5.2 LB Agar plate showing Top 10 E.coli cells transformed with M1pTHLK 
Following transformation of E.coli cells with M1pTHLK, colonies produced on a LB agar plate 
had the ability to bioluminescence when visualized using an IVIS. 	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5.2.3 Stability of the bioluminescent M1, M3 and M89 iGAS strains containing 
the replicative pTHLK plasmid 
M1pTHLK, M3pTHLK and M89pTHLK were passaged daily in THB with and without kanamycin 
(400µg/ml) and plated onto selective and non-selective media to assess the ability of the 
strains to retain the construct.  The studies showed a significant reduction in the number of 
bacteria retaining the replicative plasmid on day 4 of passage period of illustrating the in 
vitro instability of all the bioluminescent strains containing the replicative plasmid pTHLK 
(Figure 5.3A-C). 
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Figure 5.3 In vitro stability of the new bioluminescent strains: M1pTHLK, M3pTHLK and 
M89pTHLK.  
The new bioluminescent strains, (A) M1pTHLK, (B), M3pTHLK, (C) M89pTHLK, were passaged 
daily in THB with (shown in red) and without kanamycin (shown in blue) to determine the 
stability of the replicative plasmid pTHLK in vitro  (n=3 separate cultures at each time 
point).  There was a significant reduction in the number of viable bacteria retaining the 
plasmid when passaged without kanamycin in comparison to the number of bacteria 
retaining the plasmid with kanamycin. Bacterial counts were obtained through serial 
plating onto selective solid media.  Errors bars indicate median and range.  
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5.2.4 The in vivo characterization of the bioluminescent strains containing 
the replicative plasmid pTHLK 
Many cases of GAS NF develop at a site of non-penetrating injury and it is thought that in 
patients with no obvious portal of entry, seeding of soft tissues occurs via a transient 
bacteraemia from a prior respiratory tract infection (Stevens 1995). Development of an 
invasive murine lower respiratory tract model will therefore form part of the project when 
trying to develop a model of GAS NF that faithfully reproduces the interaction between 
naturally occurring GAS infection and injury.   A model using bioluminescent strains would 
allow the infection to be followed in real time in vivo, reducing the numbers of animals 
required for experiments and may provide information on the pathogenesis of iGAS. 
 
Groups of 4 female CD1 mice age 6 to 8 weeks were infected intranasally with each 
bioluminescent strain to produce a lower respiratory tract infection. Mice were imaged at 2 
and 4 hours post infection and images taken at 2h (Figure 5.4 A-C).  Despite M1pTHLK 
causing a lower respiratory tract infection, as evidenced by histopathology and culture, 
there was no visible light signal, consistent with findings in vitro (Figure 5.4 A and D). In 
comparison, mice infected with M3pTHLK and M89pTHLK where a visible light signal was seen 
in 3 out 4 mice (Figure 5.4 B, C, E and F). In one mouse there was a visible signal seen in 
the right upper quadrant (Figure 5.3C) with bacterial counts being obtained from the liver 
(data not shown) consistent with bacterial spread to the liver, a focus of infection not 
expected at this early time point.  For each infected group, one mouse was culled to obtain 
tissue for histological analysis of the inflammatory response and detection of GAS (gram 
stain, data not shown).  The lungs of the mice 2h post an intranasal infection with the 
bioluminescent strains showed an inflammatory response with infiltration of the alveoli with 
neutrophils, macrophages and proteinaceous fluid (Figure 5.4 G-I). 
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Figure 5.4 In vivo characterisation of the new bioluminescent strains: M1pTHLK, 
M3pTHLK and M89pTHLK in a pneumonia model.  
M1pTHLK, M3pTHLK and M89pTHLK were assessed in a mouse model of lower respiratory tract 
infection (LRTI) (n=4 per group). 2h following an intranasal infection with M1pTHLK, M3pTHLK 
or M89pTHLK IVIS images were obtained. A LRTI with M1pTHLK (ventral view). B LRTI with 
M3pTHLK (ventral view). C LRTI with M89pTHLK (ventral view). 2h and 4h post infection the 
mice were culled and the bacterial burden of the lung tissue assessed. Data are shown for 
individual mice at 2h. D Following LRTI with M1pTHLK there was no visible light detection 
and no correlation between bacterial burden and flux (r2=0.4).  E Following LRTI with 
M3pTHLK (r2 = 0.80) there was no significant association between bacterial burden and flux. 
F Following LRTI with M89pTHLK there was no significant association between bacterial 
burden and flux (r2 = 0.60). G-I Hematoxylin & eosin (H&E) stained sections of lung tissue 
2h following infection with M1pTHLK, H. M3pTHLK, and M89pTHLK (x20 magnification).  The 
lung sections showed inflammation with multifocal peribronchiolar infiltration by neutrophils 
and flooding of the alveoli by neutrophils, macrophages and proteinaceous fluid (indicated 
by black arrows). 
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5.2.5  The replicative plasmid pTHLK is not stable in vivo 
Despite there being no visible light production seen from the lungs in mice infected with 
M1pTHLK, more than 60% of the GAS colonies plated onto kanamycin selective media from 
the blood agar plate containing the diluted lung homogenate from mice infected with 
M1pTHLK retained the pTHLK plasmid or, at least, the kanamycin resistance gene. Further 
molecular work confirmed the presence of the lux operon using primers to identify the lux 
C gene and transformation of DHα cells produced bioluminescent colonies. A similar result 
was seen following intranasal infection with M3pTHLK.  The M89pTHLK strain was unstable 
and there was loss of plasmid by 2h following infection (Figure 5.5 A and B). The 
bioluminescent strains containing the replicative plasmid pTHLK were bright both in vitro 
and vivo, but unstable. The use of antibiotics in vivo was considered but pilot work showed 
in some mice a visible bioluminescent signal from the antibiotic injection site (data not 
shown).  Therefore it was important to produce a bioluminescent invasive GAS 
strain using a plasmid that would integrate into the chromosome, allowing the 
newly transformed bacteria to constitutively produce light. 
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Figure 5.5 The instability of the replicative plasmid pTHLK during GAS infection in 
vivo.  
A In vivo stability of pTHLK in M1, M3 and M89 GAS in lung homogenate 2h following an 
intranasal infection (n=4 per M type) Counts obtained from lung homogenate were 
compared on selective (kanamycin) and non-selective media. Bacterial growth was as 
follows: M1pTHLK (mean total = 568 cfu/mg tissue); M3pTHLK (mean total = 153 cfu/mg 
tissue); M89pTHLK (mean total = 1125 cfu/mg tissue). Represented is the percentage of 
colonies retaining the plasmid on selective (kanamycin) media.  There was a significant 
difference between bacterial counts obtained on kanamycin selective media of mice 
infected with M3pTHLK and M89pTHLK (p<0.01) at 2h but not at 4h (B). 
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5.2.6 A new bioluminescent M89 GAS strain 
In the UK, M89 GAS strains are the second commonest M serotype responsible for 
invasive GAS infections (Lamagni, Efstratiou et al. 2009). Given that M1pTHLK could not 
produce light, and that M89pTHLK was bright both in vitro and in vivo but unstable, an M89 
necrotizing fasciitis isolate (Table 3.1) was transformed with the plasmid pICL18Lux by 
electroporation (Pospiech and Neumann 1995). The plasmid pICL18Lux contains the 
luxABCDE operon and contains a region of homology targeting the spy0535 region of the 
GAS chromosome.  The spy0535 locus encodes an extinct bacteriophage gene that has 
no known function (Alam, Bateman et al. 2013); An 839 bp fragment from spy0535 has 
been cloned upstream of the lux operon in pICL18lux to allow targeted integration into this 
part of the genome, through a single cross-over recombination event (Alam, Bateman et 
al. 2013). To confirm integration into spy0535 on GAS, primers were designed to anneal to 
spy0534 and spy0536 in the GAS chromosome, thereby flanking the intended pICL18Lux 
insertion. The two primers (LF and RR) would amplify a product of 839bp in the parent 
M89 GAS strain, but a product of 10 kB if pICL18lux inserted correctly.  
  
Following transformation, PCR showed successful integration of pICL18Lux into the M89 
chromosome (Figure 5.6).  The wildtype GAS parent strains M75 and M89 produced a 
smaller product of 839bp equivalent to the size of spy0535.  A faint band of 839bp was 
observed following testing of M89lux suggesting either contamination or the instability of the 
strain. 
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Figure 5.6 Plasmid and confirmation of integration of pICL18Lux into the M89 GAS 
chromosome.  
The diagram shows the integration of plasmid pICL18Lux into the GAS chromosome via a 
single cross over event b homologous recombination at the Spy0535 inert locus. A 
representation of the integration of the plasmid into the M89 genome via a single 
crossover is shown and the position of the diagnostic primers LF and RR.  PCR using 
these primers was performed on DNA purified from M75, M89, and M89lux; and 
confirmation of integration of pICL18Lux into the genome is shown. 
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5.2.7 Characterisation of the pICL18lux-transformed M89 bioluminescent 
strain in vitro 
During broth culture, there was significant attenuation of growth of the bioluminescent 
M89Lux in comparison to its parent strain  (p<0.001).  M89Lux produced 10 fold less light 
during exponential growth than the M89pTHLK (M89 containing the replicative plasmid 
pTHLK).  Maximal light production occurred at mid-log phase of growth (5-6 h). (Figure 5.7 
A) To determine whether light production correlated with bacterial density, and to 
determine the threshold for light production, suspensions of M89ux (at stationary phase of 
growth) were serially diluted in vitro and light production measured. Approximately 5x106 
cfu/ml of M89lux was required to produce light above the limit of detection measuring total 
flux or relative light unit (Figure 5.7 B). Above the limit of detection, there was a strong 
correlation between light production, measured either as flux or RLU, and colony counts. 
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Figure 5.7 In vitro characterisation of the new bioluminescent M89Lux.  
There was a significant difference in growth of M89Lux compared to the wildtype parental 
strain over 8h (r2>0.95, p<0.001). Light production by M89Lux (green line) and the parent 
strain (black dots) were assessed (A). Serial dilutions of M89lux (n=3 at each dilution) were 
then imaged in vitro measuring total flux (photons/sec) or relative light units (RLU) and 
compared with colony counts by serial plating (B).  Error bars indicate median and range.  
There was a significant correlation between RLU and CFU (r2>0.85) and Total Flux and 
CFU (r2 >0.95) above the level of detection. 
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5.2.8 In vitro stability of M89Lux 
The M89Lux bioluminescent strain was passaged daily with and without kanamycin and 
plated onto selective and non-selective media daily to assess the chromosomal retention 
of the pICL18lux plasmid.  Unlike M89PTHLK, bioluminescent strain M89Lux was stable when 
passaged in vitro with and without antibiotic selection (Figure 5.8).  Therefore M89Lux strain 
was deemed most suitable for subsequent in vivo work. 
	  	  
 
 
 
 
 
 
Figure 5.8 Stability of M89Lux in vitro.  
M89ux carrying the integrated plasmid pICL18lux passaged either with or without antibiotic 
selection in broth culture showed no difference in colony counts when plated onto 
selective media (n=3 separate cultures at each time point).  Colony counts were obtained 
through serial dilutions. Error bars represent median and range. 
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5.2.9 Comparison of light production by two pICL18lux-transformed 
bioluminescent strains 
To determine whether the newly constructed invasive GAS strain M89lux provided any 
advantage over the previously constructed pharyngitis strain, M75lux, the amount of light 
produced by serial dilutions of M89Lux and M75Lux (grown originally at stationary phase) 
was compared by measuring total flux and relative light units (Figure 5.9). In both cases, 
in vitro, there was a tendency for the M75Lux strain to produce more light in comparison to 
M89Lux. 
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Figure 5.9 Comparison of light production by M75lux and M89lux.   
Overnight cultures of M75Lux and M89Lux (n=3 separate cultures) were serially diluted and 
the light production measured (either A, relative light units (RLU) or B, total flux 
(photons/second).  Following measurement, the bacterial burden in each serial dilution 
was obtained in triplicate. Error bars indicate median and range.  There was a significant 
correlation (r2 > 0.89) between increasing bacterial burden and RLU or Flux (p<0.01) for 
both strains.  
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5.2.10 Comparison of fitness of M89lux and M75lux in the invertebrate 
insect model Galleria mellonella compared with parent strains 
Cultures of bioluminescent strains M89Lux and M75Lux or the parent strains were grown 
overnight in THB and then centrifuged, the supernatant removed and the pellet washed 
twice with PBS (x1) and diluted to an optical density of 0.5 (OD600). Wax worms were 
inoculated with 1-2 x106 cfu of the bioluminescent or parent M75 and M89 GAS strains 
and a separate control group with PBS (n=20 per group). Following infection, the bacterial 
content of the inocula was determined by serial dilution, and then the survival of the 
waxworm larvae was monitored over a period of 4 days. PBS-inoculated larvae survived 
this period, while infected larvae did not.  Although the measured virulence of the 
bioluminescent strains appeared attenuated compared to the parent strains, this did not 
reach significance. Furthermore, there was no difference between M75 and M89 strains in 
this model  (Figure 5.10). 
  
 
 
174 
 
 
 
 
Figure 5.10 Determination of attenuation of bioluminescent strains in the wax worm 
model.  
The virulence of the bioluminescent strains (blue and red ---) was compared to each other 
and to parent strains, M89 (blue) and M75 (red) in the wax worm Galleria mellonella (n=20 
per group).  Wax worms were inoculated with a 1:100 dilution of an overnight culture (1-2x 
10 6 cfu per waxworm) of either bioluminescent or parent strain and monitored daily for 
survival over 5 days.  Kaplan-Meier survival plots of infected wax worms against a PBS-
inoculated group (control - black) are shown (log rank p<0.01) Differences between strains 
were not significant. 
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5.2.11 The use of M89Lux in a model of pneumonia 
The new stable bioluminescent M89 strain, M89Lux was used to model pneumonia in the 
mouse.  Previous work has shown that a lower respiratory tract infection (LRTI) is required 
for systemic spread to the blood, liver and spleen following intranasal administration.  A 
number of cases of GAS NF associated with injury, have previously reported a respiratory 
tract infection, thought to be responsible for a transient bacteraemia, leading to GAS 
localizing to injured muscle tissue.  A model enhanced by bioluminescent GAS could 
refine infection models, reducing animals required for experiments and potentially allowing 
the seeding of such tissues to be visualised, and the infection to be tracked in real time.  
 
5 female CD1 mice aged 6-8 weeks were intra-nasally infected with 1x 108 cfu per mouse 
of M89Lux to produce LRTI and imaged using the IVIS.  Following imaging the mice were 
culled. The lungs were harvested for bacterial counts and histopathology.  There was no 
light production from the mice immediately following an intranasal infection despite 
bacterial counts being detectable in lung tissue and evidence of pneumonia  (Figure 5.11 
A and B). All M89lux GAS bacteria remained stable when replica plated onto antibiotic 
(kanamycin) selective plates (data not shown).  
 
To determine if the lack of immediate light detection was related to failure of bacteria to 
reach the lungs, or to poor penetration of light though the chest wall, a small group of mice 
were culled and immediately inoculated transthoracically, directly into the lungs, with the 
same dose of M89Lux.  The mice were immediately imaged using the IVIS, yet, again no 
light was detected (data not shown as there was no detectable light signal).  The lungs 
were then dissected away from the cadavers and imaged using the IVIS. A bioluminescent 
signal was detected from the lungs, which correlated with bacterial burden in the lung 
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tissue (r2=0.90, p<0.05) (Figure 5.11 C and D).  This confirmed that the bioluminescent 
signal intensity could be used as a measure of bacterial burden, but that the chest wall 
provided a barrier through which light, from M89lux, penetrates poorly.  
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Figure 5.11 The use of M89Lux to model LRTI.  
A Immediately following an intranasal infection with M89Lux, the lungs of mice were imaged 
in vivo using an IVIS camera and the region of interest calculated.  There was no visible 
light production from the lungs detected either dorsally or ventrally in the animals in vivo 
(n=5 per group). B Histopathology of lung tissue illustrating the inflammatory response 24 
hours following an intranasal infection with M89Lux .C. Following direct intra-thoracic 
infection with M89Lux, the lungs of mice ex vivo were imaged using an IVIS camera and the 
region of interest calculated for the dissected tissue.  There was a positive correlation 
between bacterial burden and total flux (r2 = 0.90, p<0.05). D Pictorial display of the light 
emitted from a mouse lung following an intra-thoracic infection. 
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5.2.12 The transmission of light from the bioluminescent strains through 
tissue 
Further work to assess the transmission of light through tissue was performed using meat 
to mimic different tissue depths.  Overnight broth cultures of three bioluminescent strains 
(M89pTHLK, M89Lux and M75Lux) were each serially diluted in triplicate in a 96 well plate.  
The plates were imaged using an IVIS and the light signal obtained measured using the 
grid region of interest selection.  Following imaging meat of depths differing in 1mm steps 
was superimposed over the plate to assess the ability of light to travel through tissue at 
different depths; a maximum thickness of 5mm of meat was used.  The bioluminescent 
strain containing the replicative plasmid pTHLK demonstrated superior transmission of 
light through meat tissue in a depth-dependent manner compared with the more stable 
strains M75Lux and M89Lux.  It was apparent that the stably bioluminescent GAS strains 
containing a single gene copy of the luxABCDE operon were limited in ability to transmit 
light through tissue of greater than 1mm depth.  
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Figure 5.12 Transmission of light emitted by the new bioluminescent strains 
through tissue 
Overnight growths of M89pTHLK (red), M89Lux (green) and M75Lux (blue) were imaged and 
total flux measured.  Cooked meat of differing depths was placed on top of the wells and 
the light transmitted through the tissue was measured (in triplicate).  Shown is the light 
emitted with the three bioluminescent strains at different tissue depths. Error bars equal 
median and range.  
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5.2.13 Bioluminescent signal is detected immediately from the muscle 
following an infection with M89Lux and M75Lux 
Having established that LRTI might be difficult to monitor non-invasively using M89lux, 
further work then assessed use of M89Lux and M75lux in other models of invasive disease, 
of which the intramuscular is used frequently to mimic a local NF infection (Sriskandan, 
Moyes et al. 1996, Sriskandan, Unnikrishnan et al. 1999). Mice were infected with ten fold 
dilutions of bioluminescent strains (Table 5.1), M89Lux (Figure 5.13 A-C) and M75Lux  
(Figure 5.13 D-F) were immediately imaged using an IVIS to calculate the light production 
from the thigh.  Following imaging, the mice were culled and the muscle excised and 
harvested for bacterial counts.  The M89lux strain demonstrated in vivo light emission from 
the site of inoculation that, when measured dorsally, correlated well with the actual 
bacterial burden in the thigh muscle, when plated out. The M75lux strain failed to yield good 
correlation despite strong light signals in vivo.    
Inoculum Mean cfu/ mouse – 
M89Lux 
Mean cfu/mouse – M75Lux 
1 1.1x108 6x107 
2 7x107 2.2x107 
3 2.8x107 1x107 
4 2x107 1.2x106 
5 1x107 1x106 
6 5x106 1x106 
 
Table 5.1 Ten-fold dilutions of bioluminescent strains used in the intramuscular 
model of infection.  
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Figure 5.13 A-C Bacterial burden and light emission immediately following an 
intramuscular infection with M89Lux.   
A Bioluminescent signal from single mouse showing ventral and dorsal viewpoints 
immediately following i.m. infection with the bioluminescent strain M89lux. Total flux was 
measured using an IVIS and the region of interest (ROI) calculated. The bioluminescent 
signal (total flux from ROI) was compared to bacterial numbers obtained from the muscle 
(n=6 per group).  B Correlation between bacterial burden in thigh muscle and total flux 
obtained dorsally (r2= 0.88, (p<0.05)). C There was no significant correlation between 
bacterial burden and total flux obtained ventrally (r2=0.77) D-F Bacterial burden and light 
emission immediately following an intramuscular infection with M75Lux.  D  Bioluminescent 
signal from single mouse showing ventral and dorsal viewpoints immediately following i.m. 
Infection with the bioluminescent strain M75lux.   E Association between bacterial burden 
and total flux obtained dorsally (r2= 0.83) did not reach significance. F There was no 
significant correlation between bacterial burden and total flux obtained ventrally (r2= 0.77).  
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5.2.14 A bioluminescent signal is obtained from the thigh 24 hours 
following an intramuscular infection with M89Lux and M75Lux. 
Having established that the stable M89Lux and M75Lux bioluminescent strains yielded light 
signals from the thigh immediately following an intramuscular infection that could be 
measured non-invasively, the persistence of the signal was then evaluated in a longer 24h 
infection. Female CD1 mice aged 6-8 weeks were intramuscularly infected with 1x108 cfu 
of M89Lux and 2x108 cfu of M75Lux per mouse.  Prior to infection the mice were weighed 
and imaged at baseline.  The progression of the infection was observed for 24 hours.  
Weight loss was observed in all the mice 24h following infection with no difference 
between the two groups (data not shown).  The mice were imaged using an IVIS and the 
light production from the thigh calculated (Figure 5.14A-C).  Following imaging the mice 
were culled and the thighs dissected to assess the bacterial burden and histopathology to 
compare the local inflammatory response between bioluminescent and parent strains.  
 
In contrast to the findings immediately after infection, outlined above, and despite there 
being a detectable inflammatory infection in the thigh with histopathology showing 
extensive areas of necrosis affecting muscle and surrounding tissue with inflammation and 
bacterial colonies (Figure 5.14 D).  Surprisingly, there was no correlation between bacterial 
burden and total flux (Figure 5.14 B-C).  The study was repeated using M75lux. Again, 
although a visible signal was obtained 24h after infection (Figure 5.14E) with an 
inflammatory reaction in the thigh (data not shown), there was no correlation between flux 
and bacterial burden in the thigh muscle, whether imaged dorsally or ventrally (Figure 5.14 
F-G).  
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Figure 5.14 A-C   Bacterial burden, light emission and histopathology 24h following 
an intramuscular infection with M89Lux.   
The intensity of the light signal (total flux) obtained from imaging was compared to 
bacterial burden in the thigh (cfu/ml) 24 h following infection  (n=6 per group) A   IVIS 
images showing a pictorial display of the bioluminescent signal from a single mouse 
showing ventral and dorsal views following an intramuscular infection with M89Lux. B-C 
The apparent correlation between bacterial burden and total flux from the dorsal view point 
(r2=0.80) was not significant.  Lack of correlation between bacterial burden and total flux 
from the ventral view (r2=0.54) D Histopathology of a H&E section of muscle tissue 24h 
following an intramuscular infection with M89Lux.  Bacterial burden and light emission 24h 
following an intramuscular infection with M75Lux. E IVIS image showing a pictorial display 
of the bioluminescent signal from single mouse showing ventral and dorsal views 24h 
following an intramuscular infection with M75Lux . F-G Lack of correlation between bacterial 
burden and total flux from the dorsal view point (r2= 0.43). and ventral view point (r2= 
0.14). 
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5.2.15 Bioluminescence confers in vivo growth defects, particularly on 
dissemination to other tissues: competition assays in vivo 
Although M89Lux demonstrated an in vitro growth defect compared with the parent strain, 
earlier experiments had failed to demonstrate any clear fitness impact conferred by 
luxABCDE in the Galleria model. To determine if the bioluminescent strains were subject 
to a fitness burden during invasive infection, M89Lux and M75Lux were compared with 
parent strains in vivo in a competition assay in the thigh.  Following an intramuscular 
infection with an inoculum comprising equal CFU of each bioluminescent (1x108 M75lux or 
3.5x107 M89Lux cfu per mouse) and each parent strain, bacterial counts were obtained 
from the infected thigh and other tissues at 24h.  Table 5.2 shows the number of mice with 
detectable bacteria in each tissue and the median percentage of bacteria that have the 
pICL18lux construct  (through replica plating on selective and non selective media).  If there 
were no attenuation, one might expect that 50% of the GAS bacteria in each tissue would 
be M89lux or M75lux. The competition experiment was limited by variation between mice, 
while interpretation of data relating to distant tissues was limited by the low number of 
mice where any dissemination occurred.    Indeed, dissemination to the spleen, liver and 
blood was only seen with the M89 GAS parent strain.  The M75 GAS strain only 
disseminated to the lymph node in one mouse. Notably, dissemination was not observed 
for strains carrying the pICL18lux construct. This suggested that the strains were 
attenuated compared to the parent strains, which is perhaps unsurprising given the noted 
in vitro growth defect.  Thus although the bioluminescent strains could be used alone to 
model invasive infection, it seemed possible that attenuation related to bioluminescence 
might interfere with detailed analysis of virulence and pathogenesis. Furthermore, it raised 
the possibility that the bioluminescent strains might lose the construct in vivo.  
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Bioluminescent Strain Thigh 
muscle 
 
Lymph Node Spleen Liver Blood 
M89/M89Lux      
Number of mice 6/6 
 
3/6 4/6 3/6 3/6 
% Of M89
Lux
 
Colonies 
22.5 
 
 
73.1 5 0 0 
M75/M75Lux      
Number of mice 4/4 
 
 
1/4 0/4 1/4 0/4 
% of M75
Lux
 
colonies 
69.4 
 
 
0 N/A 0 N/A 
 
 
Table 5.2 Competition assay in the thigh 24h following an intramuscular infection 
with M89 and M75 wildtype and bioluminescent strains.   
24h following an intramuscular infection with equal inocula of bioluminescent and parent 
strains, mice were culled and organs harvested to assess the comparative bacterial 
burden in each tissue.  Colonies obtained from each organ were replica plated onto 
antibiotic selective (kanamycin) plates to assess the number of bacteria with the pICL18lux 
construct.  The proportion of bioluminescent GAS is expressed as a percentage of the 
total number of colonies in each tissue; the assumption should be that 50% of colonies 
would contain pICL18lux if there were no attenuation or fitness burden.  The table also 
illustrates the number of mice found to have bacteria in each organ. 
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5.2.16 Increased in vivo stability of the bioluminescent M89Lux strain in 
comparison to M75Lux  
Previously, female CD1 mice aged 6-8 weeks old were infected intramuscularly with 
M89Lux or M75Lux and the infection monitored for 24 hours.  The stability of the 
bioluminescent strains to retain pICL18Lux was assessed through replica plating 100 GAS 
colonies from murine muscle infected with either strain on to antibiotic selective 
(kanamycin) media.  The percentage of colonies retaining the lux construct was calculated 
(total number of colonies on the selective media/100 colonies plated).  The M89Lux 
bioluminescent strain was significantly more stable 24h following an intramuscular 
infection than the M75Lux strain in muscle tissue (Figure 5.15). Nonetheless, only 80-90% 
of colonies retained the construct at this time point based on antimicrobial susceptibility 
testing, Notably, GAS are constitutively kanamycin resistant (MIC approx. 140ug/ml) and 
high concentrations (>400ug/ml) are required for selection thus a slight reduction in 
kanamycin content of selective media could account for the apparent loss of construct. 
Based on bioluminescence on solid agar, however, 86% of M89lux colonies retained the lux 
construct 24h after infection, compared with 72% of the M75lux colonies (mean values).  
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Figure 5.15  In vivo stability of M89Lux and M75Lux 24h following an intramuscular 
infection.  
The in vivo stability of M89lux and M75Lux were assessed in the thigh muscle 24h following 
an intramuscular infection (n=6 mice per group) by plating onto selective (kanamycin) and 
non-selective media. There was a significant difference between the percentage of M89lux 
colonies and M75lux colonies retaining the Lux construct   (p<0.05).   Shown are box and 
whisker plots (with min to maximum values and median).  
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5.2.17 M89lux strain disseminates systemically to other tissues retaining 
the pICL18lux construct compared to M75lux 
The ability of the bioluminescent strains to be used in an invasive model of GAS infection 
was further assessed by monitoring dissemination of M89Lux and M75Lux to ipsilateral 
lymph node, blood, spleen and liver.    Female CD1 mice aged 6-8 weeks were infected 
intramuscularly with the bioluminescent strains M89Lux or M75Lux.  At 24h following infection 
mice were culled and the following organs harvested: thigh, ipsilateral inguinal lymph 
node, spleen, liver and blood to assess the bacterial burden in the tissues.  The colonies 
obtained from the tissues were replica plated onto antibiotic (kanamycin) selective plates 
to assess the stability of the plasmid in the strains. In the absence of parent strain 
competition, both bioluminescent strains disseminated systemically.  The M89Lux strain 
remained stable on dissemination to tissues unlike the M75Lux. 
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Bioluminescent Strain 
 
 
Lymph Node Spleen Liver Blood 
M89Lux     
Number of mice 
 
 
1/6 2/6 3/6 0/6 
M89
Lux
 
% of Colonies stable 
 
100% (10/10)* 100% (50/50, 
50/50) 
99% (43/44, 
10/10, 50/50) 
N/A 
M75Lux     
Number of mice 
 
 
3/6 2/6 2/6 4/6 
M75
Lux % of colonies 
stable 
 
0% (0/5, 0/37, 
0/50) 
0% (0/10, 0/30) 0% (0/20, 
0/20) 
0% (0/10, 0/10, 
0/10, 0/20) 
 *Brackets indicate the number of colonies obtained on antibiotic selective media/ total 
number of colonies obtained from a sample of tissue  
 
 
 
Table 5.3 Stability of bioluminescent strains on systemic dissemination.  
Shown is the number of mice with GAS in lymph node, spleen, liver or blood is compared 
to the total number of mice used in the experiment at 24h following an intramuscular 
infection. The percentage of bacteria retaining the stable construct was estimated for each 
tissue by calculating the number of colonies plated onto selective or non selective media, 
total number of colonies plated = 50, if lower it is stated in the table. 
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5.2.18 Using M89Lux to assess the ability of GAS to locate to the site of 
injury. 
Using the contusion model developed in Chapter 4, 8 female CD1 mice were injured on 
the left leg and imaged using an IVIS with X-ray to show no bony injury to the mouse.  24h 
following injury, the mice were infected intravenously via the lateral tail vein with 
1x106cfu/mouse of M89Lux, to produce a bioluminescent injury model similar to Hamilton et 
al, 2008 (Hamilton, Bayer et al. 2008). Mice were imaged immediately, 4h and 24h 
following infection.  At 0h following infection there was no visible light signal obtained in all 
the mice (data not shown).  At 4h following infection, 6/8 mice showed a visible light signal 
in the tail, corresponding to the site of tail vein injection.  At 24h following infection, 7/8 
mice showed a visible signal in the tail region, 3/8 mice showed a signal at other sites 
including nose, lung with one mouse showing a widespread systemic infection (Figure 
5.16).  Bacterial counts were obtained from the injured thigh in only 2/8 mice with evidence 
of infection systemically in these same mice (with bacteria obtained from spleen, liver 
and/or blood), thus the detection of bacteria in muscle was not specific to assume 
causality.  Illustrated in Figure 5.16 is the change in light signal following an intravenous 
infection with M89lux in the only one mouse with systemic spread (1/8). The light signal was 
seen to concentrate at the following sites: lateral tail vein injection site, retroperitoneal 
lymph nodes, kidneys, lung and nose.  Bacteria were obtained from the blood, spleen, 
liver, kidneys, injured and control muscle and lymph node. 
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Figure 5.16 Using M89Lux to model invasive GAS disease and its association with 
injury.   
24h following an injury using the mild contusion model, female CD1 mice were 
intravenously infected with M89Lux and the infection followed by imaging using the IVIS at 
0, 4 and 24h post infection.  Systemic infection to multiple sites was only illustrated in 1/8 
mice at 24h following infection. A Xray image of the mouse following injury with no 
evidence of a fracture.  B Ventral and C Dorsal IVIS images at 24h following infection 
showing GAS spread systemically. 
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5.3 Discussion 
In this Chapter, bioluminescent strains were created and characterised to assess whether 
they may be used to refine a model of invasive GAS disease and its association with 
injury.  Recent work has shown the benefit of using bioluminescent imaging to model GAS 
infection as it reduces the number of mice used in experimental models.  This occurs 
because BLI provides a method of monitoring the infection longitudinally, removing the 
requirement to cull to obtain regular bacterial counts (Andreu, Zelmer et al. 2011, Alam, 
Bateman et al. 2013, Alam, Turner et al. 2013, Alam, Turner et al. 2013).  A stable 
bioluminescent M49 GAS isolate has been used previously to model invasive GAS but the 
strain used was a skin isolate rather than an invasive isolate and only visible on dissection 
of the animal (Sheel, Pandey et al. 2010). 
 
Similar to the planning and choice of trauma model, the reporter system used for 
bioluminescent imaging was carefully considered. Importantly there was a requirement not 
to avoid any external penetrating injury to the animal. An endogenous reporter system 
using the lux operon from Photorhabdus luminescens was chosen to allow constitutive 
production of light without requirement for administration of lucifierin exogenously.  There 
was a need to produce a stably bioluminescent GAS strain, that did not rely on repeated 
antibiotic administration to maintain a replicating plasmid; pilot work demonstrated that 
bacterial seeding could occur at inoculation sites, including antimicrobial injection. This 
observation highlights the ability of BLI to identify niches of infection and hazards of 
modelling that would not otherwise be identified, and is reminiscent of murine genital tract 
seeding that was identified as a result of nasopharyngeal GAS infections reported by Alam 
et al (Alam, Bateman et al. 2013). For this work, the lux operon was rearranged and 
integrated into two plasmids, pTHLK and pICL18Lux , which may be used to transform GAS 
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strains.  The main drawback of luxABCDE, is that light is produced in the blue-green 
spectrum and the signal is therefore weaker than those in the red shifted spectrum.  Other 
bioluminescent reporter systems were considered for use in this model, particularly 
enzymes from the firefly, click beetle and Renilla reniformis with many emitting light within 
the red spectrum (fire fly and click beetle) (Zhao, Doyle et al. 2005),  though previously 
discussed, all require an exogenous substrate, unlike the simple bacterial luciferase 
system.  Newer plasmid based bioluminescent reporter systems have combined the firefly 
(FFluc) and the highly sensitive Nano Luc (NLuc) with a toxin-antitoxin stabilised  plasmid 
providing a higher copy number than can be achieved by a single genomic copy.  This 
permitted emission of light both in vitro and in vivo in the absence of antibiotic selection, 
although did require the addition of an exogenous substrate (Loh and Proft 2014). 
 
In this thesis, a number of bioluminescent invasive clinical strains have been produced 
which vary in expression of light both in vitro and in vivo.  M1, M3 and M89 isolates have 
been transformed with the replicative plasmid pTHLK. Unlike the M3 and M89 
bioluminescent strains, the M1 bioluminescent strain failed to produce light in vitro or in 
vivo.  The reduction in light produced by the transformed M1 strain was not due to the 
instability of the plasmid, as the strain retained antimicrobial resistance. Furthermore, we 
considered the possibility that M1 GAS might mutate the BLI construct, however when 
plasmid was retrieved from the M1 GAS and re-transformed into E. coli, the resultant E. 
coli strains exhibited bioluminescence, suggesting that the construct was intact, but the 
environment created by M1 GAS might not support production of bioluminescence.  
 
It is speculated that M1 GAS may generate virulence factors essential to survival that are 
to the detriment of the expression of light. To determine if M1 GAS is destroying the 
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substrates encoded by the construct, the substrates could be added exogenously to 
determine if light production occurs. Further experiments are required to determine the 
reasons for M1 GAS failure to express light; simple studies would involve use of alternate 
M1 GAS strains, including those that do and do not have mutations in major virulence 
regulators covRS; M1 GAS strains from the pre-antibiotic era that are clonally different 
from the modern M1T1 GAS, and, were it to be available, a panel of genome-wide M1 
mutants. It is possible that the promoter used in the construct cannot be used by M1 GAS, 
and this could be addressed through use of an alternate smaller gene product downstream 
of the same promoter in place of luxABCDE.  
 
Despite the brightness of the bioluminescent strains containing the replicative plasmid, 
pTHLK, their instability during passage made them undesirable for an in vivo model. 
Preliminary attempts to derive a stable M3 GAS strain using pICL18 lux were unsuccessful, 
thus, given that M89 GAS is a more common cause of invasive GAS infection in the UK, a 
stable M89 derivative was developed and characterised. M89Lux was ten fold less bright 
than the strains transformed with the replicative plasmid and showed significant 
attenuation in growth in broth.  Previous work using the same plasmid to target the 
spy0535 locus without the lux operon demonstrated that the targeting of this locus has no 
impact on growth or fitness of GAS in vivo or in vitro; any impact is directly related to 
insertion and expression of luxABCDE (Alam, Bateman et al. 2013). We speculate that the 
same fitness burden is conferred by luxABCDE in the M89 GAS strain although this has 
not been directly proven.  The expression of light is a fitness cost to GAS; it therefore 
follows that loss of bioluminescence would be advantageous to the survival of GAS, thus it 
is no surprise that the construct is lost wherever possible. 
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It was intended that the new stable M89Lux would be used to model a lower respiratory 
tract infection, similar to that reported in case reports of patients with GAS NF and injury.  
However, the strain was not bright enough to be seen in vivo in a model of pneumonia and 
was only visualised after the animal was culled and dissected.  Although there was a 
significant correlation between bacterial burden and light emitted from the lung, similar to 
that reported by Sheel et al, (Sheel, Pandey et al. 2010) the route of infection was clearly 
not practical for further work.  Further work examining direct administration of M89lux 
through the chest wall, and in vitro work comparing the two stable bioluminescent strains, 
M75Lux and M89Lux   showed that the reduction in light transmission through tissue is likely 
to explain the inability to visualise a lower respiratory tract infection following infection with 
M89Lux.   
 
In contrast to LRTI, the M89Lux strain was successfully used to model an infection in the 
thigh; although light production correlated with inoculum at the start of infection, there was 
reduction in the correlation between bacterial burden and light emitted after 24 hours of 
infection.  It is presumed that the infection produces unfavourable environmental 
conditions for the production of light as the stability of the plasmid was largely maintained 
at this time point.  Further work using the M75Lux bioluminescent throat strain as a 
comparison showed that its stability was less than the M89Lux strain following an infection 
in thigh, also with no correlation at 24 hours after an intramuscular infection. 
 
Both M89Lux and M75Lux strains demonstrated a competitive disadvantage during co-
infection with the parent strains, on dissemination to the blood, spleen and liver after an 
intramuscular infection.  This was also seen within the thigh tissue of mice.  This echoed 
the pattern of growth disadvantage observed in vitro, despite the fact that a significant 
 
 
205 
fitness burden in Galleria had not been noted. However, there was a trend towards fitness 
burden in Galleria, and it may be that the studies were not adequately powered. It is also 
unsurprising that a mouse model would show a more attenuated phenotype that the  
Galleria given the complex immune response that would operate in a mammal compared 
with an insect innate immune system. 
  
Further characterisation of the strains administered intramuscularly demonstrated that 
there was some loss of the plasmid construct upon systemic dissemination when mice 
were infected only with the chromosomally inserted bioluminescent strain.  This was only 
apparent for the M75lux strain and underlines the potential advantage of the newer M89lux 
strain for future studies of invasive GAS infection.  The risk of construct instability was 
increased through use of a single not double crossover recombination event as this 
allowed entire plasmid sequence to persist in the bacterium.  Interestingly, there appeared 
to be a greater pressure on M75Lux to lose the lux operon on dissemination systemically in 
comparison to M89Lux. 
 
Although it has its limitations, the new stable bioluminescent M89 GAS strain was 
assessed in a model of GAS NF and injury.  Using the recently characterised model of 
mild contusion, mice were infected intravenously 24 hours following injury to assess 
whether GAS locates to the site of injury.  There was systemic spread of M89Lux following 
an intravenous infection although this occurred rarely (2/8 mice).  M89Lux disseminated to 
most tissues, particularly muscle, kidney, blood, spleen and liver.  The results of this work 
need to be interpreted carefully as there is known attenuation of the bioluminescent strain, 
which will potentially affect its ability to disseminate.  However this pilot work, highlights the 
potential importance of bioluminescent strains in providing further information on 
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localisation of GAS systemically.  This model did not show evidence of specific localisation 
of M89Lux to muscle tissue.  
 
In summary this work has shown the benefits and pitfalls of bioluminescent imaging in 
modelling invasive GAS disease.  Ideally future work should focus on producing a stable 
bioluminescent strain through double crossover recombination.  This work has also shown 
the resultant GAS strains to be somewhat attenuated and dim in comparison to replicating 
plasmid-transformed bioluminescent GAS strains, and the equivalent Gram negative 
derivatives reported in the literature. It seems that GAS is somewhat resistant to 
production of light, in particular the M1 GAS that is the main focus of research into invasive 
disease.  The energy required by the invasive strains to produce light affects the virulence 
of the bacteria and hence the method may not be suitable to provide an ideal model for 
use in GAS NF and injury.  It was decided that further work would use a non-
bioluminescent M1 strain to investigate the impact of injury on systemic spread of 
GAS and localisation to contused muscle tissue.  M1 GAS strains are the commonest 
serotype involved in invasive disease worldwide being responsible in large part for the 
increase infections seen since the 1980s (Stevens 1995).   
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6 Trauma and Infection with M1 GAS 
6.1 Introduction 
 
 
In Chapter 4 a model of mild contusion was developed and characterised; histopathology 
demonstrated mild inflammation to muscle and subcutaneous tissue with no bony injury.  
The new mild contusion model is used in this Chapter to assess the impact of contusion 
on systemic infection with an M1 GAS strain.  There are many reports of cases of GAS NF 
arising from young patients with a history of a prior respiratory tract illness and minor non-
penetrating muscular injury or, in many cases, no antecedent respiratory infection.  Such 
cases are often caused by M1 GAS strains and it is hypothesised that seeding of soft 
tissues by GAS occurs via a transient bacteraemia from a prior respiratory tract infection 
promoted by an initial contusion injury (Stevens 1995).  
  
Chapter 5 described the development of bioluminescent strains used to potentially refine 
invasive models of GAS disease.  However, the work highlighted some major pitfalls in 
using bioluminescent GAS to model systemic infection, including the attenuation of 
bioluminescent bacteria in comparison to their parent strains and the effect of grooming 
(contamination of antibiotic injection sites).  Biophotonic imaging (BPI) is a useful tool 
when the bioluminescent bacteria remain stable on systemic dissemination, a feature not 
demonstrated by the throat strain M75Lux.  BPI requires that the bioluminescent bacteria 
produce a sufficient amount of light to be detected in vivo and that there is a significant 
correlation between light produced and bacterial burden, so the infection can be 
longitudinally monitored correctly. Notwithstanding the development of a new 
bioluminescent M89 GAS derivative where light production did correlate with bacterial 
burden in vitro and in vivo, production of light 24h after soft tissue infection was insufficient 
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to allow longitudinal monitoring. Worldwide, M1 GAS strains have emerged as the 
commonest serotype involved in invasive GAS disease since the 1980s and are 
particularly associated with soft tissue infections (Cole, McArthur et al. 2006), yet this 
thesis has demonstrated that M1 GAS cannot reliably express bioluminescence. The 
original intention in this project, was to apply BPI to refine our model of GAS soft tissue 
infection in the context of trauma, however the use of bioluminescent strains in this context 
appears somewhat limited. 
 
The GAS NF phenotype results from a complex interaction between virulence factors and 
host response.    As invasive infections occur in a heterogeneous environment containing 
multiple host tissue types, sophisticated animal models are required.  Presently one 
reason for the paucity of our understanding about GAS NF and its association with blunt 
trauma is due to the absence of a suitable animal model.  Two groups (Hamilton, Bayer et 
al. 2008, Seki, Saito et al. 2008) have reported the acceleration of GAS sepsis by an 
experimental traumatic injury.  However, neither group demonstrated a mechanism for this 
observation, or how the infection occurs when there is an undefined portal of entry.  
Instead, GAS bacteraemia was induced by intramuscular injection into the forelimb of the 
mouse (Seki, Saito et al. 2008) or intravenous injection into the lateral tail vein (Hamilton, 
Bayer et al. 2008).  
 
The aim of this Chapter was to therefore investigate the impact of contusion on initiation or 
progression of invasive GAS infection using a sequenced M1 clinical isolate without use of 
bioluminesnce (Turner, Dryden et al. 2013). Specifically the work set out to assess 
whether contusion influences the spread of GAS systemically and to injured muscle tissue 
using three routes of infection: lower respiratory tract infection with bacteraemia following 
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intranasal infection; bacteraemia following intravenous infection and necrotising 
fasciitis/myositis produced by intramuscular infection.  For each model, bacterial burden 
was quantified in different tissues and the host response assessed by measuring serum 
cytokines.  Histopathology compared the inflammatory response seen in the lungs and 
muscle following infection and any apparent connection between contusion and systemic 
dissemination of GAS was investigated. 
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6.2 Results 
6.2.1 Modelling GAS lower respiratory tract infection (LRTI): choice of M1 
GAS strain 
Development of a model of trauma and GAS infection ideally requires a systemic 
(bacteraemia) infection to occur via the respiratory tract as a portal of entry. As such a 
model did not exist, three different sequenced M1 strains were therefore compared in 
ability to spread systemically following an intranasal infection.  Female FVB/n mice aged 6-
8 weeks were infected intra-nasally with 1x107 - 1x108 cfu/mouse (25µl volume) of a throat 
(H800), tissue/NF (H758), or blood (H584) M1 GAS isolate (n=6 per group).  Pilot work 
showed volume and inoculum dose were sufficient to cause a lower respiratory tract 
infection (data not shown).  The mice were monitored by assessing change in weight and 
then culled at 72 hours, when there was a substantial weight change that was likely to 
represent a physiological response to GAS dissemination and systemic infection (Figure 
6.1A).  The bacterial burden in nasal tissues and lung was assessed at 72 hours (Figure 
6.1B, C) and the systemic spread to different tissues compared (Table 6.1).  
 
There was no difference in weight change over time between the three M1 GAS strains.  
All three groups demonstrated weight loss particularly at 72h following LRTI infection 
(Figure 6.1A). There was no difference in bacterial counts in nasal tissues and lung 
between the three strains (Figure 6.1 B). Table 6.1 shows the spread of the GAS strains to 
different tissues although notably there was no spread to spleen or blood. Spread to 
distant muscle was apparent for some strains, presumably via a systemic route, thus the 
failure to detect bacteria in the blood may have been a timing issue or due to limited 
volume of blood sampling.   M1 isolates H584 and H800 showed the greatest spread to 
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lung, muscle and inguinal lymph node and the M1 clinical blood isolate (H584) was chosen 
for further experimental models.   
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Figure 6.1 Lower respiratory tract infection (LRTI) caused by three M1 GAS strains.  
Female FVB/n mice age 6 to 8 weeks were intra-nasally infected with 8x107cfu/mouse  M1 
GAS at three time points following injury with the mild contusion model: 0, 24 and 48 
hours. A Weight change between the three M1 GAS-infected groups (p>0.05, Two way 
ANOVA).  Bacterial burden (cfu/mg) in (B) nasal tissue and (C) lung tissue at 72 hours 
(p>0.05, Kruskal-Wallis, Dunn’s post test). N=6 per group, error bars show median +/- 
standard error. 
 
 
GAS 
STRAINS 
 
Lung 
 
Blood 
 
Spleen 
 
Muscle (Right or 
Left) 
 
ILN (Right or 
Left) 
 
H800 
 
4/6 
 
0/6 
 
0/6 
 
2/6 
 
1/6 
 
H758 
 
2/6 
 
0/6 
 
0/6 
 
0/6 
 
1/6 
 
H584 
 
4/6 
 
0/6 
 
0/6 
 
2/6 
 
1/6 
 
Table 6.1 Systemic spread of the M1 strains (n=6 per group)  
Female FVB/n aged 6-8 weeks were infected intra-nasally with a throat, blood or tissue M1 
GAS strain.  Mice were culled at 72h following infection and organs harvested for bacterial 
spread. The table shows the proportion of mice with evidence of GAS spread to the blood, 
spleen, lymph node or thigh muscle 72h following infection (Figure 6.1).  Mice in this 
experiment were not subject to trauma. 
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6.2.2 Pilot study of GAS LRTI: the effect of mild contusion on outcome of 
GAS infection 
A pilot study was undertaken to determine the likely effect of administering a GAS LRTI to 
mice that had sustained a mild traumatic muscle injury.  Female FVB/n mice aged 6-8 
weeks (n=16/group) were administered a mild contusion injury (Chapter 4, page 135) 
under anaesthetic while controls were given anaesthetic alone. Following 
injury/anaesthetic or anaesthetic only, both groups of mice were intra-nasally infected with 
the chosen M1 GAS strain H584 and monitored for endpoint criteria over 7 d, as permitted 
by the relevant Home Office licence. The defined end points specified were loss of 
spontaneous movement, or loss of 20% of starting body weight.  All mice were subject to 
schedule 1 at the end of the protocol (no more than 7d after onset of infectious challenge). 
 
There was no difference in survival between the two groups (P>0.05, Log rank test) 
although there was a trend (p = 0.09) for decreased survival in the trauma group in 
comparison to the control group in the first 3 days (Figure 6.2). Although some mice 
reached specified humane endpoints earlier than the planned 7d duration, it was possible 
to obtain quantitative bacteriological data from those that were culled, as well as those that 
survived to 7d.  Table 6.2 shows the systemic spread of M1 GAS with or without injury to 
lung, blood, spleen, lymph node and muscle. Recorded in the table is the number of mice 
with evidence of GAS infection in a tissue, with the proportion (%) recorded.   
 
The mice that did not survive to the end of the experiment died as a result of pneumonia 
and sepsis.  There was no significant difference in GAS spread between the trauma and 
control group in the mice that died.  Furthermore, injury to the muscle tissue did not 
measurably enhance dissemination of M1 GAS to the site of trauma following a lower 
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respiratory tract infection. Although there appeared to be greater systemic spread in the 
group with the contusion injury in comparison to control, and these animals died more 
quickly than the controls, the difference did not reach significance.  
 
When the two groups were compared by stratification depending on death prior to 7d 
versus survival until the experimental endpoint (7 days), it became apparent that the 
trauma group showed a reduced ability to clear GAS from lung tissue; this difference was 
significant even without stratification.  There was also an overall difference in bacterial 
spread to distant non-injured muscle, consistent with reduced bacterial clearance in the 
trauma group. However, there was no particular localisation of M1 GAS to the injured 
muscle tissue in this model, although by 72h, there was also no evidence of bacteraemia.  
Taken together the pilot study showed no evidence of seeding to injured muscle during 
systemic infection resulting from LRTI. The data also suggested that early time points 
might be useful to identify differences between the experimental groups using more 
quantitative methods, and that delaying data collection for more than 24h after infection 
could result in losses of animals. To avoid this, all data were subsequently collected within 
24h of onset of infection.  
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Figure 6.2 The effect of mild contusion on lower respiratory tract infection with M1 
GAS strain.  
Female FVB/n mice were intra-nasally infected with M1 GAS following injury with the mild 
contusion model; controls had no trauma.  Mice were monitored for 7 days post infection, 
animals reaching set end points were culled.  There was no difference between the two 
groups (p>0.05, Log-rank, Mantel-Cox test). N=16 per group 
  
0 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
Days
Su
rv
iv
al
 (%
) No Trauma
Trauma
 
 
217 
 
  
Death prior to 7 days 
 
Survived at 7 days 
 
Chi square values 
  
Trauma 
 
 
No Trauma 
 
Trauma 
 
No Trauma 
 
P value (Chi square) 
 
Lung 
 
7/7 (100%) 
 
6/6 (100%) 
 
5/9 (56%) 
 
1/10 (10%) 
 
p<0.001 * 
 
Blood 
 
4/7 (57%) 
 
2/6 (33%) 
 
0/9 (0%) 
 
0/10 (0%) 
 
p>0.05 
 
Spleen 
 
4/7 (57%) 
 
5/6 (83%) 
 
1/9 (11%) 
 
0/10 (0%) 
 
p>0.05 
Left Lymph 
Node 
 
3/7 (43%) 
 
1/6 (17%) 
 
1/9 (11%) 
 
0/10 (0%) 
 
p>0.05 
Right Lymph 
Node 
 
3/7 (43%) 
 
1/6 (17%) 
 
2/9 (22%) 
 
1/10 (10%) 
 
p>0.05 
Injured 
Muscle (L) 
 
3/7 (43%) 
 
1/6 (17%) 
 
1/9 (11%) 
 
1/10 (10%) 
 
p>0.05 
Uninjured 
Muscle (R) 
 
4/7 (57%) 
 
1/6 (17%) 
 
2/9 (22%) 
 
1/10 (10%) 
 
P<0.05 * 
 
Table 6.2 Systemic spread to tissues of M1 GAS following an intranasal infection 
with or without injury using the mild contusion model.   
The table shows the number of mice with GAS in lung, blood, spleen, lymph node or 
muscle following an intranasal infection with or without mild contusion (proportion shown 
as a %). Data are divided as follows: The first two columns provide data for mice reaching 
endpoint prior to 7d, and were obtained by culturing tissues on the date of death. As such, 
the data cannot be strictly compared between groups but are provided for information. The 
next two columns provide data for remaining mice that survived to 7d; all tissues were 
cultured at the same time-point.  The last column provides chi-square values between 
observed and expected number of mice with GAS dissemination to different tissues 
(comparing all mice observed). 
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6.2.3 Modelling LRTI and trauma: failure of trauma to result in seeding of 
contused tissue 
The pilot work highlighted a trend for reduced survival following GAS LRTI in mice that had 
sustained minor trauma compared with controls that were only infected. Although there 
was no evidence of specific seeding of the injured muscle by GAS following LRTI, it had 
not been possible to rule out specific seeding as the tissues were not systematically 
sampled at a fixed early time point, when bacteraemia had been observed in some mice. 
Furthermore, it remained possible that the interval between trauma and infection might be 
important. To address this, an intra-nasal infection with M1 GAS (7x107 – 1x108 cfu/mouse) 
was administered to female CD1 mice at three different time points following injury: 0, 24 
and 48h (n=8 per group). At each time (delay) point a control group was infected but not 
injured.  24h following infection mice were culled and tissues were harvested to determine 
bacterial spread.  Serum was saved for further cytokine analysis. 
 
Figure 6.3 Pictorial display of the injury (using the mild contusion model) and 
infection (via the intranasal route) 
For each experimental group there was no significant difference in inocula administered 
(data not shown).  For each experiment the mice lost a small amount of weight (median 
Intranasal((
0h( 24h( 48h(
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72h(
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(and(serum(
Injury(
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2%, data not shown). Table 6.3 shows the number of mice in each group with spread of 
M1 GAS to injured or control muscle. Within the trauma groups, there was no significant 
difference in spread of M1 GAS to injured (left leg) or control muscle (right leg), 
demonstrating that the injury did not affect localisation of GAS.  The control groups (which 
were only infected and not injured) also showed spread to muscle on either side consistent 
with systemic spread. This was despite the fact that GAS bacteraemia was detected in 
only a minority of mice.  The ipsilateral and contralateral inguinal lymph nodes that drain 
the contused muscle were dissected and showed no evidence of viable GAS in either 
group.  Serum cytokines measured following infection in both groups showed a low grade 
inflammatory response with elevation of IL-6 in response to the GAS infection, although 
with no difference between the groups (Figure 6.4 A-C).  There was minimal elevation of 
other pro-inflammatory cytokines such as IL-1, TNF-alpha and KC (data not shown). 
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Table 6.3 Lack of seeding of muscle tissue following an intranasal infection with M1 
GAS with and without contusion.   
Mice were infected at three time points following injury: 0, 24 and 48 hours and then culled 
at 24 hours following intra-nasal GAS infection.  Shown in the table is the time between 
injury and infection and the number of mice with spread of M1 GAS to injured or control 
muscle and the proportion (%).   
 
  
 
Time from 
defined injury 
to infection (h) 
 
Viable GAS in Injured muscle  
(left hindlimb) 
 
Viable GAS in control muscle  
(right hindlimb) 
 Trauma 
Group  
Control  
Group  
Trauma 
Group 
Control 
Group 
0 0/8 (0%) 0/8 (0%) 0/8 (0%) 0/8 (0%) 
24 0/8 (0%) 0/8 (0%) 1/8 (12.5%) 4/8 (50%) 
48 
 
1/8 (12.5%) 2/8 (25%) 1/8 (12.5%) 1/8 (12.5%) 
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A 
 
 
B 
 
C 
 
 
Figure 6.4 A-C The IL-6 response following injury and intranasal infection.   
Serum was obtained from mice at 24 hours following infection with or without injury and 
analysed using a 20-plex mouse luminex kit.  Data are shown for mice infected at various 
delayed times after injury (A) 0h (B) 24h (C) 48h. There was minimal acute inflammatory 
response following injury and infection, except for a rise in IL-6 greater than levels seen in 
normal control mice that are un-infected.  There was no difference between the control 
and injury groups regardless of time between injury and infection.  
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6.2.4 Modelling LRTI and trauma: failure of trauma to promote GAS 
dissemination 
The preliminary work had suggested that trauma might be harmful to mice that receive a 
GAS LRTI, either by reducing survival in the mice or by enhancing the survival of GAS in 
the lung, although the data relating to spread to lung was obtained at 7d. In the previous 
experiment described, CD1 mice were given an intranasal infection with M1 GAS at three 
time points following injury: 0, 24 and 48 hours, then, 24h following intra-nasal infection, 
the mice were culled and, in addition to examining the contused and control muscle, the 
proportion (%) of mice with dissemination of M1 GAS to lung, blood, spleen was measured 
(Table 6.4). There was no difference at 24h following an intra-nasal infection with M1 GAS 
between the injury and control groups in the proportion of mice with viable GAS in the 
following tissues: lung, blood, spleen, and liver (p>0.05, Chi-Square test).  
 
Time 
between 
defined 
injury to 
infection 
(h) 
 
Proportion of Mice with Viable GAS in tissues (%) 
 
Lung 
 
Blood 
 
Spleen 
 
Liver 
  
Trauma 
 
Control  
 
Trauma 
 
Control 
 
Trauma 
 
Control 
 
Trauma 
 
Control 
 
0h 
 
(2/8)  
25% 
(5/8) 
62.5% 
1/8 
(12.5%) 
0/8  
(0%) 
0/8  
(0%) 
0/8  
(0%) 
0/8 
(0%) 
0/8  
(0%) 
24h 
 
5/8 
(62.5%) 
6/8  
(75%) 
0/8 
(0%) 
0/8  
(0%) 
1/8 
(12.5%) 
3/8 
(37.5%) 
2/8 
(25%) 
4/8 
(50%) 
48h 
 
4/8  
(50%) 
4/8  
(50%) 
0/8  
(0%) 
0/8  
(0%) 
5/8 
(62.5%) 
3/8 
(37.5%) 
4/8 
(50%) 
2/8 
(25%) 
Table 6.4 Systemic spread by GAS following an intranasal infection with or without 
injury.  
Mice were injured and then infected at 0, 24 and 48 hours following injury as for Table 6.3. 
The table shows the proportion of mice (%) with spread to lung, blood, spleen and liver 
24h following infection (n=8 per group). 
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6.2.5 Modelling intravenously administered bacteraemia and trauma: Trauma 
does not affect bacterial spread to muscle following a known 
bacteraemia 
Previously injury did not influence the dissemination of M1 GAS to muscle or other tissues 
via a lower respiratory tract infection.  It was noted that despite the intra-nasal model 
producing systemic dissemination to tissues there was limited evidence of GAS in the 
blood. Previous work by Hamilton et al, 2008 reported increased spread of GAS to a site 
of injury 6 hours following an intravenous infection (Hamilton, Bayer et al. 2008). To 
replicate and investigate whether injury does enhance the spread of GAS to the site of 
injury or increase systemic dissemination following a bacteraemia, an intravenous model 
of M1 GAS infection was used.  Pilot work in female CD1 mice, established that 2x107 
cfu/mouse produced systemic dissemination to the spleen, liver, muscle and lymph node 
at 24h following an intravenous infection with M1 GAS.  
 
In this work, an intravenous infection into the lateral tail vein of female FVB/n mice aged 6-
8 weeks with M1 GAS was given at three time points following injury using the mild 
contusion model: 0, 24 and 48h. The mice were observed for 24h following infection, then 
culled and organs harvested for bacterial counts and serum for host cytokine responses.   
A proportion of the mice were culled by schedule 1 prior to the experimental end point as 
they had reached a critical end point. Only mice surviving to the 24h point were included in 
the results.  Mild contusion injury did increase dissemination of M1 GAS to muscle tissue 
following an intravenous infection (Table 6.5). Although GAS were recovered from muscle 
tissue, this was not specific to the injured tissue and occurred in the uninjured muscle as 
well (p>0.05, Chi-Square).  Initial experiments showed no difference in the cytokine 
responses between the trauma and control groups (data not shown).  
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Proportion of Viable GAS in Muscle Tissue (%) 
 
Time 
between 
injury and 
infection 
 
Injured muscle (left leg) 
 
Control muscle (right leg) 
 
 
Group (n=6) 
 
Trauma 
 
Control 
 
Trauma 
 
Control 
 
0* 
 
2/5 (40%) 
 
2/4 (50%) 
 
1/5 (20%) 
 
1/4 (25%) 
 
24** 
 
3/6 (50%) 
 
3/6 (50%) 
 
4/6 (67%) 
 
3/6 (50%) 
 
48*** 
 
1/4 (25%) 
 
2/5 (40%) 
 
0/4 (0%) 
 
3/5 (60%) 
 
Table 6.5 The proportion of mice with seeding of muscle tissue following an 
intravenous infection with M1 GAS.  
Female FVB/n mice aged 6-8 weeks were divided into groups (n=6 per group) with or 
without trauma using the mild contusion model.   Mice were given an intravenous infection 
with M1 GAS at three time points following injury (0, 24 and 48h). The table shows the 
proportion of mice with seeding of muscle tissue with and without injury.   
Only surviving mice are shown.  
* 1 death in the trauma group and 2 deaths in the control (uninjured) groups 
** No deaths 
***2 deaths in the trauma group and 1 death in the control (uninjured) group 
There was no significant difference between the systemic spread of M1 GAS to muscle 
tissue between the injury and control group (p>0.05, Chi-Square).  
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6.2.6 Modelling bacteraemia and trauma: trauma does not affect systemic 
dissemination. 
The same experiment also assessed whether injury influenced the dissemination of M1 
GAS to other tissue sites including lung, blood, spleen and liver, noting that data was not 
collected from mice that had reached a humane end point and were culled prior to the end 
of the experiment.  Contusion injury did not lead to an increased dissemination to tissues.   
A large proportion of mice showed dissemination to the lung, blood, liver and spleen 
greater than that seen previously following an intranasal infection which presumably 
reflects a higher bacterial burden in the blood stream, although there was no difference 
between trauma and control groups (Table 6.6). Although not shown in the Table, the 
magnitude of bacterial burden also did not differ between trauma and non-trauma groups 
(Appendix 1).  
 
The host response 24h following initiation of GAS bacteraemia was observed by 
measuring the serum cytokine response using a mouse 20-plex luminex kit (previously 
described). Surprisingly the majority of cytokines remained below the limit of detection 
(data not shown).  Within each group there was a rise in IL-6 and KC, higher than seen 
previously in the intranasal model, with no difference between the injury and control group 
(data not shown). 
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Time 
delay 
(h) 
 
Blood 
 
Spleen 
 
Liver 
  
Trauma 
 
Control 
 
Trauma 
 
Control 
 
Trauma 
 
Control 
 
0 
 
4/5 
(80%) 
4/4 
(100%) 
4/5 
(80%) 
(3/4) 
(75%) 
3/5 
(60%) 
2/4  
(50%) 
24 
 
3/6  
(50%) 
4/6 
(67%) 
5/6  
(83%) 
5/6 
(83%) 
4/6 
(67%) 
4/6 
(67%) 
48 
 
4/4 
(100%) 
5/5 
(100%) 
4/4 
(100%) 
5/5 
(100%) 
2/4 
(50%) 
5/5 
(100%) 
 
Table 6.6 Proportion (%) of mice with dissemination of M1 GAS to the lung, blood, 
spleen, or liver.   
Female FVB/n mice aged 6 to 8 weeks (n=6 per infected group) were intravenously 
infected with M1 GAS at three time points following injury with the mild contusion model: 0, 
24, 48h. Injury did not affect the dissemination of M1 GAS to different tissues following an 
intravenous infection (p>0.05, Chi- square for each time point and tissue group).  
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6.2.7 Modelling intramuscular soft tissue infection and trauma: Injury does 
not affect M1 GAS clearance in muscle tissue 
As the intention of the project was to determine whether trauma might influence 
development of soft tissue NF, a soft tissue model of GAS infection was used to produce a 
direct infection of the soft tissues of the thigh via intramuscular injection of GAS. Female 
FVB/n mice aged 6 to 8 weeks were infected intramuscularly with M1 GAS at three time 
points following mild contusion injury of the ipsilateral limb with time delays following 
trauma of 0, 24 and 48h.  A control group were infected intramuscularly without prior injury 
but having had anaesthetic. Mice were observed for 24h, weighed and then culled and the 
organs harvested for bacterial counts and serum for cytokines.  
 
There were no differences in the inocula given into the thigh at each time point, with the 
average inoculum administered, 1x108 cfu per mouse (data not shown).   24h after 
infection, weight change and bacterial counts in the thigh were compared between the 
trauma and non-trauma groups at each time point, however no difference was seen  
(Figure 6.5 A and B). There was evidence of a systemic illness as the majority of the mice 
lost more than 10% of their starting body weight following infection. 
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A 
 
 
B 
 
 
Figure 6.5 Injury does not affect bacterial viability or clearance in local muscle 
tissue.  
Female FVB/n mice aged 6 to 8 weeks were given an intramuscular infection of M1 GAS 
at defined time points following injury with the mild contusion model: 0, 24 and 48h. There 
was no difference between trauma and control mice in weight (A) or bacterial counts (B) in 
the muscle tissue in the three timed groups.  Note red = Trauma and blue = control group.   
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6.2.8 Modelling soft tissue infection and trauma: Mild contusion injury did 
not affect M1 GAS spread systemically to other tissues 
The previous model illustrated that mild contusion injury did not affect clearance of M1 
GAS locally in the muscle tissue following an intramuscular infection.  In contrast to the 
LRTI model, there was spread of M1 GAS to the majority of the tissues.  The majority of 
the mice were bacteraemic at the defined experimental end point. 
 
Serum was obtained at the defined experimental end points to assess the host cytokine 
response to local injury and infection.  Cytokines were measured using a 20-plex Luminex 
kit.  There was a log fold rise in IL-6 and KC with no difference observed between the 
trauma and control groups (Figure 6.6). 
 
 
Time 
delay 
(h) 
 
Blood 
 
Spleen 
 
Liver 
  
Trauma 
 
Control 
 
Trauma 
 
Control 
 
Trauma 
 
Control 
0 
 
3/6 
(50%) 
4/6 
(60%) 
6/6 
(100%) 
6/6 
(100%) 
6/6 
(100%) 
6/6 
(100%) 
24 
 
6/6 
(100%) 
6/6 
(100%) 
6/6 
(100%) 
6/6 
(100%) 
6/6 
(100%) 
6/6 
(100%) 
48 
 
3/6 
(50%) 
4/6 
(60%) 
6/6 
(100%) 
6/6 
(100%) 
6/6 
(100%) 
6/6 
(100%) 
 
Table 6.7 Proportion of mice with dissemination to blood, spleen and liver following 
an intramuscular infection with M1 GAS.  
As previously described, female FVB/n mice were infected in the thigh with M1 GAS at 
three time points following injury: 0, 24 and 48h. Injury did not affect the dissemination of 
M1 GAS to different tissues (n=6 per group). 
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A 
 
B 
 
Figure 6.6 The host IL-6 and KC response to local intramuscular infection following 
mild contusion injury.   
Female FVB/n mice were intramuscularly infected with M1 GAS at three time points 
following mild contusion injury (0, 24 and 48h) and then the host cytokine response was 
assessed in serum.  Shown is the response of (A) IL-6 and (B) KC following injury and 
infection.  Red indicates the trauma group and blue is the control (n=6 per group). 
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6.2.9 Modelling soft tissue infection and trauma: Mild contusion injury did 
not affect the inflammatory response in histopathological sections of 
muscle tissue. 
Using the model of local muscle infection, histology of the muscle was evaluated by an 
experienced histopathologist, Professor Cheryl Scudamore.  24 hours following a local 
intramuscular infection with 1x108 cfu per mouse of M1 GAS with or without injury and 
PBS as a control (n=3 per group), mice were culled and the muscle tissue was formalin 
fixed and sent for routine processing, decalcification and sectioning to produce 
Haematoxylin and Eosin (H&E) stained sections and Gram-stained sections (where tissue 
was infected). Shown in Table 6.8 is the gram stain and pathological results of the 
sections.  Figure 6.7 A-C shows an example of H&E stained tissue following intramuscular 
infection with PBS, M1 GAS (no injury) and M1 GAS with injury. 
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Muscle 
Sample 
 Gram stain Pathology 
Control  
 
 
1 -ve NAD 
2 -ve NAD 
3 -ve NAD 
M1 GAS 
(no 
injury) 
 
 
1 +ve bacteria coincide with area of 
inflammation 
Mixed inflammatory cell infiltrate*, slight caudal 
to stifle in connective tissue 
2 +ve bacteria coincide with area of 
inflammation + area of haem/lysis 
Mixed inflammatory cell infiltrate*, slight caudal 
to stifle in connective tissue and between 
muscle fibres. Myodegeneration slight, muscle 
caudal to stifle. Area of haemorrhage/cell lysis. 
3 +ve large amounts of bacteria 
associated with lytic areas 
Mixed inflammatory cell infiltrate*, slight. Large 
areas of muscle with no defined features and 
possible bacterial colonies - could be lysis. 
M1 GAS 
with 
injury 
 
 
1 -ve Mixed inflammatory cell infiltrate*, slight caudal 
to stifle in connective tissue and along fascial 
plane. Myodegeneration minimal 
2 +ve bacteral colonies mainly within 
connective tissue 
Mixed inflammatory cell infiltrate*, slight caudal 
to stifle in connective tissue and between 
muscle fibres. Myodegeneration slight, muscle 
caudal to stifle. 
3 -ve NAD 
 
 
Table 6.8 Gram stain and pathological results of sections of muscle tissue following 
injury and infection with M1 GAS, infection with M1 GAS or infection with PBS. 
Female mice aged 6-8 weeks were infected with M1 GAS with or without injury with the 
mild contusion model (n=3 per group), a further group of mice were infected with PBS to 
serve as a control (n=3).  Shown in the table are the gram stain and pathological results of 
the muscle tissue sections. 
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A 
 
 
 
B 
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C 
 
 
Figure 6.7 Histopathology of muscle tissue 24 hours following an infection with 
PBS, M1 GAS with or without injury. 
24 hours following an intramuscular infection with PBS or M1 GAS with or without injury, 
FVB(n) mice were culled and muscle tissue was formalin fixed and sent for routine 
processing.  Shown in this figure are H&E stained muscle tissue infected with A PBS B M1 
GAS (no injury) C M1 GAS immediately (Injury with the mild contusion model). A Normal 
muscle no inflammatory cell infiltrate. B Mixed inflammatory cell infiltrate with slight 
myodegeneration, haemorrhage and cell lysis. C Mixed inflammatory cell infiltrate with 
slight myodegeneration and cell lysis. 
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6.2.10 Injury influences the spread of M1 GAS to the ipsilateral and 
contralateral lymph node 
Following an intramuscular infection as previously described, injury increases the spread 
of M1 GAS to the ipsilateral lymph node immediately following trauma using the mild 
contusion model with a significant difference in bacterial load obtained (p<0.05). There is 
no change in the spread of M1 GAS to the lymph node at 24h following injury. There is 
decreased dissemination of M1 GAS to both ipsilateral and contralateral lymph node at 
48h following injury (p<0.05).  Figure 6.8 shows the bacterial burden obtained from 
ipsilateral and contralateral lymph nodes at different time points following injury using the 
mild contusion model.  
 
 
Figure 6.8 Bacterial burden obtained from the ipsilateral and contralateral inguinal 
lymph node and three time points following injury (0, 24 and 48h) 
Female FVB/n mice aged 6 to 8 weeks were intramuscularly infected at three time points 
following injury as previously described.  Bacterial burden obtained from the ipsilateral and 
contralateral lymph nodes was quantified (cfu/LN).  Noticeably there was an increased 
bacterial burden in the ipsilateral injured lymph node immediately following injury.  
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6.2.11 There is enhanced spread of M1 GAS to the ipsilateral inguinal 
lymph node immediately following injury with the mild contusion 
model. 
Although the data showed no increase in viable GAS in the thigh following trauma, there 
was increased dissemination to the ipsilateral lymph node in mice that had been 
immediately infected following injury in comparison to non-trauma controls. Based on 
quantification data, the dissemination to the ipsilateral LN occurred via local lymphatic 
drainage and not via blood, because counts from the contralateral LN were much lower. 
To determine if this was a chance observation, the experiment was repeated twice and the 
pooled data are shown below (Figure 6.9 A).  There was a significant difference in 
bacterial counts observed in the ipsilateral lymph node of mice following injury in 
comparison to controls (p<0.005, two tailed Mann-Whitney U).  Of particular note during 
these experiments, a change in bacterial colony morphology was observed in colonies 
cultured from the lymph nodes. The colonies appeared somewhat mucoid, and the finding 
of mucoid colonies occurred more frequently in mice subject to trauma than the controls. 
This was apparent both in an individual expt  (Figure 6.9 B) and in the pooled expts 
(Figure 6.9 C).    
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Figure 6.9 Increased dissemination of M1 GAS to the ipsilateral lymph node of mice 
injured and then immediately infected in comparison to controls.   
Female FVB (n) mice aged 6-8 weeks were given a mild contusion injury followed by an 
immediate intramuscular infection of M1 GAS.  Controls received intramuscular infection 
only. A There was a significant difference in bacterial counts in the lymph node in the 
trauma compared to control group. (Mann-Whitney U, p<0.005) B There was significant 
difference in bacterial counts and proportion of mucoid colonies (p<0.01) (n=6 mice per 
group). C There were significantly more mucoid colonies in the trauma group in 
comparison to the control group (p<0.01, one tailed Mann-Whitney U. 
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6.2.12 Modelling soft tissue infection and trauma: the mucoid phenotype 
was seen in other tissues. 
The experiments above had shown that more GAS were recovered from the ipsilateral 
draining lymph node in mice subject to trauma compared with controls. This could be 
because trauma disrupted some aspect of host defence, for example lymphatic channels, 
or because trauma triggered a change in the bacterial virulence.  The development of a 
mucoid phenotype suggested that the latter could provide an explanation for the findings. 
Importantly, however, the mucoid phenotype was observed in colonies recovered from 
other tissues.  Shown in the table below are the proportion of mucoid colonies observed 
from three separate experiments comparing the ipsilateral lymph node with muscle, blood, 
spleen and liver.  The inoculum did not reveal any mucoid colonies, thus this was a 
phenomenon developing after in vivo passage. Overall, the development of a mucoid 
colony phenotype appeared to characterise colonies that were recovered from blood, 
spleen, and liver, as opposed to the site of the local infection (muscle). The acquisition of a 
mucoid phenotype did appear however to also be characteristic of colonies that were 
recovered from the ipsilateral lymph node, and this appeared to be greater in mice subject 
to trauma  
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.  
  
Median Proportion of mucoid colonies found in each tissue group (%) 
 
Expt 
 
Ipsilateral lymph 
node 
 
Muscle 
 
Blood 
 
Spleen 
 
Liver 
  
Trauma 
 
 
Control 
 
Trauma 
 
Control 
 
Trauma 
 
Control 
 
Trauma 
 
Control 
 
Trauma 
 
Control 
1 85% 56% 14% 13% 37% 74% 72% 61% 52% 18% 
Mean 
cfu 
 
3x105 
 
6x103 
 
1.1x107 
 
1.1x107 
 
672 
 
420 
 
2079 
 
551 
 
39 
 
8 
2 17% 1% 0% 0% 24% 24% 0% 8% 1% 0% 
Mean 
cfu 
 
7.4x105 
 
7.5x103 
 
1.4x107 
 
8.2x106 
 
2345 
 
1875 
 
261 
 
1002 
 
45 
 
1173 
3 1% 0% 0% <1% 1% 0% 12% 4% ND ND 
Mean 
Cfu 
 
2.3x104 
 
585 
 
9.7x106 
 
2.5x107 
 
120 
 
128 
 
6 
 
8 
ND ND 
 
Table 6.8 Proportion of mucoid colonies observed in injured muscle, blood, spleen 
and liver following local infection with M1 GAS to injured muscle tissue. 
In all three experiments the proportion of mucoid colonies observed was assessed in 
ipsilateral lymph node, injured muscle, blood, spleen and liver 24h following an 
intramuscular infection of M1 GAS into injured muscle tissue.  Shown in the table are 
proportion of colonies that were mucoid in each tissue for each group (%) and the mean 
total cfu obtained from tissues: Lymph node = mean cfu/LN; muscle = mean cfu/mg tissue; 
blood = mean cfu/ml; spleen = mean cfu/mg tissue and liver = mean cfu/mg tissue. Three 
separate experiments were performed (n=6 mice per group on each occasion).  
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6.2.13 The mucoid phenotype is associated with an increased 
production of capsule. 
 
To assess whether the mucoid phenotype observed related to a specific increase in 
production of hyaluronan capsule, GAS capsular hyaluronic acid was extracted as 
previously described (Lynskey, Goulding et al. 2013) for 10 mucoid and 10 non mucoid 
colonies retrieved from both the blood and ipsilateral lymph node.  The quantification of 
eluted capsular hyaluronic acid was assessed using the hyaluronan DuoSet ELISA (R&D).  
Data was standardised for total GAS cfu and calculated in triplicate for each sample. 
 
There was a significant difference in amount of capsule production between the mucoid 
versus non mucoid colonies recovered from both the blood and lymph node (both 
p<0.001).  The production of capsule in these isolates was greater than that observed 
previously amongst a collection of clinical isolates including M1 GAS strains, although was 
still less than levels measured in the classically hyper-encapsulated M18 strains (Lynskey, 
Goulding et al. 2013). 
  
 
 
242 
A 
 
B 
 
Figure 6.10 Hyauronan capsule production by emergent mucoid M1 GAS strains in 
lymph node and blood   
Mucoid and non mucoid colonies were assessed for production of HA using a hyaluronan 
Duoset ELISA.  There was significantly more capsule produced in the mucoid strains in 
comparison to the non mucoid strains (p<0.001) isolated from the  ipsilateral lymph node 
and the blood.  
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6.2.14 Likely genetic basis for mucoid phenotype and exclusion of a 
mutation in covRS among lymph node mucoid isolates.   
Further work was performed to investigate if there was an underlying genetic change 
responsible for the phenotypic change observed in colonies recovered directly from the 
model.  Triplicate samples of mucoid and non mucoid lymph node colonies obtained from 
an injured and intramuscularly infected mouse were passaged from broth onto CBA twice, 
and the mucoid phenotype was maintained on CBA. This indicated that the phenotype was 
stable in vitro and therefore was likely related to a genetic change.  Following overnight 
growth to stationary phase, DNA from the mucoid colonies was extracted and PCR 
performed to sequence the CovRS regulatory system. The CovRS regulatory system is 
responsible for negatively regulating the hasABC operon and it is well known that 
mutations in this system can be responsible for de-repression of the operon and 
consequent production of mucoid colonies (Walker, Hollands et al. 2007). Indeed it is 
proposed that such a mutation underpins the normal transition from colonising to invasive 
M1 GAS (Sumby, Whitney et al. 2006).  
 
Systematic sequence analysis of the covRS regulatory gene amplified from five mucoid 
isolates cultured from the ipsilateral lymph node revealed no mutation in the covRS 
sequence in comparison to the parent M1 GAS strain.  A number of additional regulatory 
systems have recently been described to impact on capsule expression by GAS and could 
be responsible for the change in phenotype observed in these colonies (Figure 6.6). To 
delineate the likely candidates, DNA was extracted from mucoid and non mucoid colonies 
(5 in each group) obtained from lymph node and mucoid colonies from the spleen (5). The 
DNA was submitted for Illumina whole genome sequencing.   
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6.2.15 Whole Genome sequencing of mucoid and non mucoid colonies 
revealed multiple mutations in isolates spreading to lymph node and 
spleen: covR, has promoter and M protein 
As described above, DNA was extracted from mucoid and non-mucoid colonies in the 
ipsilateral lymph node and mucoid colonies in the spleen and this was subjected to 
Illumina WGS.   In the spleen, DNA from 5/5 mucoid colonies revealed a single nucleotide 
polymorphism in covR resulting in a codon and amino acid change from ACC (Threonine) 
to CCC (Proline) at position 65 (out of 228) (Figure 6.11A).   
 
In 5/5 non-mucoid colonies obtained from the ipsilateral lymph node there was a mutation 
in the gene emm encoding M protein: a SNP resulting in a codon change GAA (glutamic 
acid) to TAA (stop codon) at position 199 (484) led to premature termination of translation 
and a truncated, anchorless M protein (Figure 6.11B). In 5/5 mucoid colonies obtained 
from the ipsilateral lymph node there was a large deletion in the promoter of the HasABC 
operon shown on the diagram between points 1 and 2 (Figure 6.11C) a region 
incorporating the P2 promoter, HasS region and one covR DNA binding site. 
 
Hence, among colonies that had acquired a mucoid phenotype, those recovered from the 
spleen had acquired a genetic change in covR, the repressor component of the covRS two 
component system, mutations in which are known to underlie over-expression of up to 40 
virulence factors including capsule, and potential in vivo invasiveness of modern M1 GAS, 
albeit that mutations are more normally observed in covS.  In contrast, among mucoid 
strains recovered from the lymph node, mutations in covRS were not seen. Instead, the 
mucoid phenotype could be ascribed to a large deletion in the capsule promoter region 
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that would normally be subject to covR repression. Thus the impact of the mutation would 
likely relate to capsule only. 
 
The parent M1 GAS strain used in these experiments has previously been sequenced and 
has no prior mutations in key genes. Strains recovered from the experiment and lacking a 
mucoid phenotype were anyway sequenced as controls, and de novo mutations were not 
expected. However colonies that were recovered from the locally draining lymph node 
were found to have acquired a mutation resulting in truncation and potential shedding of 
the M protein.   
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A CovR mutation in mucoid GAS colonies recovered from spleen 
 
 
B emm stop codon mutation in non-mucoid colonies recovered from lymph 
node – truncated M protein 
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C Mutation in has promoter: mucoid colonies recovered from lymph node 
 
 
 
Figure 6.11 Genetic changes present in mucoid and non mucoid colonies on 
systemic dissemination of GAS to the tissues. 
The DNA was extracted and WGS from mucoid and non mucoid colonies obtained from 
ipsilateral lymph node and spleen (5 per group).  A DNA from mucoid colonies from the 
spleen showed a single nucleotide polymorphism (SNP) in covR resulting in a base and 
hence amino acid change, ACC (Threonine) to CCC (Proline) occurring at codon 65 (out of 
228). B DNA obtained from non-mucoid colonies in the ipsilateral lymph node showed a 
SNP in the emm1 sequence resulting in an amino acid change, GAA (Glutamic acid) to 
TAA (stop codon) leading to a truncated M protein through termination of translation.   C 
DNA obtained from mucoid colonies in the ipsilateral lymph node showed a deletion in the 
Has operon between 1 and 2 on the nucleotide sequence which incorporates the P2 
promoter, HasS and one covR binding site. Below the nucleotide sequence is a schematic 
representation of the new mutant with the number of deleted nucleotides shown in the 
triangle. Grey arrow indicates the has transcription start site. 
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6.3 Discussion 
The work in this chapter has focused on assessing the impact of a blunt traumatic injury on 
systemic infection of GAS using a common invasive M1 isolate.  As previously described 
since the 1980s, M1 GAS has evolved as the commonest serotype causing invasive GAS 
disease worldwide, particularly responsible for the increase in developed countries (Table 
1.1).  Noticeably, many infections have been associated with a prior respiratory tract 
illness or non-penetrating injury (Stevens 1995).   
 
Initial work in the Chapter was designed to investigate whether it was feasible to model the 
seeding of injured muscle tissue through a systemic infection with M1 GAS.  Strain H584 
was selected for use in the models as pilot work had shown its ability to cause systemic 
infection when administered intra-nasally. Furthermore, the strain was a clinical blood 
isolate associated with a devastating outbreak of lethal invasive peripartum infection, and 
had been fully sequenced.   
 
Previous work has attempted to model injury and systemic GAS infection by either 
producing a crush injury using forceps followed by a local muscle infection (Seki, Saito et 
al. 2008), or an eccentric contraction muscle injury followed by intravenous infection with 
GAS (Hamilton, Bayer et al. 2008).  I wanted to attempt to model the actual process of 
disease reported in the literature in many case reports  (Table 1.3) whereby there is an 
upper respiratory tract infection leads to a transient bacteraemia, prior to which there is an 
injury to the muscle.   
 
Once the intra-nasal model had been established with H584 (M1 GAS), the impact of 
contusion on infection of M1 GAS via the respiratory route was assessed through looking 
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at survival of the animals following injury and infection compared to infection only.  
Although there was no significant difference in the survival of the mice, there was an early 
trend in the first 72 hours to suggest that trauma had an initial impact on survival, leading 
to early death of mice in the injury group.  There was a greater spread of bacteria to the 
lungs of the trauma group in comparison to controls, in both the mice dying prior to the 
experimental end point and those surviving to 7 days (p<0.05, Chi-Square), although exact 
comparison is difficult as the mice dying prior to 7 days were culled at different time points. 
Death prior to the experimental end point (7 days) was due to a lower respiratory tract 
infection and sepsis with mice showing evidence of bacterial spread to lungs and systemic 
tissues, with a trend for reduced survival in the injury group. In both groups there was 
seeding of injured and control muscle tissue with no overall impact of trauma on seeding 
to the injured leg. 
 
Following the observation that injury may affect spread of GAS at earlier time points, 
further work compared specific groups of outbred CD1 mice administered intra-nasal GAS 
infection at 0, 24 and 48 hours following injury.  In this work there was found to be no 
difference between injury and control groups in spread of GAS to injured muscle tissue or 
systemic spread to blood, spleen or liver and there was no associated change in the 
cytokine response seen in the serum of these animals.  There was limited evidence of M1 
GAS in the blood of mice infected intra-nasally following injury, suggesting that low 
bacterial burden in blood may influence the reduced spread of M1 GAS to injured muscle 
tissue.   
 
The previous demonstration that GAS can localise to a site of moderate eccentric 
contraction injury following an intravenous infection (Hamilton, Bayer et al. 2008) required 
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an external break to the skin of mice (and a potential point of seeding) and a bacteraemia 
produced by infection via the intravenous route.  There was also only increased binding of 
GAS following a moderate muscle injury and no significant difference in bacterial seeding 
of muscle between groups after a minimal injury. We considered the possibility that the 
injury caused to our mice was insufficient to replicate the findings of Hamilton et al. 
However, any greater increase to the force applied in our model was known to result in a 
fracture, an injury well beyond what is reported in the literature pertaining to clinical cases 
of invasive GAS following minor trauma.   
 
To increase the burden of bacteraemia, and maximise the possibility that GAS might seed 
injured soft tissue, the effect of an infection of M1 GAS via the intravenous route was 
assessed at three time points following injury.  Injection of M1 GAS via the lateral tail vein 
produced a bacteraemia in mice at 24 hours following infection.  Spread of M1 GAS to 
muscle tissue was seen frequently following an intravenous infection in comparison to 
GAS administration via the intra-nasal route but this was seen equally in both traumatised 
and control animals, and was probably due to the overwhelming bacteraemia.  Systemic 
dissemination to all tissues (blood, spleen, liver, lymph nodes and muscle) was observed 
with no statistical difference between the groups.  Infection via the intravenous route was 
associated with a systemic cytokine response with elevation in IL-6 and KC, with no 
difference between the injury and control groups.  The remainder of the cytokines 
analysed showed no difference between the trauma/non-trauma groups.   
 
Finally, the effect of a local infection with M1 GAS via the intramuscular route was 
assessed following mild contusion. There was no difference in bacterial load recovered 
from the infected muscle tissue in both injury and control groups at all three time points (0, 
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24 and 48h following injury).  24 h following an intramuscular infection of M1 GAS, Gram 
positive bacteria were seen associated with a mixed inflammatory infiltrate in the 
connective tissue and muscle with no visible difference between the groups. In contrast, 
intramuscular infection with PBS resulted in no histopathological change to the tissue.  
 
Furthermore, there was no difference in bacterial spread to the spleen, liver and blood 
between the injury and control group following a local muscle infection.  Unexpectedly, 
there was increased dissemination of GAS to the ipsilateral lymph node observed in those 
mice infected with GAS immediately after mild contusion, compared with non-trauma 
controls.  This finding was replicated in further experiments. Spread to the ipsilateral lymph 
node was several orders of magnitude greater than spread to the contralateral lymph 
node, suggesting that spread had occurred via local lymphatic channels rather than blood.  
 
Furthermore, a change in morphology of M1 GAS was noted on systemic dissemination to 
the lymph node and other tissues.  Phenotypically the new colonies appeared more 
mucoid than the wildtype parent H584 strain and were abundant in blood, spleen and 
ipsilateral lymph node in comparison to muscle, from which non- mucoid colonies were 
predominantly cultured. Significantly more mucoid colonies were recovered from the 
ipsilateral lymph node of injured mice in comparison to controls when 3 separate 
experiments were combined. This was consistent with the observed increase in bacterial 
abundance in the ipsilateral lymph node of injured mice.   
 
The “mucoid” phenotype was investigated to see whether the change visualised on 
Columbian blood agar was due to an increase in hyaluronic acid production of the capsule 
of GAS.  “ Mucoid” colonies from the blood and lymph node were compared to “non-
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mucoid” colonies with regard to hyaluronic acid (HA) capsule production. Significantly 
more HA was produced by mucoid colonies found in the blood and lymph node in 
comparison to the non-mucoid colonies.  Furthermore, the new mucoid colonies from the 
blood, spleen and lymph node were stable when passaged in broth and blood agar 
illustrating a genetic change was likely to be responsible for the phenotype observed.  
 
CovRS is one of twelve two-component regulatory systems found in GAS and has the 
greatest impact, regulating up to 15% of GAS genes involve in virulence including nearly 
all factors interacting with the innate immune system such as capsule and SpyCEP.  
CovRS normally represses the expression of capsule through regulation of the has operon 
(Walker, Barnett et al. 2014).  Work has shown that CovR binds to the has promoter 
directly in vitro and that phosphorylation of covR is important for the regulation of the 
promoter, with phosphorylated covR binding to a greater affinity than unphosphorylated 
covR (Falaleeva, Zurek et al. 2014).  Furthermore phosphorylation of covR is required for 
the repression of the has promoter in vivo (Gusa, Gao et al. 2006). Homeostatic regulation 
of virulence factors by this system is essential to GAS survival allowing GAS to adapt to 
certain environmental conditions which may occur following infection such as low pH, 
production of LL-37 and elevation in temperature (Gryllos, Tran-Winkler et al. 2008).  
Indeed, mutation of covRS is detrimental to GAS survival in the oropharynx and 
transmission, presumably because of a fitness cost (Alam, Turner et al. 2013). However, 
acquisition of mutations in this two-component system can promote GAS survival in 
deeper tissues, dissemination to distant organs (Walker, Hollands et al. 2007, Cole, Pence 
et al. 2010, Li, Liu et al. 2014).  In one survey of invasive M1 blood GAS isolates, nearly 
50% of strains harboured a mutated covS gene (Sumby, Whitney et al. 2006, Ikebe, Ato et 
al. 2010), although there are many examples of invasive GAS strains which have an intact 
covRS, suggesting other regulators/factors may be implicated (Zheng, Chung et al. 2013).  
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Within a sample of mucoid colonies found in the ipsilateral lymph node of injured and 
infected mice in our study, there were no mutations in the covRS system suggesting that 
another genetic mutation was responsible for the increase in capsule found. 
 
In view of the number of potential other regulators that could explain the observed 
phenotype, I used whole genome sequencing to assess a sample of colonies from the 
ipsilateral lymph node and spleen.  Further analysis of the colonies sequenced revealed 
mutations emerging in covR, hasABC promoter and emm.  The tendency to develop 
mutations in invasive M1 GAS has been ascribed to the presence of a mutator phenotype 
in this serotype that results from the insertion of a phage-like chromosomal island (SpyCI) 
in the DNA mismatch repair gene, mutL (Nguyen and McShan 2014). The SpyCI is 
present during stationary phage growth conferring a tendency to mutation, but excises to 
become episomal during logarithmic phase growth. The excess virulence of M1 GAS may 
in part be related to this CI insertion and resultant susceptibility to mutation. 
 
In the spleen there was a single nucleotide polymorphism (SNP) at position 65 of covR, 
resulting in a base and amino acid change: ACC (Threonine) to CCC (Proline) compared 
to the emm 1 strain in the inoculum.  Mutations in covR lead to an increase in capsule 
production through the reduction of covR binding to the has operon depressing capsule 
production   The covR mutation described in my study is new and has not previously been 
reported.  More commonly, mutations in the sensor kinase covS are seen in emm1 iGAS 
infections in comparison to mutations in the cognate repressor covR, although the latter 
seems to have more substantial phenotypic impact on HA production and virulence factors 
(Ikebe, Ato et al. 2010). In a large study of isolates obtained from patients in Japan with 
iGAS or STTS, a high proportion of strains had acquired mutations in covS or covR, 
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mutations occurred within M types other than M1 including M3 and M89 (Ikebe, Ato et al. 
2010).   
 
In contrast, within the lymph node, I found that a covRS mutation was not responsible for 
the “mucoid” phenotype observed. Further WGS of these “mucoid” colonies demonstrated 
a deletion within the promoter region of the hasABC operon. The deleted region 
incorporates the very recently described P2 promoter, HasS region, and one covR binding 
site and would be predicted to prevent the repressive action of covR (Falaleeva, Zurek et 
al. 2014) resulting in an increase in capsule production.  Although Falaleeva et al have 
described clinical strains with variation in this locus, the development of a mutation in this 
region during infection has not previously been demonstrated. Work in this project has 
shown that the mucoid colonies within the lymph node with the P2 promoter deletion do 
produce significantly more capsule than the non mucoid colonies.  It has been assumed 
that increased capsule provides GAS with a selective advantage in vivo, with regard to 
resistance to opsonophagocytosis. This is readily apparent when covRS mutants are 
studied, however such mutants have additional properties including upregulation of around 
15% of the genome including SpyCEP production.  In contrast, the deletion in hasABC will 
only affect capsular HA production. Recent data from our laboratory show that the 
lymphatic vascular endothelial hyaluronan receptor  (LYVE-1)  acts as a specific receptor 
for the GAS HA capsule (Lynskey NE et al, submitted). Furthermore, deletion or blockade 
of LYVE-1 prevents rapid dissemination of GAS to the ipsilateral lymph node following 
muscle infection.  Thus enhancement of HA expression may be required for lymph node 
spread, without any requirement for increased expression of other virulence factors. 
Whether this is for the benefit of the host or bacterium is unclear, however the change was 
associated with an increase in GAS recovery from the lymph node.  Further work will aim 
to answer these questions and how trauma enhances this process. Potentially trauma 
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could trigger a change in the bacterium, which selects for specific mutants, which can 
resist phagocytosis.  Or does injury trigger a breakdown in lymphatic tissue allowing earlier 
transit to lymphatics (evading neutrophils in the tissues) and selection of mutants, which 
attach to the lymphatic endothelium.  What is not known is how the mutants behave to a 
level to be in sufficient numbers to lead to iGAS.  How do the new mutants compare to 
their parent wildtype strain.  Are the mutations reproducible or reversible and do they 
cause a more severe form of disease than originally seen? 
 
Surprisingly, WGS of non-mucoid colonies obtained from the ipsilateral lymph node 
revealed a SNP (G to T) in the emm gene leading to an amino acid change at codon 199 
(of 484) from GAA (Glutamic acid) to TAA (stop codon).  As a result there is premature 
termination of translation, and likely production of a truncated M protein. Further analysis 
against the NCBI reference GAS M1 genome, MGAS5005 reveals that the truncated M1 
protein should retain  the B repeats in the N terminus of the mature protein (Smeesters, 
McMillan et al. 2010) but lose  the C terminus which is anchored to the cell wall and 
contains the highly conserved C and D repeat regions (Akesson, Schmidt et al. 1994).  M 
proteins are anchored to the bacterial cell wall via the LPXTG motif, so loss of this region 
in this mutant will lead to the truncated M protein being secreted into the extracellular 
medium by the bacterium. As the M protein is one of the largest cell wall proteins that 
projects through the HA capsule, one possible consequence of the mutation, is that the 
capsular surface of the bacterium is smoother, and better able to interact with LYVE-1 and 
reach the lymphatic endothelium. Evasion of anti-M1 antibodies may also be important, 
however this is an unlikely scenario in the mouse model.  
In this particular case the truncated M protein retains its B repeat regions, which can bind 
to fibrinogen to form complexes.  M1 protein- fibrinogen complexes have been known to 
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induce vascular leakage, through interacting with β2 integrins, activating PMNs and 
inducing a massive inflammatory response (Herwald, Cramer et al. 2004, Macheboeuf, 
Buffalo et al. 2011).  Recombinant soluble M1 protein lacking the membrane spanning 
region has been found to be a potent inducer of inflammation and lung haemorrhage; the 
specific action of M1 protein has been ascribed to the irregularities in the heptameric 
coiled-coil structure of M1 protein that aggregates more fibrinogen than other M proteins . 
To date, the only mechanism by which soluble M1 protein has been shown to arise is 
through proteolytic cleavage by other GAS enzymes such as speB, which are 
downregulated in invasive strains such as covRS mutants. To our knowledge this is the 
first possible demonstration of soluble M1 protein released through a naturally occurring 
mutation. It is of specific interest here, because strain H584 was associated with two 
rapidly fatal cases of STSS, one of which was accompanied by lung haemorrhage. 
Importantly, 7-8 bacterial strains cultured from several sites from the clinical cases (blood, 
genital tract, nasopharynx, lung) were subject to WGS but did not reveal any mutations in 
emm or hasABC or covRS. Notably however, only single colonies were selected for 
submission to and from the reference laboratory and it is possible that the diagnostic 
laboratories may not have selected colonies that looked atypical.  
 
What is not known, is the impact of these genetic changes on the virulence of M1 GAS 
H584 and whether environmental conditions, specifically mild trauma, may be responsible 
for this change.  Why were two genetic mutations detected within the lymph node, and did 
these arise in the muscle, in transit, or within the lymph node itself? Did any wild type GAS 
reach the lymph node, or were these mutations necessary for lymph node transit as 
opposed to survival in the spleen?  What are the advantages of a secreted M protein, and 
is this another example of adaptation to environment?  Is one mutant competitively more 
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advantageous than the other or do they somehow work together?  Further work following 
this project will assess the impact of these genetic changes. 
 
Of course, additional questions remain regarding the part played by trauma, which was the 
original focus of this work. Did trauma reveal the various mutations by damaging 
lymphatics, and enhancing spread of GAS into the lymphatic system, and might this be an 
important conduit for GAS infection, often recognised by clinicians during syndromes such 
as lymphangitis. Or, did the trauma result in an environment that was conducive to 
selection of mutants because of antecedent inflammation? However, earlier work in 
Chapter 5 revealed remarkably little cytokine response within the contused tissues, though 
notably measurements of certain factors such as LL37 and other neutrophil defensins 
were not made. Perhaps prior injection of an alternative inflammatory agent , for example 
a chemokine or LL37, could reproduce these findings?  It seems possible that a 
combination of these factors may be important.  
 
In summary, work in this Chapter has shown that it is difficult to model the dissemination of 
GAS from the lower respiratory tract (via the intra-nasal route) or blood (via the 
intravenous route) specifically to injured muscle tissue.  M1 GAS does disseminate to 
muscle tissue during bacteraemia infection  but this was not specific to injured muscle and 
dissemination was seen in control (uninjured) muscles.  Although my  results could be 
explained if the method of contusion was too mild, the results of others are subject to 
variability and use of penetrating as opposed to blunt trauma (Hamilton, Bayer et al. 2008).  
It is impossible to monitor the spread of bacteria longitudinally following contusion given 
the drawbacks of biophotonic imaging, and this has to be a potential limitation to the 
results seen in this project.  We know that GAS NF is a very rare event and hence it could 
 
 
258 
be that the  failure to localise to injured muscle arises purely by chance . Importantly 
however, work with an M1 GAS isolate has revealed that the progression of soft tissue 
infection may be influenced by local trauma, possibly by development of mutations and 
enhanced lymphatic spread.   
 
Interestingly, other infections have been shown develop following an injury to soft tissue, 
and these include Staphylococcus aureus, Clostridium spp and mycobacterial infection,  
suggesting that there may be a shared pathogenesis triggered  by the injury process that 
enhances the development of infection, and that this process is not unique to GAS 
(Svensson, Brookstone et al. 1985, Ferris, Goldie et al. 1987, McHenry, Piotrowski et al. 
1995, Barr, Whittington et al. 2013). An important consideration, however, is the possibility 
of recall bias. Careful epidemiological studies are lacking that demonstrate unequivocal 
association between antecedent trauma and infection at the site of trauma. The pain of an 
infection may be recalled as the pain of an injury or muscle strain. In the case of GAS 
however, one study has been undertaken that demonstrated that recalled trauma was 
specifically associated with GAS NF as opposed to GAS cellulitis (Nuwayhid, Aronoff et al. 
2007). However most clinicians are more likely to ask about trauma in the context of GAS 
NF, and much epidemiological data does not distinguish between penetrating trauma, 
which provides an obvious portal of entry, and non-penetrating trauma.   
 
 
 
 
 
 
259 
7 Discussion 
7.1 Background 
 
The original aim of my research was to produce a model of GAS NF developing after blunt 
trauma injury, using bioluminescent imaging to refine and enhance the model.  There have 
been many reports of GAS NF associated with injury in the literature (Table 1.3) with one 
prospective epidemiological study (Nuwayhid, Aronoff et al. 2007) but still little known 
about the pathogenesis of this devastating disease process.  Two groups have attempted 
to model the infection in mice (Hamilton, Bayer et al. 2008, Seki, Saito et al. 2008), yet 
neither group demonstrated the seeding of injured muscle tissue following an upper 
respiratory tract illness as reported within the literature (Stevens 1995).  The aims of this 
project was to produce and characterise a reproducible model of mild to moderate 
contusion injury in mice which could then be used to determine the impact of such injury 
on progression of GAS infection, using bioluminescent imaging to enhance the model.  
 
7.2 Key Findings 
In this project, I have produced reproducible models of both moderate and mild contusion ; 
each has been characterised histologically and  with regard to inflammatory response, yet 
show minimal cytokine response in the tissues and the blood.  I have characterised a new 
bioluminescent strain of M89 GAS and shown the limitations of using bioluminescent GAS 
to model infection in comparison to wild-type parent strains.  Furthermore I have 
demonstrated that injury does not enhance the dissemination of M1 GAS to injured muscle 
tissue following systemic GAS infection resulting either from LRTI or an intravenous 
injection.  However mild contusion does increase dissemination of M1 GAS to local 
lymphatics and this  was associated with a change in phenotype of the bacteria to appear 
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more “mucoid”.  The mucoid phenotype was associated with a significantly increased HA 
capsule in comparison to the parent strain and a stable genetic change in the capsule 
promoter locus, while other bacteria demonstrated a change in the M protein locus.  
 
7.2.1 A new model of mild contusion 
 
Using a controlled weight drop device, new models of moderate and mild contusion were 
characterised using histopathology.  The moderate model of contusion was not used for 
future experiments as bony injury complicated the injury in a majority of the mice although 
this was not evident clinically; indeed mice gained eight despite bony injury. Nonetheless, 
bony injury was not compatible with modelling a blunt muscle contusion injury and the mild 
contusion model was selected for further study.  Further characterisation of the model as 
undertaken by analysing the cytokine response in serum (CD1 and FVB/n mice) and 
muscle (FVB/n mice only).  Although the mild contusion model produced inflammatory 
changes consistent with muscle injury at both 24 and 48 hours following injury, there was 
little change in the local cytokine response.  In fact, only a small acute rise in IL-6 was 
noted in the serum of CD1 mice 1 hour following injury.  This weight drop device was then 
used to assess the effect of injury on infection with M1 GAS. 
 
7.2.2 Using BLI to model invasive GAS infection 
Bioluminescent imaging (BLI) has been used to model nasopharyngeal infections with 
GAS (Alam, Bateman et al. 2013, Alam, Turner et al. 2013) but little work has been 
undertaken to model invasive GAS , except for one study assessing the impact of J8-DT 
antibody-mediated protection on dissemination of M49 GAS, a skin (not invasive) isolate 
(Sheel, Pandey et al. 2010), where visualisation of bioluminescence required dissection of 
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individual organs.  In this project, new bioluminescent derivatives of M3 and M89 GAS 
were developed using a replicative plasmid pTHLK, which were bright but not stable in 
vitro or in vivo. Unlike the M3 and M89 GAS derivatives, the M1 GAS derivative produced 
minimal light during growth in vitro and in vivo.  We considered the possibility that the 
mutator phenotype of M1 GAS may have led to mutation of pTHLK, however, 
transformation of E.coli with plasmid pTHLK derived from the M1 GAS transformants 
showed that pTHLK could still result in light production by E. coli. This suggests that 
mutation of luxABCDE is unlikely to be the cause of the failure of pTHLK transformed 
M1GAS to produce light, although cannot exclude this possibility altogether. It points to the 
likelihood that M1 GAS may resist expression of luxABCDE through post translational 
modification or some other means of inhibition.    
 
Further work in this chapter focused on characterising a new stable M89 bioluminescent 
strain which could be used to track invasive infection with GAS, although light as produced 
at the cost of reduced virulence; the bioluminescent strain was significantly attenuated in 
comparison to the wild type parent strain.  It was decided that that the new bioluminescent 
strain would not be suitable for further models of injury and infection because of the 
attenuation in virulence, although it maybe of use in models that are less susceptible to 
subtle changes in phenotype . 
 
7.2.3 Injury influences the phenotype of M1 GAS locally 
Further work in this project assessed the impact of injury on progression of GAS in three 
mouse models of systemic infection focussing on M1 GAS:   lower respiratory tract, 
intravenous and intramuscular.  There was no difference in bacterial spread or cytokine 
response between injury and control groups in spread to muscle and other systemic 
 
 
262 
tissues in the LRTI (intranasal) or intravenous models.  Injury increased dissemination 
of M1 GAS to local lymphatics and this was associated with a change in phenotype. 
 
Genetic changes were found in mucoid and non mucoid colonies within the lymph node, 
both with potential impact on M1 GAS virulence.  “Mucoid” colonies in the lymph node 
were associated with a deletion in the has promoter region, potentially altering the covR 
binding site, de-repressing the effect of covR and enhancing capsule production.  “Non 
mucoid” colonies were associated with a SNP in the emm gene leading to a hypothetical 
truncated M protein, that should retain its ability to bind to fibrinogen but is no longer 
attached to the cell wall. Potentially both mutations could enhance the dissemination of M1 
GAS within the lymphatic system  with unknown consequences for the host or bacterium. 
There may be additional impact on overall virulence since the secreted M1 protein may 
have devastating effects on cytokine production while the increase in capsule may 
aggravate bacterial clearance.    Mucoid colonies were also observed in the spleen but this 
as not specifically associated with trauma and were associated with a novel SNP in covR, 
which may lead to de-repression of the has promoter and increased expression of 
capsule. Whether this mutation directly influences binding of covR to target promoters, or 
whether  it affects phosphorylation or response to covS is unknown.  
 
7.3 Future work 
7.3.1 Characterisation of the mutations arising in M1 GAS 
Work in this project has demonstrated mutations in the lymph node and spleen.  Further 
work should explore whether these mutations occur in other sites and whether they are 
specific to a single mouse, tissue type or associated with injury. The function of these 
mutations requires investigation 
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7.3.1.1 Experimental procedures 
• DNA extraction from mucoid and non mucoid colonies within different organs 
following repeat intramuscular infection with M1 GAS H584, to reassess whether 
mutations re-occur during infection and, if so, whether within the same mouse or 
tissue types and whether any of the mutations are specific to injury, or whether 
mutation frequency is enhanced by injury. The site and timing of mutation 
development will be of interest (whether in thigh muscle or exclusively in lymphoid 
tissue). Screening techniques to detect the highlighted mutations require 
development, to avoid the need for WGS of multiple colonies. Hyper-encapsulation 
is readily visible on agar however M protein truncation is not. CovRS mutants are 
discernible both by increased capsule but also by altered speB and SpyCEP 
expression, thus colony dot blotting could be used.  
• Further characterisation of the new mutants will include: 
o HasABC promoter deletion mutant. Quantification of HA capsule 
production and hasA transcription in comparison to parent strain. EMSA 
studies to determine if binding of covR is influenced by the deletion. 
Introduction of same mutation into heterologous GAS strains to observe if 
effect on HA production is reproduced, however this seems likely based on 
the recent findings of Falaleeva et al. Functional studies to compare 
susceptibility to opsonophagocytosis, performance in a Lancefield whole 
blood assay,  binding to LYVE-1 on HDLEC,  and transit to locally  draining 
lymph node in comparison to parent strain and covR encapsulated mutant. 
o covR mutant. Quantification of HA and hasA transcript  plus other virulence 
factors such as speB, SpyCEP, Streptolysin O, SIC, in comparison to parent 
strain. Functional studies to compare susceptibility to opsonophagocytosis, 
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Lancefield assay, binding to LYVE-1 on HDLEC,  and transit to locally  
draining lymph node in comparison to parent strain and has promoter 
mutant.  
o emm1 mutant. Determine if truncated M protein is expressed and is stable: 
SDS PAGE of concentrated supernatant followed by western blotting using 
specific anti-M1 antiserum; comparison with parent strain. Compare 
supernatant of mutant and parent strain for pro-inflammatory activity when 
incubated with whole blood, mononuclear cells (cytokine release) or 
neutrophils (HBP production). Co-culture emm1 mutant or parent GAS strain 
in either immune or non-immune whole blood to determine susceptibility to 
phagocytosis in each setting. Immune blood should control growth of the 
parent strain but will have unclear effects on the mutant strain, although 
other anti-GAS antibodies may negate any differential effects. More specific 
anti-M1 antisera could be used to determine if the mutant has an advantage 
over the wild type.  It is possible that the emm1 defective mutant may not 
survive well in blood, whether immune or non-immune since the binding of 
fibrinogen and other anti-phagocytic factors by M protein embedded in the 
bacterial cell wall  is believed to protect GAS from phagocytosis. Shedding of 
M1 protein by the mutant in whole blood may well have the anticipated pro-
inflammatory effect and this may impact on bacterial clearance.  
o Emm1 mutant. Construct Lactococcus lactis that expresses full length (cell 
wall embedded ) M1 protein or the mutant M1 protein that is shed and 
compare as above. Finally, determine the impact of the shed M1 protein on 
virulence in different mouse models, specifically LRTI and intramuscular. 
Determine if there is an advantage conferred with regard to spread to local 
LN and whether there is a measurable pro-inflammatory effect.  Determine if 
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the mutant emm1 GAS strain results in pulmonary injury as reported for 
injected soluble M1 protein.  
o Screen invasive M1 GAS tissues and isolates from patient to determine if 
these mutations are apparent in clinical disease. 
 
7.3.2 Does the mucoid phenotype occur with other M types  
Further in vivo work will assess whether this mucoid phenotype can occur in other M1 
strains and other M types.  Using the mild contusion model, female FVB/n mice will be 
given an intramuscular infection of another sequenced M1 GAS or different M type and 
then dissemination locally and systemic to other tissues will be observed and quantified by 
harvesting specific organs for bacterial counts and assessing the bacterial phenotype. 
 
7.3.2.1 Experimental procedures 
• Comparison with another M1 GAS strain, firstly to see whether mucoid colonies are 
produced and to assess local lymphatic dissemination following injury.   
• Comparison with other M types like M3 and M89 to assess systemic spread. 
 
7.3.3 The local factors in injured tissue which may be implicated in the new 
mucoid phenotype 
Previous work has highlighted the production of local antimicrobial peptides that may be 
responsible for some of the genetic changes observed (Johansson, Thulin et al. 2008).  
LL-37 or c-RAMP in mice his produced following injury by keratinocytes (Dorschner, 
Pestonjamasp et al. 2001) and at certain levels may favour a genetic changes that result 
in a mutation in covRS (Velarde, Ashbaugh et al. 2014). The levels of cRAMP (murine 
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equivalent of LL-37) and other defensins could be measured in tissues . Reproduction of 
covRS  mutations ex vivo has been attempted by many investigators but with little 
success; mutations appear to be largely selected in vivo presumably via selective 
clearance. It may be possible to demonstrate that selection of covRS mutants does not 
arise in C-RAMP deficient mice, or that selection of hasABC promoter mutants does not 
occur in LYVE-1 knockout mice.   
 
Although histological studies have been undertaken in the contusion model, demonstration 
of damaged lymphatic tissue will likely  require specialised immunohistochemistry using 
fluorescent antibodies to LYVE-1 and podoplanin using dedicated blocks that are not 
paraffin embedded.    
 
7.3.3.1 Experimental procedures 
• The production of cRAMP in FVB/n female mice following injury with the mild 
contusion model using a mouse CRAMP ELISA kit. 
• The introduction of varying concentrations of LL-37 or CRAMP to whole blood 
models  to determine if genetic changes occur. 
• Immunohistochemistry to determine the extent of lymphatic damage in contusion 
model 
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8 Appendices 
8.1 Appendix 1. Bacterial burden in the blood, spleen and liver at 3 time 
points following injury and intravenous infection with M1 GAS 
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Historical Review
Bromine, bear-claw scratch fasciotomies, and the Eagle 
eﬀ ect: management of group A streptococcal necrotising 
fasciitis and its association with trauma
Lucy E M Lamb, Shiranee Sriskandan, Lionel K K Tan
Necrotising fasciitis is a rare, but potentially fatal, soft-tissue infection. Historical depictions of the disease have been 
described since classical times and were mainly recorded in wartime reports of battle injuries. Although several 
diﬀ erent species of bacteria can cause necrotising fasciitis, perhaps the most widely known is group A streptococcus 
(GAS). Infection control, early surgical debridement, and antibiotic therapy are now the central tenets of the clinical 
management of necrotising fasciitis; these treatment approaches all originate from those used in wars in the past 
150 years. We review reports from the 19th century, early 20th century, and mid-20th century onwards to show how 
the management of necrotising fasciitis has progressed in parallel with prevailing scientiﬁ c thought and medical 
practice. Historically, necrotising fasciitis has often, but not exclusively, been associated with penetrating trauma. 
However, along with a worldwide increase in invasive GAS disease, recent reports have cited cases of necrotising 
fasciitis following non-combat-related injuries or in the absence of antecedent events. We also investigate the speciﬁ c 
association between GAS necrotising fasciitis and trauma. In the 21st century, molecular biology has improved our 
understanding of GAS pathogenesis, but has not yet aﬀ ected attributable mortality.
Introduction
Phagedena, hospital gangrene, haemolytic streptococcal 
gangrene, and ﬂ esh-eating disease are various terms 
used to describe necrotising fasciitis.1 Although the cause 
is often polymicrobial, necrotising fasciitis is most assoc-
iated with the Gram-positive bacterium Streptococcus 
pyogenes, also known as group A streptococcus (GAS), in 
part because it was implicated in the ﬁ rst large case 
series of necrotising fasciitis described.2 The original 
term necrotising fasciitis was suggested by Wilson in 
1952,3 and is based on the pathological changes: a rapidly 
progressing infection that consistently resulted in fascial 
necrosis. Despite its varied nomenclature, this potentially 
life-threatening soft-tissue infection is easily recognised 
in historical reports.
Hippocrates described the association between a 
necrotising soft-tissue infection and injury in the 5th 
century BCE: “Many were attacked by the erysipelas … when 
the exciting cause was a trivial accident or a very small 
wound…the erysipelas would quickly spread wisely in all 
directions… Flesh, sinews, and bones fell away in large 
quantities…”4 Subsequently, there are many disorders 
consistent with necrotising fasciitis in medical literature 
(ﬁ gure 1), with particular reference to traumatic wounds 
acquired during wartime.6–8 The American Civil War in 
the late 19th century changed the epidemiology and 
management of necrotising fasciitis (ﬁ gure 1), with 
detailed descriptions of hospital gangrene9 and a trial of 
bromine antisepsis for this disease.10 Around the same 
time, the specialty of microbiology was developing and 
in 1874, the name Streptococcus was proposed for the 
organisms isolated from wound infections.11 The two 
World Wars and the intervening period improved our 
understanding of streptococci and necrotising fasciitis, 
and emphasised the importance of surgery.2,12,13 
World War 2 stimulated large-scale antibiotic production, 
which was a major transition in the management of 
combat-related wounds.14,15
At the end of the 20th century, the incidence of 
necrotising fasciitis increased in some countries, such 
as New Zealand.16 In particular, reports increased of 
severe necrotising fasciitis caused by GAS worldwide in 
countries such as the UK, Norway, Canada, and the 
USA.17–21 Although GAS necrotising fasciitis is rare (UK 
incidence is 1·7 per 1 000 000 people per year),22 recent 
case fatality rates are 13–31%,23–26 and rise to more than 
40% when associated with streptococcal toxic shock 
syndrome (STSS).22 This morbidity prompted the 
introduction of antibiotics targeted at toxin production 
and the use of adjunctive intravenous immunoglobulin. 
Notable in the modern literature are reports of necro-
tising fasciitis following non-penetrating, minor injury 
such as muscle contusion27–34 by contrast with historical 
reports, which were ostensibly linked to penetrating 
injury typiﬁ ed by combat wounds.4,9,12,35,36
In this Historical Review, we focus on GAS necrotising 
fasciitis and use historical data to review how manage-
ment of the disorder developed during three distinct 
periods (the late 19th century, the early 20th century, and 
after World War 2), leading to the multifaceted approach 
used nowadays. We also examine the association 
between blunt or penetrating trauma and GAS necro-
tising fasciitis. Although reporting bias during wartime 
could partly account for the association between trauma 
and necrotising fasciitis, evidence from peacetime also 
supports this association. Because the term necrotising 
fasciitis was only conceived in 1952, we focus on 
disorders that have descriptive similarities with necro-
tising fasciitis in the medical literature. In the 21st 
century, modern scientiﬁ c techniques to understand 
underlying pathophysiology will hopefully further reﬁ ne 
management of this devastating disease process.
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Infectious diseases pre-19th century: miasmas 
and laudable pus
Hippocrates (ﬁ fth century BCE) and Galen (second 
century CE) greatly inﬂ uenced medical practice in Europe 
up to the 19th century, before which infectious diseases 
were assumed to originate from miasmas–poisonous 
vapours emanating from decomposing organic matter. 
Furthermore, Hippocrates believed that disease suscepti-
bility was related to an imbalance of four bodily ﬂ uids or 
humours. Galen proposed that pus expelled from wounds 
rebalanced the humours (pus bonum et laudabile) and was 
beneﬁ cial to patients.37 Unfortunately, Galen’s theory was 
interpreted as pus being necessary for wound healing, 
and pus formation was actively encouraged. Thick, 
creamy laudable pus (most probably staphylococcus 
infection) was encouraged and distinguished from thin, 
watery pus (most probably streptococcus or Gram-
negative infection), which was associated with mortality. 
The erroneous concept of laudable pus was not refuted 
until the second half of the 19th century with the 
introduction of antisepsis by Joseph Lister.38
The late 19th century: hospital gangrene, 
infection control, and bromine during the 
American Civil War
An estimated 700 000 soldiers died during the American 
Civil War from 1861 to 1865,9 the bloodiest war in US 
history.5 However, only a third of deaths were directly 
related to battleﬁ eld trauma, the remainder were caused 
by infectious diseases such as typhoid, dysentery, and 
yellow fever.39 Of the 253 142 wounds reported in the 
permanent registers of the US Surgeon General’s oﬃ  ce, 
59 376 (23%) were ﬂ esh wounds, which included hospital 
gangrene.5 Although hospital gangrene has been 
attributed to S pyogenes, other organisms cannot be ruled 
out without historical specimens.
Joseph Jones, a Confederate Army surgeon, described 
vividly the rapid progression of hospital gangrene9 and 
the eﬀ ect on the underlying tissues: “…a purple or blue 
spot is ﬁ rst perceived…I have seen the skin in the 
aﬀ ected spot melt away in twenty-four hours into a 
greyish and greenish slough, whilst a deep blue and 
purple, almost black areola, surrounding the dead mass, 
spread rapidly in ever increasing circles…Hospital 
gangrene destroys the cellular and adipose tissues most 
rapidly; the muscles, nerves, large blood-vessels, and the 
bones resist its action for a greater length of time.”9 
Although French and British naval surgeons recognised 
hospital gangrene before the American Civil War,1 Jones’ 
depiction has been credited as the ﬁ rst modern desc-
ription of necrotising fasciitis.40 Although skin 
discolouration is a late feature of GAS necrotising 
fasciitis, this description is also compatible with 
cutaneous anthrax and clostridial necrosis and thus, 
whether Jones is describing GAS necrotising fasciitis 
remains inconclusive.
Jones believed in miasma theory and attributed the 
spread of hospital gangrene to “crowding together of sick 
and wounded soldiers in imperfectly ventilated and ﬁ lthy 
hospitals…”,9 which he felt led to favourable conditions 
for the “…development of hospital gangrene upon 
reception of wounds”.9 Jones recommended infection 
control measures to tackle hospital gangrene and noted 
that “the wounded should never be placed in wards with 
patients suﬀ ering from anyone of the contagious or 
infectious diseases…erysipelas, pyaemia, or hospital 
gangrene; and these various diseases should not be 
indiscriminately mixed together”.9
Figure 1: 19th century illustrations of hospital gangrene
(A) Hospital gangrene aﬀ ecting the hand following a lancet puncture of an abscess. Watercolour by William Alfred Delamotte, 1847. (B) Hospital gangrene of an 
arm stump. Reproduced with permission from plate XV in The Medical and Surgical History of the War of the Rebellion, 1861–65.5 Images are courtesy of Wellcome 
images, the Wellcome Trust.
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Middleton Goldsmith was a Union surgeon in Louis-
ville, Kentucky during the American Civil War. He was 
struck by the high mortality associated with hospital 
gangrene and rapid spread on wards, and believed the 
disorder happened spontaneously “where the wounded 
are crowded together—where the wards are ﬁ lled with 
the stench of traumatic proﬂ uvia, and receive the air of 
sewers and cellars”.10 He postulated that epidemics were 
linked, and that their control should reduce mortality. 
Goldsmith reviewed various treatments including 
corrosive acids and caustic alkalis, which prevented 
tissue spread of gangrene, but destroyed remaining 
viable tissue and were only applicable to open wounds.10 
He became interested in halogens like chlorine, 
ﬂ uorine, and bromine after noticing patients recovered 
better on wards in which bromine deodorants were 
being used as disinfectants.39
Goldsmith recommended surgical debridement for 
hospital gangrene followed by bromine injections into 
muscle layers and exposed surfaces. He monitored 
disease progression through the wound’s odour. He did 
a trial of bromine therapy in 334 patients with hospital 
gangrene, 304 of whom received bromine either alone 
or after other treatments (ﬁ gure 2). Eight patients who 
received bromine died (2·7% mortality) compared with 
eight of 13 given nitric acid (61·5% mortality) and ﬁ ve of 
13 given other remedies (38·5% mortality).10 Treatments 
that were used before bromine was trialled by 
Goldsmith, which included lead salts, caustic potash, or 
nitric or carbolic acid, yielded mortality rates of around 
25%,36,41 and cumulative mortality from hospital 
gangrene was 45·6%.5 His work acknowledged the 
importance of infection control through antisepsis in 
wound infection management.
Germ theory and the rise of streptococcus
In the late 19th century, when America was being 
reconstructed after the Civil War, microbiology research 
was developing in Europe. During this time, 
streptococcus was recognised as a cause of disease. The 
scientiﬁ c community was attempting to identify the 
cause of suppurative infections. Research often included 
inoc ulating samples from aﬀ ected individuals (animals 
or human beings) into other animals to observe disease 
progression. One proponent was Robert Koch. In 1876, 
when investigating the cause of traumatic infective 
diseases, Koch isolated anthrax bacillus, thus proving 
the germ theory of disease and beginning the golden age 
of bacteriology.42,43
In 1868, German surgeon Theodor Billroth isolated 
chain-forming bacteria from wound pus and named 
them Streptococcus (from the Greek strepto for chain, 
and kokkus for berry).11 Louis Pasteur isolated a chain-
forming coccus from the blood and uterus of a woman 
with puerperal fever 11 years later in France, attributing 
the disease to microorganisms invading the wounded 
uterine surface after childbirth.44 In 1882, another 
German surgeon, Friedrich Fehleisen, cultured strepto-
cocci from the skin of patients with erysipelas and 
reproduced signs of erysipelas following inoculation 
into human beings, thus supporting the association 
between streptococcus and erysipelas.45,46 The German 
physician Friedrich Julius Rosenbach isolated strepto-
cocci from the pus of an infected wound 2 years later 
and named it S pyogenes (from Greek pyon for pus, and 
genein which means to produce).47 He believed the 
streptococci from pus were separate from erysipelas-
associated streptococci. This controversy was only 
resolved with improved identiﬁ cation techniques,48 and 
the publication of the streptococcal classiﬁ cation 
system by Rebecca Lanceﬁ eld in 1933. This classiﬁ cation 
system was based on the carbohydrate composition of 
bacterial cell-wall antigens, and S pyogenes was classiﬁ ed 
as group A.49
The 19th century ended with miasma theory being 
superseded by germ theory and an improved under-
standing of gangrene associated with penetrating 
wounds. With this shift in understanding, the 
management of infectious diseases advanced. Although 
limiting the spread to others through infection control 
had been the focus of Middleton’s trial of bromine,10 a 
microbiological rationale for these measures now existed. 
However, infection eradication did not become the focus 
of hospital gangrene management until the 20th century, 
through surgical advances and antibiotic discovery.
Early 20th century: the surgeon’s scalpel and the 
antibiotic chemists
“Prior to the war, the surgeon gave most of his attention 
to aseptic methods, his great object being to exclude 
microbes from the wound. The question of how to deal 
with the bacteria after they were in possession was a 
problem of much less interest to him.”35
Although the term necrotising fasciitis was not coined 
until after World War 2, several clinical syndromes 
resembling necrotising fasciitis were described in the 
early 20th century in association with traumatic processes 
including childbirth, burns, and penetrating war wounds 
Figure 2: Results of the trial of bromine for the treatment of hospital gangrene undertaken by 
Middleton Goldsmith in Louisville, KY, USA during the American Civil War
Reproduced with permission from A report on hospital gangrene, erysipelas and pyaemia: as observed in the 
Departments of the Ohio and the Cumberland with cases appended.10
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(table 1). Barrier nursing and infection control, anti-
microbial treatment, and eﬀ ective debridement of 
necrotic tissue are consistent themes in the medical 
literature from this period (table 1). Although infection 
control was rooted in the hospital gangrene pioneers of 
the 19th century, much of the modern management of 
necrotising fasciitis is based on work done during the 
World Wars.
Streptococci and wounds during World War 1
The Scottish physician-scientist Alexander Fleming 
described the predominance of streptococci in war 
wounds in 1915.12 While stationed in France with the 
Royal Army Medical Corps, he studied the bacterial ﬂ ora 
of over 200 wounds and described a transition between 
early stage infections, which contained anaerobic 
organisms, to late-stage infections containing mainly 
pyogenic cocci (ﬁ gure 3). Penetrating traumatic wounds 
contained streptococci and he implicated short-chained 
streptococci in the development of gangrene. Additionally, 
blood cultures from febrile wounded soldiers isolated 
streptococci. Fleming thus noted, “streptococcus is 
without doubt the most important member of this group 
as regards infection of wounds.”12 His management was 
not to rely on antiseptics alone because they did not 
penetrate into deep tissues. He encouraged irrigation 
with hypertonic saline35 and emphasised surgical 
debridement: “…if it were possible for the surgeon to 
remove completely the dead tissue I am quite sure the 
infections would sink into insigniﬁ cance”.12
During World War 1, surgical techniques were reﬁ ned to 
manage infected wounds. The pioneering French military 
vascular surgeon Alexis Carrel and biochemist 
Henry Dakin devised a wound-care technique using a 
chlorine-based disinfectant (Dakin’s solution) and rubber 
Carrel tubes for wound irrigation.56 Belgian surgeon 
Antoine Depage proposed that Dakin’s solution be 
introduced after tissue debridement, excision of 
contaminated tissue, and epluchage (“peeling” of wounds 
before dressing).57 Depage advocated delayed primary 
wound closure depending on the bacteriology and noted 
that “for streptococci infection never to suture but to 
submit the wound to adequate treatment…to wait until the 
Location Presentation (N) and cause Management
Penetrating wounds 
caused by explosives12,35
Boulogne, France Infected wounds (210) from penetrating trauma;
177 (84%) of 210 isolated streptococci
Avoid antiseptics, irrigate wounds with hypertonic 
saline, and debridement of dead infected tissue
Haemolytic 
streptococcal 
gangrene2,13
Peking Union 
Medical College, 
Peking, China
Haemolytic streptococcal gangrene (20);
seven (41%) of 17 blood cultures positive for 
haemolytic streptococcus
Surgical debridement, hygiene and infection control 
measures, and wounds irrigated using Dakin’s solution
Puerperal sepsis50,51 Queen Charlotte’s 
Hospital, London, UK
Haemolytic streptococcal puerperal fever (38 and 
26 cases);
36 (95%) of 38 and 25 (96%) of 26 group A 
streptococcus
Treatment with sulphonamides (prontosil), and 
eﬀ ective infection control
Infected open wounds 
during World War 252–54
France Haemolytic streptococcus isolated from wound 
infections
Dusting of wounds with sterile sulphonamide powder 
(American soldiers in a ﬁ rst aid kit) or given systemically
Patients with burns55 Glasgow Royal 
Inﬁ rmary, Glasgow, 
UK
Infection contaminating burns (516);
69 (13%) of 516 haemolytic streptococcus
Treatment in specialised burn units, cubicle isolation to 
minimise contamination, strict barrier nursing, and 
chloroxylenol disinfectant
Table 1: Patterns of injury or trauma leading to Streptococcus pyogenes gangrene and recommended management of these cases during the early 20th century 
Figure 3: Analysis of bacteriological examination of a series of wounds 
undertaken by Alexander Fleming of the Royal Army Medical Corps while 
stationed in Boulogne, France during World War 1
(A) The diﬀ erent bacteria seen in wounds during three diﬀ erent stages, based on 
the days after infection. Streptococci are present in all stages of infection. 
(B) Drawing from ﬁ lms of pus taken from wounds showing the late stage of 
infection with pyogenic cocci, wisp bacilli, and many pus cells. Reproduced with 
permission from On the bacteriology of septic wounds.12
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streptococci had disappeared, or had become attenuated 
suﬃ  ciently to permit primary union”.57 He has been 
credited with making the most important contribution to 
wartime surgery during any war.58
Between the World Wars and the start of the 
antibiotic era
In 1924, Frank Meleney, an American missionary surgeon 
working in China, reported an outbreak of 20 cases of 
haemolytic streptococcal gangrene in a Peking hospital, 
with 20% mortality. Meleney showed that surgery is 
needed to reduce mortality,2,13 and noted that gangrene was 
caused by either anaerobic bacteria or haemolytic 
streptococci. He noted that the “infection usually starts 
from a superﬁ cial break in the skin, a scratch, a hypodermic 
injection, a cut, a pimple, or a boil but occasionally develops 
without any point of origin”, implying that penetrating 
trauma is not a prerequisite for necrotising fasciitis. 
Meleney successfully treated cases of gangrene with bear-
claw scratch debridement,2,13 building on the work of 
World War 1 surgeons. In this method, single, long 
incisions were made to the deep fascia on either side of the 
aﬀ ected limb (similar to the appearance of a scratch from a 
bear claw) to just beyond the necrotic area. Extending 
incisions too far spread infection, but if done correctly, this 
method negated the need for amputation.13 The bear-claw 
technique was subsequently superseded in favour of more 
extensive fascial exposure and debridement.59
In 1932, the German histopathologist and bacteriologist 
Gerhard Domagk reported that mice and rabbits given 
the red dye prontosil rubrum, derived from sulpha-
nilamide, survived lethal infections with haemolytic 
streptococci and staphylococci.60 He received the Nobel 
Prize for Medicine in 1939 for his work on the 
sulphonamides, which revolutionised the treatment of 
infected war wounds. Studies in animals showed the 
beneﬁ t of sulphonamides in preventing wound infections 
when sprinkled in the wound.51 During World War 1, 
8·3% of wounded soldiers in the US army died. Mortality 
was reduced to 4·5% in World War 2, during which 
American soldiers were issued sulphonamide powder in 
ﬁ rst-aid packs. Furthermore, improved surgical 
techniques probably contributed to the fall in deaths of 
soldiers.52,61 The use of sulphonamide on wounds 
escalated from 1942, but rather than sprinkling, the drug 
was dumped in lumps on wounds, thereby reducing drug 
absorption. Meanwhile, the importance of adequate 
wound debridement was neglected. Wounds became 
infected, and thus it was misinterpreted that sulpho-
namide powder was detri mental to wounds.58 Leonard 
Colebrook, a contem porary of Fleming, also investigated 
the use of sulphonamides to treat puerperal sepsis,50,62 
which is usually attributed to GAS and follows maternal 
tissue injury during childbirth.63 Colebrook successfully 
treated 38 patients with haemolytic strepto coccal 
puerperal fever with sulphonamides, reducing mortality 
from 24·4% in 1935 to 4·7% in 1936.50,64
After World War 1, Fleming returned to work at 
St Marys’ Hospital in London. In 1929, he described the 
antibacterial properties of penicillin, which was 
produced from the mould Penicillium rubrum.35 However, 
it was not until 1939 that biochemist Ernst Chain and 
pathologist Howard Florey, along with colleagues 
Edward Abraham and Norman Heatley, working at the 
Dunn School of Pathology in Oxford, UK, were able to 
produce suﬃ  cient penicillin to do clinical trials.14 Florey, 
Chain, and Fleming were awarded the 1945 Nobel Prize 
for Medicine for their discovery.65
Insuﬃ  cient funds for research led Florey and Heatley 
to the USA in June 1941 to gain the support of the 
American pharmaceutical industry. Through improved 
deep fermentation techniques and isolation of Penicillium 
strains with higher penicillin yields, further clinical trials 
in military and civilian populations took place and 
suﬃ  cient penicillin was produced to accompany troops 
for the D-Day landings.66 Penicillin use during 
World War 2 was clearly documented.67,68 British Army 
surgeons in Italy prevented wound infections by 
inoculating penicillin-sulphathiazole powder into 
wounds following debridement in ﬁ eld hospitals; 
however, there was “…no tendency on the part of 
surgeons to neglect surgery and rely too much on 
penicillin”.67,68 Clearly, for traumatic battle wounds, 
surgery was the main priority, although a combination of 
surgery and penicillin was emphasised, “…for the knife 
alone cannot get rid of infection”.67,68
Infection control revisited: World War 2 and the 
mid-20th century
In 1847, Ignaz Semmelweiss showed the importance of 
handwashing for the prevention of puerperal sepsis.69 
During World War 2, nosocomial transmission of GAS 
was a recognised problem.6 Thus, the role of infection 
control was revisited. Wards were reorganised to prevent 
patient-to-patient transmission, and environmental 
sampling and cleaning were introduced. Health-care 
workers were advised to clean hands and use masks and 
sterile instruments. A wound-dressing technique was 
developed that included so-called clean and dirty 
nurses.6,70 The dirty nurse and a dresser would remove 
and apply bandages to a patient’s wound, washing their 
hands between patients. Meanwhile, the clean nurse 
would not have direct patient contact and would look 
after the contents of the dressing trolley only, washing 
their hands only after the dressing round. This method 
reduced GAS wound infection from 15·4% to 1·1% in 
one wartime neurosurgical unit.70 Many practices 
advocated during this time are still recommended for the 
prevention of nosocomial transmission of GAS 
nowadays.71
In 1952, Ben Wilson, a surgeon at Parkland Hospital, 
Dallas, TX, USA, coined the term necrotising fasciitis, 
which was adopted into widespread use. He reported that 
fascial necrosis was a consistent manifestation in 
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22 patients admitted at the hospital from 1948 to 1951, and 
in previous cases reported in the medical literature.3 He 
also noted that necrotising fasciitis “…may start in an 
operative wound, in a trivial injury…or may appear 
spontaneously”.3 Notably, although haemolytic strepto-
cocci were cultured from all of Meleney’s cases,13 
haemolytic bacteria were grown in pure culture in 58% of 
Wilson’s cases studied bacteriologically, of which 88% 
were identiﬁ ed as staphylococci.3 Furthermore, mortality 
in Wilson’s cohort was only 8·7% compared with 20% 
reported by Meleney. Wilson stressed the importance of 
early recognition, prompt surgery, penicillin, and support 
for abnormal physiology.3
By the mid-20th century, infection control advocated by 
American Civil War surgeons was combined with 
antibiotics targeted at S pyogenes and eﬀ ective surgical 
debridement, as emphasised by Fleming, Meleney, and 
Wilson, in the battle against streptococcal gangrene. 
Indeed, after World War 2, reports of GAS necrotising 
fasciitis in conﬂ icts in Korea, Vietnam, and the Falklands 
were rare, perhaps because of the measures described, 
which resulted in fewer infections. However, the 
eﬀ ectiveness of penicillin was questioned, and the last 
two decades of the 20th century saw a worldwide re-
emergence of invasive GAS infections.
Late 20th century: the Eagle eﬀ ect, 
immunoglobulins, and hyperbaric oxygen
The development of penicillin was a major transition 
point in the management of necrotising fasciitis. However, 
in 1948, Harry Eagle described the Eagle eﬀ ect, the 
paradoxical reduced antibacterial eﬀ ect of penicillin 
against various Staphylococcus and Streptococcus species 
when given at high doses in vitro.72 GAS were not subject 
to the Eagle eﬀ ect, and no GAS isolates have been resistant 
to penicillin.73 However, treatment failure despite 
penicillin sensitivity and high mortality assoc iated with 
severe disease led to the hypothesis that when GAS 
reaches the stationary growth phase—eg, where the initial 
infection is with a large number of bacteria—expression 
of penicillin-binding proteins is reduced and susceptibility 
to β-lactams is diminished.21,74 Eagle also showed that 
delayed initiation of treatment with penicillin after 
infection with GAS in a mouse model of myositis resulted 
in an apparent reduction in bactericidal eﬀ ect (ﬁ gure 4).74 
In the 1980s, this eﬀ ect was revisited. The eﬃ  cacy of 
penicillin, erythromycin, and clindamycin were compared 
in mouse models of GAS myositis and, unlike penicillin, 
the eﬃ  cacy of clindamycin was not adversely aﬀ ected by a 
heavy burden of infection (ﬁ gure 4).75 This ﬁ nding lent 
support to the use of clindamycin for necrotising fasciitis 
treatment (in combination with a penicillin), particularly 
when necrotising fasciitis was associated with toxic shock 
syndrome, because clindamycin inhibits toxin production.76 
Retrospective clinical studies have generally been supportive 
of adjunctive clindamycin therapy in severe disease;77–79 
however, outbreaks by clindamycin-resistant GAS80 could 
limit the usefulness of this drug.
STSS and GAS septic shock have a high mortality and 
are associated with almost 50% of necrotising fasciitis 
cases.18 Patients need supportive measures in a high 
dependency or intensive care setting. Additionally, 
intravenous pooled human immunoglobulin has been 
advocated. Bacterial toxins, including superantigens, 
lead to the release of inﬂ ammatory cytokines, tissue 
destruction, and shock.81 Augmenting the humoral 
immune response with intravenous immunoglobulin 
neutralises superantigens,82 enhances GAS clearance, 
Figure 4: The Eagle eﬀ ect in an in vivo model of myositis
(A) Eagle showed in vivo the reduced bactericidal eﬀ ect of delaying penicillin 
treatment. Mice were infected intramuscularly with 5 x 107 Streptococcus 
pyogenes, divided into groups (0, 1·5, 3, 6, and 9 h), and given procaine 
penicillin (0·15 cc of suspension at 10 000 units/mL). Each point represents 
the median number of organisms recovered from the infected muscle tissue. 
The mortality of the animals increased as treatment was delayed. Eagle 
suggested that the reduced activity of penicillin in older infections is not only 
caused by the large number of organisms, but also caused by the likely 
physiological state of the bacteria and the host tissue environment. 
Reproduced with permission from Experimental approach to the problem of 
treatment failure with penicillin. I. Group A streptococcal infection in mice.74 
(B) The Eagle eﬀ ect was later revisited by comparing penicillin, erythromycin, 
and clindamycin in mice with myositis. When treatment was delayed to 6 h 
postinfection, mice given penicillin had a similar mortality to untreated 
control animals, whereas 80% of the clindamycin group survived. Reproduced 
with permission from The Eagle eﬀ ect revisited: eﬃ  cacy of clindamycin, 
erythromycin, and penicillin in the treatment of streptococcal myositis.75
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and has an anti-inﬂ ammatory eﬀ ect.83 Owing to the rise 
of variant Creutzfeldt-Jakob disease in the 1990s,84 the 
use of intravenous immunoglobulin is strictly 
controlled in the UK and elsewhere. Studies assessing 
intravenous immunoglobulin in severe invasive GAS 
disease are scarce. One randomised, double-blind, 
placebo-controlled trial85 was underpowered to reach 
statistical signiﬁ cance because of the small numbers of 
patients recruited.85 Retrospective reports are comp-
licated by many confounding factors, including use of 
historical controls with higher mortality rates86 or 
children with less severe disease.87 In 2014, two retro-
spective cohort analyses seemed to favour intravenous 
immunoglobulin in severe invasive GAS, but both 
studies had small numbers of patients and were again 
underpowered.77,88 The large sample size needed for 
clariﬁ cation of the role of intravenous immunoglobulin 
in this rare disease89 means that the deﬁ nitive answer is 
not forthcoming.
Hyperbaric oxygen therapy was another approach to 
treatment studied in the late 20th century. This adjunctive 
therapy is thought to increase tissue partial pressure of 
oxygen up to four times normal, thus increasing bacterial 
killing and facilitating wound healing.90 However, the few 
studies that have investigated hyperbaric oxygen therapy 
in GAS necrotising fasciitis show little outcome 
beneﬁ t,91–93 and transferring patients to a centre with 
hyperbaric oxygen therapy might delay eﬀ ective surgical 
debridement.91,94
Diagnosis is still one of the most challenging aspects of 
management of GAS necrotising fasciitis. Diagnostic 
delay is common in historical and current medical 
literature2,33 and could result in adverse outcomes.33 The 
innocuous appearance of the infection, relation to muscle 
contusion, or attribution of pain to an injury might delay 
presentation or mislead clinicians.31,33 Skin discolouration, 
blistering, and visible necrosis are late features of 
necrotising fasciitis and are ominous signs. Nowadays, 
imaging and frozen sections with good histological 
examination might help diagnosis, but intraoperative 
assessment and exploration is preferable when diagnostic 
uncertainty is present.95
Worldwide GAS resurgence and the association 
with trauma
Since the 1980s, GAS diseases, such as necrotising fasciitis 
and STSS, have resurged worldwide.96 GAS infects 
wounds in which skin integrity has been broken;97 
however, blunt trauma leading to muscle contusion 
preceding GAS necrotising fasciitis is also recognised 
(table 2).27–33,98,99,102 In larger studies of GAS necrotising 
fasciitis from North America and the UK, non-penetrating 
trauma or injury was present in about 25% of cases of 
necrotising fasciitis.18,103–105 In a case-control analysis, a 
signiﬁ cant association was noted between non-penetrating 
trauma and GAS necrotising fasciitis, but not cellulitis.106 
Other predisposing factors include burns, surgery, and 
varicella infection. Varicella infections are often 
problematic because of secondary bacterial infections, 
including necrotising fasciitis,107,108 and in countries where 
children receive the varicella vaccine, paediatric invasive 
GAS has become less common.109
GAS necrotising fasciitis generally aﬀ ects more men 
than women, although this diﬀ erence might result from 
reporting bias. Furthermore, many cases of GAS 
necrotising fasciitis have no obvious portal of entry. For 
example, in a cluster of six necrotising fasciitis cases in 
the UK, two had no predisposing history;110 eight of 
20 patients with invasive GAS infection in the USA had 
no portal of entry;20 and ﬁ ve of 14 consecutive necrotising 
fasciitis cases over 5 years in northern Australia had a 
similar lack of relevant history.91 Occasionally, patients 
reported mild upper respiratory tract infection.111 
Diabetes, obesity, and chronic alcohol use also predispose 
an individual to necrotising fasciitis.23,112,113
The management of patients in these reports is similar: 
initial broad-spectrum antibiotics, rationalised to benzyl-
penicillin and clindamycin once GAS is identiﬁ ed. 
Surgical debridement is always done, and repeated 
intervention is often necessary. Mortality is high, despite 
intensive care support, and patients have long hospital 
stays and need long-term rehabilitation (table 2).
The worldwide resurgence of GAS has been documented 
speciﬁ cally in military personnel. Training facilities have 
seen outbreaks of the whole spectrum of GAS disease 
including pyoderma, ecthyma, necrotising fasciitis, and 
STSS, and postinfectious sequelae including rheumatic 
fever and glomerulonephritis.114–117 This morbidity among 
military cohorts has been attributed to crowded conditions, 
reduced hygiene, and an absence of type-speciﬁ c 
immunity. Consequently, the US military has used 
prophylactic penicillin (or macrolides in soldiers with 
penicillin allergy) in basic military trainees since 1953.118–120
Necrotising fasciitis and gas gangrene caused by 
pathogens other than GAS
GAS was historically the most commonly recognised 
cause of necrotising fasciitis; however, widespread use of 
antibiotics and improved bacterial identiﬁ cation have 
increased the diversity of bacteria found in penetrating 
wound infections, many of which are polymicrobial and 
contain resistant organisms. In 2010, an earlier 
classiﬁ cation121 was updated and necrotising fasciitis was 
divided into four aetiological types: polymicrobial 
necrotising fasciitis (type I), as distinguished from 
monomicrobial necrotising fasciitis caused by Gram-
positive bacteria (type II), Gram-negative bacteria 
(type III), or fungi (type IV).122 Some case series report 
necrotising fasciitis as being mostly polymicrobial,112,123,124 
whereas in others, single pathogens are more 
common.125–127 However, limitations in culture methods 
might explain these ﬁ ndings.125 Meticillin-resistant 
Staphylococcus aureus, Klebsiella pneumoniae, 
Pseudomonas aeruginosa, Vibrio parahaemlyticus, and 
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Actineobacter baumanii have all been isolated, with the 
predominant organism dependent on geography.36,125–129
One form of polymicrobial necrotising fasciitis is 
Fournier’s gangrene, a necrotising perineal and genital 
infection ﬁ rst described in healthy young men by 
venereologist Jean-Alfred Fournier in 1883. He also noted 
the association of gangrene with diabetes, alcoholism, and 
urological trauma.130 Organisms in Fournier’s gangrene 
are usually commensals, with aerobic and anaerobic 
bacteria acting synergistically through mutually beneﬁ cial 
nutrient and toxin production.131 Widespread antibiotic use 
has resulted in bacterial resistance, necessitating the use of 
broad-spectrum antibiotics for this disorder at the outset.132
No historical review of necrotising fasciitis would be 
complete without mentioning the ubiquitous Gram-
positive anaerobic bacterium, the Clostridium spp. Gas 
gangrene, also known as clostridial myonecrosis, has 
been associated with soil containing Clostridium spp, 
which contaminates battleﬁ eld wounds. Estimates of the 
incidence of gas gangrene in the wounded during 
World War 1 are about 10%, and less than 1% for 
World War 2.133 Although advances in weaponry led to 
tissue destruction favouring anaerobic growth, improved 
surgical techniques including debride ment and delayed 
primary closure reduced mortality from gas gangrene.134 
Clostridium perfringens was historically the most common 
cause of necrotising infections resulting from penetrating 
trauma; however, Clostridium septicum and Clostridium 
sordellii have also been implicated in infection at sites of 
minor injury.135
Into the 21st century: molecular pathogenesis 
of GAS necrotising fasciitis
The development of molecular biology over the past 
40 years has improved our understanding of the 
mechanisms by which GAS causes disease. GAS aﬀ ects 
only human beings and usually colonises people via the 
nasopharynx or skin. After colonisation, immune evasion 
is a prerequisite for bacterial invasion and establishment 
of deep tissue infection. Molecular biology has improved 
our understanding of the pathogenesis of GAS necrotising 
fasciitis (ﬁ gure 5).
Age 
(years)
Sex Country Site Risk factors Cause Trauma Mortality Management
Adams et al27 
(n=2)
58 and 40 1 male, 
1 female
USA Limb None Streptococcus 
pyogenes
Skin injury 100% Surgical debridement, intravenous penicillin, 
and ITU support
Svensson 
et al98 (n=4)
38, 29, 43, 
and 41
1 male, 
3 female
South 
Africa
Arm Obesity 75% isolated 
S pyogenes
Contusion of arm 50% of 
S pyogenes cases
Debridement and intravenous penicillin, 
tobramycin, and metronidazole
Hird et al30 
(n=1)
17 Male USA Thigh None S pyogenes Bruise from sport 100% High-dose benzylpenicillin, fasciotomy and 
debridement of thigh, and ITU support
Sellers et al99 
(n=8)
Mean 46 
(range 
32–63)
6 male, 
2 female
USA 6 limb, 2 
GAS 
pneumonia 
with 
pupura 
fulminans
5 of 8 had a history 
of chronic illness 
(alcohol abuse, 
cirrhosis, COPD, or 
previous GAS 
cellulitis)
S pyogenes 2 blunt trauma, 1 bee 
sting, and 1 ulcer 
25% Surgical debridement, and 6 of 8 patients 
started on clindamycin in combination with 
penicillin or cephalosporins. 1 given 
clindamycin, vancomycin, and imipenem 
and cilastin. 1 given vancomycin and 
ceftriaxone
Nothwang 
et al28 (n=1)
19 Male Germany Thigh None S pyogenes Fall on side 0% Debridement and ITU support; antibiotic 
regimen not described except for candida 
sepsis with diﬂ ucan
Hirose et al100 
(n=1)
36 Female Japan Right hip None S pyogenes Injury to right hip 100% Supportive care as arrived at hospital in 
extremis
Dahl et al101 
(n=2)
61 and 32 Both male USA Hand Rheumatoid 
arthritis (61 years 
old)
S pyogenes Blunt trauma to the 
hand
50% Debridement, ITU support, clindamycin, 
penicillin, and intravenous immunoglobulin
Jallali et al29 
(n=1)
42 Male UK Anterior 
chest wall
Epilepsy and heavy 
alcohol intake
S pyogenes Collapse following 
convulsion
0% Ceftriaxone, ﬂ ucloxacillin, and 
metronidazole changed to benzylpenicillin, 
ciproﬂ oxacin, and clindamycin owing to 
intraoperative ﬁ ndings, surgery, and ITU 
support
Raﬀ oul 
et al32 (n=1)
46 Female France Hand and 
arm
None S pyogenes Contusion 0% Surgery and antibiotics not speciﬁ ed
Heinze et al31 
(n=1)
47 Male Germany Leg Likely NSAID 
injection
S pyogenes Minor trauma to left leg 
during tennis
100% Surgical exploration and debridement; 
antibiotic treatment not mentioned
Radovan 
et al102 (n=2)
48 and 57 1 male, 
1 female
Serbia Chest wall, 
upper limb, 
and trunk
NSAIDs (naproxen, 
aspirin, and 
diclofenac)
S pyogenes Injury, and fall 100% Died on admission
Baker33 (n=1) 33 Male UK Hamstring None S pyogenes Muscle strain 100% Surgical exploration and amputation; no 
antibiotics
ITU=intensive treatment unit. GAS=group A streptococcus. COPD=chronic obstructive pulmonary disease. NSAID=non-steroidal anti-inﬂ ammatory drug. 
Table 2: Case reports showing the potential association between blunt trauma or non-penetrating muscular injury and the development of Streptococcus pyogenes necrotising fasciitis
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GAS expresses several virulence factors to evade 
humoral immune eﬀ ectors.137,140–142,145 The best studied 
GAS virulence determinant is the M protein. Although 
there are more than 100 M serotypes, M1 and M3 isolates 
predominate in invasive disease.146,147 This predominance 
is probably related to virulence genes carried by these 
M types, coupled with a serotype-speciﬁ c ability to evade 
the immune response. Through its interaction with host 
immune proteins, the M protein itself might help 
invading bacteria. Additionally, some necrotising fasciitis 
pathophysiology might be attributable to M protein 
binding ﬁ brinogen, which initiates a cascade resulting in 
vascular leakage and toxic shock.148
GAS has several mechanisms to evade neutrophils, 
key players in host innate immunity, such as the 
hyaluronic acid capsule, streptolysins, and DNases.141,149,150 
GAS expresses the protease SpyCEP that cleaves the 
chemokine interleukin 8, which is involved in the 
recruitment and activation of neutrophils,143 perhaps 
explaining the scarcity of neutrophil inﬁ ltrates in histo-
pathological sections from cases of severe necrotising 
fasciitis. SpyCEP enables survival and dissemination of 
GAS,151 and high SpyCEP activity is associated with 
increased disease severity and poor clinical outcome.143 
Other GAS proteases are implicated in immune evasion 
and the pathological changes noted in necrotising 
fasciitis.137,139,142 Notably, the cysteine protease SpeB might 
be associated with tissue necrosis139 and phenotypic 
switching of bacteria during invasive infection.138 
Genetic reasons behind the aggressive phenotype of 
GAS isolates causing necrotising fasciitis are also being 
established. For example, mutations in the CovR/S 
regulatory system, which enables the bacteria to respond 
to their environment, occur readily in M1 isolates. 
CovR/S mutations are associated with invasive bacterial 
phenotypes with reduced SpeB production and 
increased SpyCEP expression.143,144 Furthermore, a 
single-nucleotide polymorphism in the mtsR gene of 
some M3 isolates, which encode a transcriptional 
regulator, is associated with a reduced propensity to 
cause necrotising fasciitis.152 Other virulence determ-
inants have been implicated in necrotising fasciitis 
pathogenesis, and the unique mechanisms by which 
GAS is exquisitely adapted to its host.153
To replicate the ﬁ nding that GAS necrotising fasciitis 
can occur with minor injury, mice inoculated with GAS 
were bruised at a site distant to the original inoculation. 
The investigators reported higher mortality than that in 
unbruised controls, implying that distant muscle sites 
might harbour bacteria.154 Furthermore, M1 and M3 GAS 
adhere to damaged skeletal muscle cells, possibly via 
cytoskeletal vimentin,155 and, in mice, GAS seed to 
moderately damaged muscle after non-penetrating injury 
(in association with upregulated vimentin expression).156 
Although these studies have their limitations, they 
suggest a possible mechanism for the association of GAS 
necrotising fasciitis and non-penetrating trauma.
Our understanding of GAS molecular pathogenesis has 
not had a profound eﬀ ect on management of necrotising 
fasciitis. Ultimately, molecular biology might lead to a 
GAS vaccine, which would prevent the whole GAS disease 
spectrum. GAS vaccine development has a long and varied 
history, and was discussed by Fleming in 1915.12 Inactivated 
whole-cell vaccines were unsuccessful in the 1940s,157 and 
M protein-containing vaccines have only slowly advanced 
to clinical trials.158,159 Other vaccine targets include SpyCEP160 
and C5a peptidase.161 Because necrotising fasciitis is rare, 
the success of vaccines at preventing GAS necrotising 
fasciitis and other invasive GAS infections will be diﬃ  cult 
to quantify and a surrogate of protection is needed.
Conclusion
Despite postoperative supportive care on technologically 
advanced intensive care wards, and adjunctive therapies 
such as intravenous immunoglobulin and hyperbaric 
oxygen, the outcome from GAS necrotising fasciitis 
Figure 5: Bacterial virulence factors associated with invasive streptococcal disease
Streptococcus pyogenes possesses several virulence factors, which enable the bacteria to evade the host innate and 
adaptive immune defences and establish a deep tissue infection. Surface-expressed proteins such as the M protein 
and C5a peptidase are implicated in complement evasion,136,137 whereas SpyCEP and C5a peptidase aﬀ ect neutrophil 
recruitment. The secreted protein SpeB is implicated in tissue necrosis in necrotising fasciitis and phenotypic 
switching of bacteria in invasive infection.138,139 Other secreted proteins include: SIC that helps complement and 
antimicrobial peptide evasion,140 the DNAase Sda1 that acts on neutrophil-derived extracellular traps,141 and the 
immunoglobulin-degrading protein IdeS.142 The two component regulatory system CovR/S is implicated in the 
regulation of some of these virulence factors and might be associated with more invasive bacterial phenotypes.143,144
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remains poor. Mortality is as high as 40%,22 which is 
almost 20-times greater than that in Goldsmith’s patients 
who were given bromine in 1863.10 In the authors’ 
experience, failure to recognise necrotising fasciitis 
contributes to the high death rate. Why the mortality 
remains so high is unknown. Although historical 
reporting bias might contribute, an alternative view is 
that GAS has become more virulent.20,21 Developments in 
molecular biology will hopefully answer this question 
and lead to improved disease prevention through an 
eﬀ ective GAS vaccine, which would be the ultimate 
successor to bromine, bear-claw scratch fasciotomies, 
and the Eagle eﬀ ect.
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